

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 4118198 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 12 N 9/22 (2006.01)** **C 12 N 15/113 (2010.01)**
- (45) Oversættelsen bekendtgjort den: **2025-05-19**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2025-02-19**
- (86) Europæisk ansøgning nr.: **21725880.5**
- (86) Europæisk indleveringsdag: **2021-04-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2023-01-18**
- (86) International ansøgning nr.: **US2021028843**
- (87) Internationalt publikationsnr.: **WO2021217002**
- (30) Prioritet: **2020-04-24 US 202063014970 P** **2020-09-11 US 202063077211 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Life Edit Therapeutics, Inc., 300 Morris Street, Suite 300, Durham, NC 27701, USA**
- (72) Opfinder: **BOWEN, Tyson D., 137 Waltons Creek Road, Morrisville, North Carolina 27560, USA**
COYLE, Michael, 407 N. Elliott Road, Chapel Hill, North Carolina 27514, USA
CRAWLEY, Alexandra Briner, 1220 Scott Place, Cary, North Carolina 27511, USA
ELICH, Tedd D., 5 Alumwood Place, Durham, North Carolina 27705, USA
- (74) Fuldmægtig i Danmark: **Inspicos P/S, Agern Allé 24, 2970 Hørsholm, Danmark**
- (54) Benævnelse: **RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE**
- (56) Fremdragne publikationer:
WO-A1-2016/186946
WO-A1-2018/007980
WO-A1-2018/172556
WO-A1-2019/195379
WO-A1-2019/236566
WO-A1-2021/030344
WO-A2-2020/139783
CN-A- 110 551 762
US-A1- 2019 264 232
DING WENTAO ET AL: "Development and Application of CRISPR/Cas in Microbial Biotechnology", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, vol. 8, 1 January 2020 (2020-01-01), pages 711, XP055808086, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338305/pdf/fbioe-08-00711.pdf> DOI: 10.3389/fbioe.2020.00711

DESCRIPTION

Description

STATEMENT REGARDING THE SEQUENCE LISTING

[0001] The Sequence Listing associated with this application is provided in ASCII format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The ASCII copy named L103438_1200WO_0084_1_SL is 878,362 bytes in size, and was created on April 21, 2021.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of molecular biology and gene editing, and is defined by the appended claims.

BACKGROUND OF THE INVENTION

[0003] Targeted genome editing or modification is rapidly becoming an important tool for basic and applied research. Initial methods involved engineering nucleases such as meganucleases, zinc finger fusion proteins or TALENs, requiring the generation of chimeric nucleases with engineered, programmable, sequence-specific DNA-binding domains specific for each particular target sequence. RNA-guided nucleases, such as the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) proteins of the CRISPR-Cas bacterial system, allow for the targeting of specific sequences by complexing the nucleases with guide RNA that specifically hybridizes with a particular target sequence. Producing target-specific guide RNAs is less costly and more efficient than generating chimeric nucleases for each target sequence. Such RNA-guided nucleases can be used to edit genomes optionally through the introduction of a sequence-specific, double-stranded break that is repaired via error-prone non-homologous end-joining (NHEJ) to introduce a mutation at a specific genomic location. Alternatively, heterologous DNA may be introduced into the genomic site via homology-directed repair. RNA-guided nucleases (RGNs) can also be used for base editing when fused with a deaminase.

[0004] US 2019/264232 A1 and CN110551762 A each discloses a sequence described as a Cas9 enzyme having 79.5% sequence identity with present SEQ ID NO: 83 over 1053 amino acid positions.

BRIEF SUMMARY OF THE INVENTION

[0005] In a first aspect, the invention provides a nucleic acid molecule comprising a polynucleotide encoding an RNA-guided nuclease (RGN) polypeptide, wherein said polynucleotide comprises a nucleotide sequence encoding an RGN polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 83;

wherein said RGN polypeptide is capable of binding a target DNA sequence in an RNA-guided sequence specific manner when bound to a guide RNA (gRNA) capable of hybridizing to said target DNA sequence, and

wherein said RGN polypeptide recognizes a protospacer adjacent motif (PAM) sequence comprising the consensus sequence of SEQ ID NO: 82.

[0006] In one embodiment, the nucleic acid molecule is codon optimized for expression in a eukaryotic cell. In one embodiment, said polynucleotide encoding an RGN polypeptide is operably linked to a promoter. In one embodiment, said promoter is heterologous to said polynucleotide. In one embodiment, the RGN polypeptide is operably fused to an effector domain. In one embodiment, the effector domain comprises a cleavage domain, a deaminase domain, or an expression modulator domain. In one embodiment, the effector domain is operably fused at the N-terminus, the C-terminus, or at an internal location of said RGN polypeptide.

[0007] In a second aspect, the invention provides a vector comprising the nucleic acid molecule of the first aspect. In one embodiment, the vector further comprises at least one nucleotide sequence encoding said gRNA capable of hybridizing to said target DNA sequence.

[0008] In a third aspect, the invention provides a cell comprising the nucleic acid molecule of the first aspect.

[0009] In a fourth aspect, the invention provides an isolated RNA-guided nuclease (RGN) polypeptide, wherein said RGN polypeptide

comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 83; and

wherein said RGN polypeptide is capable of binding a target DNA sequence of a DNA molecule in an RNA-guided sequence specific manner when bound to a guide RNA (gRNA) capable of hybridizing to said target DNA sequence; and

wherein said RGN polypeptide recognizes a protospacer adjacent motif (PAM) sequence comprising the consensus sequence of SEQ ID NO: 82.

[0010] In one embodiment, the RGN polypeptide is operably fused to an effector domain. In one embodiment, the effector domain comprises a cleavage domain, a deaminase domain, or an expression modulator domain. In one embodiment, the effector domain is operably fused at the N-terminus, the C-terminus, or at an internal location of said RGN polypeptide.

[0011] In a fifth aspect, the invention provides a system for binding a target DNA sequence of a DNA molecule, said system comprising:

1. a) one or more guide RNAs capable of hybridizing to said target DNA sequence or one or more polynucleotides comprising one or more nucleotide sequences encoding the one or more guide RNAs (gRNAs); and
2. b) an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 83, or a polynucleotide comprising a nucleotide sequence encoding the RGN polypeptide;

wherein the one or more guide RNAs are capable of hybridizing to the target DNA sequence;

wherein the one or more guide RNAs are capable of forming a complex with the RGN polypeptide in order to direct said RGN polypeptide to bind to said target DNA sequence of the DNA molecule; and

wherein said RGN polypeptide recognizes a protospacer adjacent motif (PAM) sequence comprising the consensus sequence of SEQ ID NO: 82.

[0012] In one embodiment, at least one of said nucleotide sequences encoding the one or more guide RNAs and said nucleotide sequence encoding the RGN polypeptide is operably linked to a promoter heterologous to said nucleotide sequence. In one embodiment, said target DNA sequence is a eukaryotic target DNA sequence. In one embodiment, the nucleotide sequences encoding the one or more guide RNAs and the nucleotide sequence encoding an RGN polypeptide are located on one vector. In one embodiment, said gRNA is selected from:

1. a) a gRNA comprising a CRISPR repeat sequence having at least 90% sequence identity to SEQ ID NO: 84 and a tracrRNA having at least 90% sequence identity to SEQ ID NO: 85; and
2. b) a gRNA comprising a CRISPR repeat sequence having at least 90% sequence identity to SEQ ID NO: 84 and a tracrRNA having at least 90% sequence identity to SEQ ID NO: 78.

[0013] In one embodiment of the first, fourth, or fifth aspect, said RGN polypeptide is nuclease inactive or is a nickase. In one embodiment of the first, fourth, or fifth aspect, the RGN polypeptide is operably fused to a base-editing polypeptide. In one embodiment, the base-editing polypeptide is a deaminase. In one embodiment of the first, fourth, or fifth aspect, the RGN polypeptide comprises one or more nuclear localization signals.

[0014] In a sixth aspect, the invention provides an *in vitro* or *ex vivo* method for binding a target DNA sequence of a DNA molecule comprising delivering a system according to the fifth aspect, to said target DNA sequence or a cell comprising the target DNA sequence, wherein the method is not a process for modifying the germ line genetic identity of a human being.

[0015] In a seventh aspect, the invention provides an *in vitro* or *ex vivo* method for cleaving and/or modifying a target DNA sequence of a DNA molecule, comprising contacting the DNA molecule with:

1. a) an RNA-guided nuclease (RGN) polypeptide, wherein said RGN comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 83; and
2. b) one or more guide RNAs capable of targeting the RGN of (a) to the target DNA sequence;

wherein said RGN polypeptide recognizes a protospacer adjacent motif (PAM) sequence comprising the consensus sequence of SEQ ID NO: 82;

wherein the one or more guide RNAs hybridize to the target DNA sequence, thereby directing said RGN polypeptide to bind to said target DNA sequence and cleavage and/or modification of said target DNA sequence occurs, and

wherein the method is not a process for modifying the germ line genetic identity of a human being.

[0016] In one embodiment, cleavage by said RGN polypeptide generates a double-stranded break or a single-stranded break. In one embodiment, said modified target DNA sequence comprises:

1. a) deletion of at least one nucleotide from the target DNA sequence; or
2. b) mutation of at least one nucleotide in the target DNA sequence.

[0017] In one embodiment of the first, second, third, fourth, fifth, sixth, or seventh aspect, said RGN polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 83.

[0018] Compositions and methods for binding a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, detection of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs (crRNAs), trans-activating CRISPR RNAs (tracrRNAs), guide RNAs (gRNAs), nucleic acid molecules encoding the same, and vectors and host cells comprising the nucleic acid molecules. Also provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Thus, methods disclosed herein are drawn to binding a target sequence of interest, and in some embodiments, cleaving or modifying the target sequence of interest. The target sequence of interest can be modified, for example, as a result of non-homologous end joining, homology-directed repair with an introduced donor sequence, or base editing.

[0019] References to methods of treatment by therapy with a composition, system or other agent are to be interpreted as references to the composition, system or other agent for use in those methods.

DETAILED DESCRIPTION

I. Overview

[0020] RNA-guided nucleases (RGNs) allow for the targeted manipulation of specific site(s) within a genome and are useful in the context of gene targeting for therapeutic and research applications. In a variety of organisms, including mammals, RNA-guided nucleases have been used for genome engineering by stimulating non-homologous end joining and homologous recombination, for example. The compositions and methods described herein are useful for creating single- or double-stranded breaks in polynucleotides, modifying polynucleotides, detecting a particular site within a polynucleotide, or modifying the expression of a particular gene.

[0021] The RNA-guided nucleases disclosed herein can alter gene expression by modifying a target sequence. In specific embodiments, the RNA-guided nucleases are directed to the target sequence by a guide RNA (gRNA) as part of a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA-guided nuclease system. The RGNs are considered "RNA-guided" because guide RNAs form a complex with the RNA-guided nucleases to direct the RNA-guided nuclease to bind to a target sequence and in some embodiments, introduce a single-stranded or double-stranded break at the target sequence. After the target sequence has been cleaved, the break can be repaired such that the DNA sequence of the target sequence is modified during the repair process. Thus, provided herein are methods for using the RNA-guided nucleases to modify a target sequence in the DNA of host cells. For example, RNA-guided nucleases can be used to modify a target sequence at a genomic locus of eukaryotic cells or prokaryotic cells.

II. RNA-guided nucleases

[0022] Provided herein are RNA-guided nucleases according to the fourth aspect. The term RNA-guided nuclease (RGN) refers to a polypeptide that binds to a particular target nucleotide sequence in a sequence-specific manner and is directed to the target nucleotide sequence by a guide RNA molecule that is complexed with the polypeptide and hybridizes with the target sequence. Although an RNA-guided nuclease can be capable of cleaving the target sequence upon binding, the term RNA-guided nuclease also encompasses nuclease-dead RNA-guided nucleases that are capable of binding to, but not cleaving, a target sequence. Cleavage of a target sequence by an RNA-guided nuclease can result in a single- or double-stranded break. RNA-guided nucleases only capable of cleaving a single strand of a double-stranded nucleic acid molecule are referred to herein as nickases.

[0023] The RNA-guided nucleases disclosed herein include the APG01604 RNA-guided nuclease, the amino acid sequence of which is set forth as SEQ ID NO: 83, and active fragments or variants thereof that retain the ability to bind to a target nucleotide sequence in an RNA-guided sequence-specific manner. In some of these embodiments, the active fragment or variant of APG01604 RGN is capable of cleaving a single- or double-stranded target sequence. An active variant of the APG01604 RGN comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence set forth as SEQ ID NO: 83. In certain embodiments, an active fragment of the APG01604 RGN comprises at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050 or more contiguous amino acid residues of the amino acid

sequence set forth as SEQ ID NO: 83. The RNA-guided nuclease provided herein can comprise at least one nuclease domain (e.g., DNase, RNase domain) and at least one RNA recognition and/or RNA binding domain to interact with guide RNAs. Further domains that can be found in RNA-guided nucleases provided herein include, but are not limited to: DNA binding domains, helicase domains, protein-protein interaction domains, and dimerization domains. In specific embodiments, the RNA-guided nucleases provided herein can comprise at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to one or more of a DNA binding domain, helicase domain, protein-protein interaction domain, and dimerization domain.

[0024] A target nucleotide sequence is bound by an RNA-guided nuclease provided herein and hybridizes with the guide RNA associated with the RNA-guided nuclease. The target sequence can then be subsequently cleaved by the RNA-guided nuclease if the polypeptide possesses nuclease activity. The terms "cleave" or "cleavage" refer to the hydrolysis of at least one phosphodiester bond within the backbone of a target nucleotide sequence that can result in either single-stranded or double-stranded breaks within the target sequence. The presently disclosed RGNs can cleave nucleotides within a polynucleotide, functioning as an endonuclease or can be an exonuclease, removing successive nucleotides from the end (the 5' and/or the 3' end) of a polynucleotide. In other embodiments, the disclosed RGNs can cleave nucleotides of a target sequence within any position of a polynucleotide and thus function as both an endonuclease and exonuclease. The cleavage of a target polynucleotide by the presently disclosed RGNs can result in staggered breaks or blunt ends.

[0025] The presently disclosed RNA-guided nucleases can be wild-type sequences derived from bacterial or archaeal species. Alternatively, the RNA-guided nucleases can be variants or fragments of wild-type polypeptides. The wild-type RGN can be modified to alter nuclease activity or alter PAM specificity, for example. In some embodiments, the RNA-guided nuclease is not naturally-occurring.

[0026] In certain embodiments, the RNA-guided nuclease functions as a nickase, only cleaving a single strand of the target nucleotide sequence. Such RNA-guided nucleases have a single functioning nuclease domain. In particular embodiments, the nickase is capable of cleaving the positive strand or negative strand. In some of these embodiments, additional nuclease domains have been mutated such that the nuclease activity is reduced or eliminated.

[0027] In other embodiments, the RNA-guided nuclease lacks nuclease activity altogether and is referred to herein as nuclease-dead or nuclease inactive. Any method known in the art for introducing mutations into an amino acid sequence, such as PCR-mediated mutagenesis and site-directed mutagenesis, can be used for generating nickases or nuclease-dead RGNs. See, e.g., U.S. Publ. No. 2014/0068797 and U.S. Pat. No. 9,790,490.

[0028] RNA-guided nucleases that lack nuclease activity can be used to deliver a fused polypeptide, polynucleotide, or small molecule payload to a particular genomic location. In some of these embodiments, the RGN polypeptide or guide RNA can be fused to a detectable label to allow for detection of a particular sequence. As a non-limiting example, a nuclease-dead RGN can be fused to a detectable label (e.g., fluorescent protein) and targeted to a particular sequence associated with a disease to allow for detection of the disease-associated sequence.

[0029] Alternatively, nuclease-dead RGNs can be targeted to particular genomic locations to alter the expression of a desired sequence. In some embodiments, the binding of a nuclease-dead RNA-guided nuclease to a target sequence results in the reduction in expression of the target sequence or a gene under transcriptional control by the target sequence by interfering with the binding of RNA polymerase or transcription factors within the targeted genomic region. In other embodiments, the RGN (e.g., a nuclease-dead RGN) or its complexed guide RNA further comprises an expression modulator that, upon binding to a target sequence, serves to either repress or activate the expression of the target sequence or a gene under transcriptional control by the target sequence. In some of these embodiments, the expression modulator modulates the expression of the target sequence or regulated gene through epigenetic mechanisms.

[0030] In other embodiments, the nuclease-dead RGNs or an RGN with only nickase activity can be targeted to particular genomic locations to modify the sequence of a target polynucleotide through fusion to a base-editing polypeptide, for example a deaminase polypeptide or active variant or fragment thereof, that directly chemically modifies (e.g., deaminates) a nucleobase, resulting in conversion from one nucleotide base to another. The base-editing polypeptide can be fused to the RGN at its N-terminal or C-terminal end. Additionally, the base-editing polypeptide may be fused to the RGN via a peptide linker. A non-limiting example of a deaminase polypeptide that is useful for such compositions and methods includes a cytidine deaminase or an adenosine deaminase (such as the adenine deaminase base editor described in Gaudelli et al. (2017) *Nature* 551:464-471, U.S. Publ. Nos. 2017/0121693 and 2018/0073012, and International Publ. No. WO 2018/027078, or any of the deaminases disclosed in International Publ. No. WO 2020/139873). Further, it is known in the art that certain fusion proteins between an RGN and a base-editing enzyme may also comprise at least one uracil stabilizing polypeptide that increases the mutation rate of a cytidine, deoxycytidine, or cytosine to a thymidine, deoxythymidine, or thymine in a nucleic acid molecule by a deaminase. Non-limiting examples of uracil stabilizing polypeptides include those disclosed in U.S. Provisional Appl. No. 63/052,175, filed July 15, 2020, including USP2 (SEQ ID NO: 1089), and a uracil glycosylase inhibitor (UGI) domain (SEQ ID NO: 212), which may increase base editing efficiency. Therefore, a fusion protein may comprise an RGN described herein or variant thereof, a deaminase, and optionally at least one uracil stabilizing polypeptide, such as UGI or USP2. In certain embodiments, the RGN that is fused to the base-editing polypeptide is a nickase that cleaves the DNA strand that is not acted upon by the base-editing polypeptide (e.g., deaminase).

[0031] RNA-guided nucleases that are fused to a polypeptide or domain can be separated or joined by a linker. The term "linker," as

used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., a binding domain and a cleavage domain of a nuclease. In some embodiments, a linker joins a gRNA binding domain of an RNA guided nuclease and a base-editing polypeptide, such as a deaminase. In some embodiments, a linker joins a nuclease-dead RGN and a deaminase. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.

[0032] The presently disclosed RNA-guided nucleases can comprise at least one nuclear localization signal (NLS) to enhance transport of the RGN to the nucleus of a cell. Nuclear localization signals are known in the art and generally comprise a stretch of basic amino acids (see, e.g., Lange et al., J. Biol. Chem. (2007) 282:5101-5105). In particular embodiments, the RGN comprises 2, 3, 4, 5, 6 or more nuclear localization signals. The nuclear localization signal(s) can be a heterologous NLS. Non-limiting examples of nuclear localization signals useful for the presently disclosed RGNs are the nuclear localization signals of SV40 Large T-antigen, nucleoplasmin, and c-Myc (see, e.g., Ray et al. (2015) Bioconjug Chem 26(6):1004-7). In particular embodiments, the RGN comprises the NLS sequence set forth as SEQ ID NO: 251 or 253. The RGN can comprise one or more NLS sequences at its N-terminus, C-terminus, or both the N-terminus and C-terminus. For example, the RGN can comprise two NLS sequences at the N-terminal region and four NLS sequences at the C-terminal region.

[0033] Other localization signal sequences known in the art that localize polypeptides to particular subcellular location(s) can also be used to target the RGNs, including, but not limited to, plastid localization sequences, mitochondrial localization sequences, and dual-targeting signal sequences that target to both the plastid and mitochondria (see, e.g., Nassoury and Morse (2005) Biochim Biophys Acta 1743:5-19; Kunze and Berger (2015) Front Physiol dx.doi.org/10.3389/fphys.2015.00259; Herrmann and Neupert (2003) IUBMB Life 55:219-225; Soll (2002) Curr Opin Plant Biol 5:529-535; Carrie and Small (2013) Biochim Biophys Acta 1833:253-259; Carrie et al. (2009) FEBS J 276:1187-1195; Silva-Filho (2003) Curr Opin Plant Biol 6:589-595; Peeters and Small (2001) Biochim Biophys Acta 1541:54-63; Murcha et al. (2014) J Exp Bot 65:6301-6335; Mackenzie (2005) Trends Cell Biol 15:548-554; Glaser et al. (1998) Plant Mol Biol 38:311-338).

[0034] In certain embodiments, the presently disclosed RNA-guided nucleases comprise at least one cell-penetrating domain that facilitates cellular uptake of the RGN. Cell-penetrating domains are known in the art and generally comprise stretches of positively charged amino acid residues (i.e., polycationic cell-penetrating domains), alternating polar amino acid residues and non-polar amino acid residues (i.e., amphipathic cell-penetrating domains), or hydrophobic amino acid residues (i.e., hydrophobic cell-penetrating domains) (see, e.g., Milletti F. (2012) Drug Discov Today 17:850-860). A non-limiting example of a cell-penetrating domain is the trans-activating transcriptional activator (TAT) from the human immunodeficiency virus 1.

[0035] The nuclear localization signal, plastid localization signal, mitochondrial localization signal, dual-targeting localization signal, and/or cell-penetrating domain can be located at the amino-terminus (N-terminus), the carboxyl-terminus (C-terminus), or in an internal location of the RNA-guided nuclease.

[0036] The presently disclosed RGNs can be fused to an effector domain, such as a cleavage domain, a deaminase domain, or an expression modulator domain, either directly or indirectly via a linker peptide. Such a domain can be located at the N-terminus, the C-terminus, or an internal location of the RNA-guided nuclease. In some of these embodiments, the RGN component of the fusion protein is a nuclease-dead RGN.

[0037] In some embodiments, the RGN fusion protein comprises a cleavage domain, which is any domain that is capable of cleaving a polynucleotide (i.e., RNA, DNA, or RNA/DNA hybrid) and includes, but is not limited to, restriction endonucleases and homing endonucleases, such as Type IIS endonucleases (e.g., *FokI*) (see, e.g., Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Linn et al. (eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993).

[0038] In other embodiments, the RGN fusion protein comprises a deaminase domain that deaminates a nucleobase, resulting in conversion from one nucleobase to another, and includes, but is not limited to, a cytidine deaminase or an adenine deaminase base editor (see, e.g., Gaudelli et al. (2017) Nature 551:464-471, U.S. Publ. Nos. 2017/0121693 and 2018/0073012, U.S. Patent No. 9,840,699, and International Publ. No. WO/2018/027078).

[0039] In some embodiments, the effector domain of the RGN fusion protein can be an expression modulator domain, which is a domain that either serves to upregulate or downregulate transcription. The expression modulator domain can be an epigenetic modification domain, a transcriptional repressor domain or a transcriptional activation domain.

[0040] In some of these embodiments, the expression modulator of the RGN fusion protein comprises an epigenetic modification domain that covalently modifies DNA or histone proteins to alter histone structure and/or chromosomal structure without altering the DNA sequence, leading to changes in gene expression (i.e., upregulation or downregulation). Non-limiting examples of epigenetic modifications include acetylation or methylation of lysine residues, arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and sumoylation of histone proteins, and methylation and hydroxymethylation of cytosine residues in DNA. Non-limiting examples of epigenetic modification domains include histone acetyltransferase domains, histone deacetylase domains, histone

methyltransferase domains, histone demethylase domains, DNA methyltransferase domains, and DNA demethylase domains.

[0041] In other embodiments, the expression modulator of the fusion protein comprises a transcriptional repressor domain, which interacts with transcriptional control elements and/or transcriptional regulatory proteins, such as RNA polymerases and transcription factors, to reduce or terminate transcription of at least one gene. Transcriptional repressor domains are known in the art and include, but are not limited to, Sp1-like repressors, IκB, and Kriippel associated box (KRAB) domains.

[0042] In yet other embodiments, the expression modulator of the fusion protein comprises a transcriptional activation domain, which interacts with transcriptional control elements and/or transcriptional regulatory proteins, such as RNA polymerases and transcription factors, to increase or activate transcription of at least one gene. Transcriptional activation domains are known in the art and include, but are not limited to, a herpes simplex virus VP 16 activation domain and an NFAT activation domain.

[0043] The presently disclosed RGN polypeptides can comprise a detectable label or a purification tag. The detectable label or purification tag can be located at the N-terminus, the C-terminus, or an internal location of the RNA-guided nuclease, either directly or indirectly via a linker peptide. In some of these embodiments, the RGN component of the fusion protein is a nuclease-dead RGN. In other embodiments, the RGN component of the fusion protein is an RGN with nickase activity.

[0044] A detectable label is a molecule that can be visualized or otherwise observed. The detectable label may be fused to the RGN as a fusion protein (e.g., fluorescent protein) or may be a small molecule conjugated to the RGN polypeptide that can be detected visually or by other means. Detectable labels that can be fused to the presently disclosed RGNs as a fusion protein include any detectable protein domain, including but not limited to, a fluorescent protein or a protein domain that can be detected with a specific antibody. Non-limiting examples of fluorescent proteins include green fluorescent proteins (e.g., GFP, EGFP, ZsGreen1) and yellow fluorescent proteins (e.g., YFP, EYFP, ZsYellow1). Non-limiting examples of small molecule detectable labels include radioactive labels, such as ³H and ³⁵S.

[0045] RGN polypeptides can also comprise a purification tag, which is any molecule that can be utilized to isolate a protein or fused protein from a mixture (e.g., biological sample, culture medium). Non-limiting examples of purification tags include biotin, myc, maltose binding protein (MBP), glutathione-S-transferase (GST), and 3X FLAG tag.

II. Guide RNA

[0046] The present disclosure provides guide RNAs and polynucleotides encoding the same. The term "guide RNA" refers to a nucleotide sequence having sufficient complementarity with a target nucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of an associated RNA-guided nuclease to the target nucleotide sequence. Thus, an RGN's respective guide RNA is one or more RNA molecules (generally, one or two), that can bind to the RGN and guide the RGN to bind to a particular target nucleotide sequence, and in those embodiments wherein the RGN has nickase or nuclease activity, also cleave the target nucleotide sequence. In general, a guide RNA comprises a CRISPR RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). Native guide RNAs that comprise both a crRNA and a tracrRNA generally comprise two separate RNA molecules that hybridize to each other through the repeat sequence of the crRNA and the anti-repeat sequence of the tracrRNA.

[0047] Native direct repeat sequences within a CRISPR array generally range in length from 28 to 37 base pairs, although the length can vary between about 23 bp to about 55 bp. Spacer sequences within a CRISPR array generally range from about 32 to about 38 bp in length, although the length can be between about 21 bp to about 72 bp. Each CRISPR array generally comprises less than 50 units of the CRISPR repeat-spacer sequence. The CRISPRs are transcribed as part of a long transcript termed the primary CRISPR transcript, which comprises much of the CRISPR array. The primary CRISPR transcript is cleaved by Cas proteins to produce crRNAs or in some cases, to produce pre-crRNAs that are further processed by additional Cas proteins into mature crRNAs. Mature crRNAs comprise a spacer sequence and a CRISPR repeat sequence. In some embodiments in which pre-crRNAs are processed into mature (or processed) crRNAs, maturation involves the removal of about one to about six or more 5', 3', or 5' and 3' nucleotides. For the purposes of genome editing or targeting a particular target nucleotide sequence of interest, these nucleotides that are removed during maturation of the pre-crRNA molecule are not necessary for generating or designing a guide RNA.

[0048] A CRISPR RNA (crRNA) comprises a spacer sequence and a CRISPR repeat sequence. The "spacer sequence" is the nucleotide sequence that directly hybridizes with the target nucleotide sequence of interest. The spacer sequence is engineered to be fully or partially complementary with the target sequence of interest. In various embodiments, the spacer sequence can comprise from about 8 nucleotides to about 30 nucleotides, or more. For example, the spacer sequence can be about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, or more nucleotides in length. In some embodiments, the spacer sequence is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides in length. In some embodiments, the spacer sequence is about 10 to about 26 nucleotides in length, or about 12 to about 30 nucleotides in length. In particular embodiments, the spacer sequence is about 30 nucleotides in length. In some embodiments, the spacer sequence is 30 nucleotides in length. In some embodiments, the degree of complementarity between a spacer sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is between 50% and 99% or more, including but not limited to about or more than about 50%, about 60%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about

87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more. In particular embodiments, the degree of complementarity between a spacer sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more. In particular embodiments, the spacer sequence is free of secondary structure, which can be predicted using any suitable polynucleotide folding algorithm known in the art, including but not limited to mFold (see, e.g., Zuker and Stiegler (1981) *Nucleic Acids Res.* 9:133-148) and RNAfold (see, e.g., Gruber et al. (2008) *Cell* 106(1):23-24).

[0049] The CRISPR RNA repeat sequence comprises a nucleotide sequence that forms a structure, either on its own or in concert with a hybridized tracrRNA, that is recognized by the RGN molecule. In various embodiments, the CRISPR RNA repeat sequence can comprise from about 8 nucleotides to about 30 nucleotides, or more. For example, the CRISPR repeat sequence can be about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, or more nucleotides in length. In particular embodiments, the CRISPR repeat sequence is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides in length. In some embodiments, the degree of complementarity between a CRISPR repeat sequence and its corresponding tracrRNA sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, about 60%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more. In particular embodiments, the degree of complementarity between a CRISPR repeat sequence and its corresponding tracrRNA sequence, when optimally aligned using a suitable alignment algorithm, is 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more.

[0050] In particular embodiments, the CRISPR repeat sequence comprises the nucleotide sequence of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, or an active variant or fragment thereof that when comprised within a guide RNA, is capable of directing the sequence-specific binding of an associated RNA-guided nuclease provided herein to a target sequence of interest. In certain embodiments, an active CRISPR repeat sequence variant of a wild-type sequence comprises a nucleotide sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the nucleotide sequence set forth as SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124. In certain embodiments, an active CRISPR repeat sequence fragment of a wild-type sequence comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 contiguous nucleotides of the nucleotide sequence set forth as SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124.

[0051] In certain embodiments, the crRNA is not naturally-occurring. In some of these embodiments, the specific CRISPR repeat sequence is not linked to the engineered spacer sequence in nature and the CRISPR repeat sequence is considered heterologous to the spacer sequence. In certain embodiments, the spacer sequence is an engineered sequence that is not naturally occurring.

[0052] A trans-activating CRISPR RNA or tracrRNA molecule comprises a nucleotide sequence comprising a region that has sufficient complementarity to hybridize to a CRISPR repeat sequence of a crRNA, which is referred to herein as the anti-repeat region. In some embodiments, the tracrRNA molecule further comprises a region with secondary structure (e.g., stem-loop) or forms secondary structure upon hybridizing with its corresponding crRNA. In particular embodiments, the region of the tracrRNA that is fully or partially complementary to a CRISPR repeat sequence is at the 5' end of the molecule and the 3' end of the tracrRNA comprises secondary structure. This region of secondary structure generally comprises several hairpin structures, including the nexus hairpin, which is found adjacent to the anti-repeat sequence. The nexus forms the core of the interactions between the guide RNA and the RGN, and is at the intersection between the guide RNA, the RGN, and the target DNA. The nexus hairpin often has a conserved nucleotide sequence in the base of the hairpin stem, with the motif UNANNC (SEQ ID NO: 132) found in many nexus hairpins in tracrRNAs. Interestingly, several of the RGNS of the invention use tracrRNAs that comprise non-canonical sequences in the base of the hairpin stem of their nexus hairpins, including UNANNA, UNANNU, UNANNG, and CNANNC (SEQ ID NOs: 129, 130, 131, and 133, respectively). There are often terminal hairpins at the 3' end of the tracrRNA that can vary in structure and number, but often comprise a GC-rich Rho-independent transcriptional terminator hairpin followed by a string of U's at the 3' end. See, for example, Briner et al. (2014) *Molecular Cell* 56:333-339, Briner and Barrangou (2016) *Cold Spring Harb Protoc*; doi: 10.1101/pdb.top090902, and U.S. Publication No. 2017/0275648.

[0053] In various embodiments, the anti-repeat region of the tracrRNA that is fully or partially complementary to the CRISPR repeat sequence comprises from about 8 nucleotides to about 30 nucleotides, or more. For example, the region of base pairing between the tracrRNA anti-repeat sequence and the CRISPR repeat sequence can be about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, or more nucleotides in length. In particular embodiments, the region of base pairing between the tracrRNA anti-repeat sequence and the CRISPR repeat sequence is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides in length. In some embodiments, the degree of complementarity between a CRISPR repeat sequence and its corresponding tracrRNA anti-repeat sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, about 60%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more. In particular embodiments, the degree of complementarity between a CRISPR repeat sequence and its corresponding tracrRNA anti-repeat sequence, when optimally aligned using a suitable alignment algorithm, is 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more.

[0054] In various embodiments, the entire tracrRNA can comprise from about 60 nucleotides to more than about 210 nucleotides. For example, the tracrRNA can be about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, or more nucleotides in length. In particular embodiments, the tracrRNA is 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 150, 160, 170, 180, 190, 200, 210 or more nucleotides in length. In particular embodiments, the tracrRNA is about 80 to about 90 nucleotides in length, including about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, and about 90 nucleotides in length. In particular embodiments, the tracrRNA is 80 to 90 nucleotides in length, including 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, and 90 nucleotides in length.

[0055] In particular embodiments, the tracrRNA comprises the nucleotide sequence of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, or an active variant or fragment thereof that when comprised within a guide RNA is capable of directing the sequence-specific binding of an associated RNA-guided nuclease provided herein to a target sequence of interest. In certain embodiments, an active tracrRNA sequence variant of a wild-type sequence comprises a nucleotide sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the nucleotide sequence set forth as SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125. In certain embodiments, an active tracrRNA sequence fragment of a wild-type sequence comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more contiguous nucleotides of the nucleotide sequence set forth as SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125.

[0056] Two polynucleotide sequences can be considered to be substantially complementary when the two sequences hybridize to each other under stringent conditions. Likewise, an RGN is considered to bind to a particular target sequence within a sequence-specific manner if the guide RNA bound to the RGN binds to the target sequence under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" is intended conditions under which the two polynucleotide sequences will hybridize to each other to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is at least about 30°C for short sequences (e.g., 10 to 50 nucleotides) and at least about 60°C for long sequences (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulfate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C. Optionally, wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash time will be at least a length of time sufficient to reach equilibrium.

[0057] The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched sequence. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284: $T_m = 81.5^\circ\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 0.61 (\% \text{ form}) - 500/L$; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York); and Ausubel et al., eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

[0058] The term "sequence specific" can also refer to the binding of a target sequence at a greater frequency than binding to a randomized background sequence.

[0059] The guide RNA can be a single guide RNA or a dual-guide RNA system. A single guide RNA comprises the crRNA and tracrRNA on a single molecule of RNA, whereas a dual-guide RNA system comprises a crRNA and a tracrRNA present on two distinct RNA molecules, hybridized to one another through at least a portion of the CRISPR repeat sequence of the crRNA and at least a portion of the tracrRNA, which may be fully or partially complementary to the CRISPR repeat sequence of the crRNA. In some of those embodiments wherein the guide RNA is a single guide RNA, the crRNA and tracrRNA are separated by a linker nucleotide sequence. In general, the linker nucleotide sequence is one that does not include complementary bases in order to avoid the formation of secondary structure within or comprising nucleotides of the linker nucleotide sequence. In some embodiments, the linker nucleotide sequence between the crRNA and tracrRNA is at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or more nucleotides in length. In particular embodiments, the linker nucleotide sequence of a single guide RNA is at least 4 nucleotides in

length. In certain embodiments, the linker nucleotide sequence is the nucleotide sequence set forth as SEQ ID NO: 249.

[0060] The single guide RNA or dual-guide RNA can be synthesized chemically or via *in vitro* transcription. Assays for determining sequence-specific binding between an RGN and a guide RNA are known in the art and include, but are not limited to, *in vitro* binding assays between an expressed RGN and the guide RNA, which can be tagged with a detectable label (e.g., biotin) and used in a pull-down detection assay in which the guide RNA:RGN complex is captured via the detectable label (e.g., with streptavidin beads). A control guide RNA with an unrelated sequence or structure to the guide RNA can be used as a negative control for non-specific binding of the RGN to RNA. In certain embodiments, the guide RNA is SEQ ID NO: 4, 11, 18, 25, 32, 39, 46, 53, 59, 66, 73, 79, 86, 92, 99, 106, 113, 120, or 126, wherein the spacer sequence can be any sequence and is indicated as a poly-N sequence.

[0061] In certain embodiments, the guide RNA can be introduced into a target cell, organelle, or non-human embryo as an RNA molecule. The guide RNA can be transcribed *in vitro* or chemically synthesized. In other embodiments, a nucleotide sequence encoding the guide RNA is introduced into the cell, organelle, or non-human embryo. In some of these embodiments, the nucleotide sequence encoding the guide RNA is operably linked to a promoter (e.g., an RNA polymerase III promoter). The promoter can be a native promoter or heterologous to the guide RNA-encoding nucleotide sequence.

[0062] In various embodiments, the guide RNA can be introduced into a target cell, organelle, or non-human embryo as a ribonucleoprotein complex, as described herein, wherein the guide RNA is bound to an RNA-guided nuclease polypeptide.

[0063] The guide RNA directs an associated RNA-guided nuclease to a particular target nucleotide sequence of interest through hybridization of the guide RNA to the target nucleotide sequence. A target nucleotide sequence can comprise DNA, RNA, or a combination of both and can be single-stranded or double-stranded. A target nucleotide sequence can be genomic DNA (*i.e.*, chromosomal DNA), plasmid DNA, or an RNA molecule (e.g., messenger RNA, ribosomal RNA, transfer RNA, micro RNA, small interfering RNA). The target nucleotide sequence can be bound (and in some embodiments, cleaved) by an RNA-guided nuclease *in vitro* or in a cell. The chromosomal sequence targeted by the RGN can be a nuclear, plastid or mitochondrial chromosomal sequence. In some embodiments, the target nucleotide sequence is unique in the target genome.

[0064] The target nucleotide sequence is adjacent to a protospacer adjacent motif (PAM). A protospacer adjacent motif is generally within about 1 to about 10 nucleotides from the target nucleotide sequence, including about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 nucleotides from the target nucleotide sequence. In particular embodiments, a PAM is within 1 to 10 nucleotides from the target nucleotide sequence, including 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the target nucleotide sequence. The PAM can be 5' or 3' of the target sequence. In some embodiments, the PAM is 3' of the target sequence for the presently disclosed RGNs. Generally, the PAM is a consensus sequence of about 3-4 nucleotides, but in particular embodiments it can be 2, 3, 4, 5, 6, 7, 8, 9, or more nucleotides in length. In various embodiments, the PAM sequence recognized by the presently disclosed RGNs comprises the consensus sequence set forth as SEQ ID NOs: 7, 14, 21, 28, 35, 42, 49, 62, 69, 79, 82, 95, 102, 109, or 116.

[0065] An RNA-guided nuclease having SEQ ID NO: 83 or an active variant or fragment thereof binds a target nucleotide sequence adjacent to a PAM sequence set forth as SEQ ID NO: 82. In some embodiments, the RGN binds to a guide sequence comprising a CRISPR repeat sequence set forth in SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, respectively, or an active variant or fragment thereof, and a tracrRNA sequence set forth in SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, respectively, or an active variant or fragment thereof. The RGN systems are described further in Examples 1-3 and Tables 1 and 2 of the present specification.

[0066] Variants of RGN APG05586 (SEQ ID NO: 63) were produced and have amino acid sequences of SEQ ID NOs: 570-579. RGNs having any one of SEQ ID NOs: 63 and 570-579 can bind a target nucleotide sequence adjacent to a PAM sequence set forth as SEQ ID NO: 79. These RGN systems are described further in Example 5 of the present specification.

[0067] It is well-known in the art that PAM sequence specificity for a given nuclease enzyme is affected by enzyme concentration (see, e.g., Karvelis *et al.* (2015) *Genome Biol* 16:253), which may be modified by altering the promoter used to express the RGN, or the amount of ribonucleoprotein complex delivered to the cell, organelle, or non-human embryo.

[0068] Upon recognizing its corresponding PAM sequence, the RGN can cleave the target nucleotide sequence at a specific cleavage site. As used herein, a cleavage site is made up of the two particular nucleotides within a target nucleotide sequence between which the nucleotide sequence is cleaved by an RGN. The cleavage site can comprise the 1st and 2nd, 2nd and 3rd, 3rd and 4th, 4th and 5th, 5th and 6th, 7th and 8th, or 8th and 9th nucleotides from the PAM in either the 5' or 3' direction. In some embodiments, the cleavage site may be over 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides from the PAM in either the 5' or 3' direction. As RGNs can cleave a target nucleotide sequence resulting in staggered ends, in some embodiments, the cleavage site is defined based on the distance of the two nucleotides from the PAM on the positive (+) strand of the polynucleotide and the distance of the two nucleotides from the PAM on the negative (-) strand of the polynucleotide.

III. Nucleotides Encoding RNA-guided nucleases, CRISPR RNA, and/or tracrRNA

[0069] The present disclosure provides polynucleotides comprising the presently disclosed CRISPR RNAs, tracrRNAs, and/or sgRNAs and polynucleotides comprising a nucleotide sequence encoding the presently disclosed RNA-guided nucleases, CRISPR RNAs, tracrRNAs, and/or sgRNAs. Presently disclosed polynucleotides include those comprising or encoding a CRISPR repeat sequence comprising the nucleotide sequence of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, or an active variant or fragment thereof that when comprised within a guide RNA is capable of directing the sequence-specific binding of an associated RNA-guided nuclease to a target sequence of interest. Also disclosed are polynucleotides comprising or encoding a tracrRNA comprising the nucleotide sequence of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, or an active variant or fragment thereof that when comprised within a guide RNA is capable of directing the sequence-specific binding of an associated RNA-guided nuclease to a target sequence of interest.

[0070] In accordance with the first aspect of the invention, polynucleotides are also provided that encode an RNA-guided nuclease comprising the amino acid sequence set forth as SEQ ID NO: 83, and active fragments or variants thereof that retain the ability to bind to a target nucleotide sequence in an RNA-guided sequence-specific manner.

[0071] The use of the term "polynucleotide" or "nucleic acid molecule" is not intended to limit the present disclosure to polynucleotides comprising DNA. Those of ordinary skill in the art will recognize that polynucleotides can comprise ribonucleotides (RNA) and combinations of ribonucleotides and deoxyribonucleotides. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. These include peptide nucleic acids (PNAs), PNA-DNA chimeras, locked nucleic acids (LNAs), and phosphothiorate linked sequences. The polynucleotides disclosed herein also encompass all forms of sequences including, but not limited to, single-stranded forms, double-stranded forms, DNA-RNA hybrids, triplex structures, stem-and-loop structures, and the like.

[0072] The nucleic acid molecules encoding RGNs can be codon optimized for expression in an organism of interest. A "codon-optimized" coding sequence is a polynucleotide coding sequence having its frequency of codon usage designed to mimic the frequency of preferred codon usage or transcription conditions of a particular host cell. Expression in the particular host cell or organism is enhanced as a result of the alteration of one or more codons at the nucleic acid level such that the translated amino acid sequence is not changed. Nucleic acid molecules can be codon optimized, either wholly or in part. Codon tables and other references providing preference information for a wide range of organisms are available in the art (see, e.g., Campbell and Gowri (1990) *Plant Physiol.* 92:1-11 for a discussion of plant-preferred codon usage). Methods are available in the art for synthesizing plant-preferred genes or mammalian (for example human) codon-optimized coding sequences. See, for example, U.S. Patent Nos. 5,380,831, and 5,436,391, and Murray et al. (1989) *Nucleic Acids Res.* 17:477-498.

[0073] Polynucleotides encoding the RGNs, crRNAs, tracrRNAs, and/or sgRNAs provided herein can be provided in expression cassettes for *in vitro* expression or expression in a cell, organelle, non-human embryo, or organism of interest. The cassette will include 5' and 3' regulatory sequences operably linked to a polynucleotide encoding an RGN, crRNA, tracrRNAs, and/or sgRNAs provided herein that allows for expression of the polynucleotide. The cassette may additionally contain at least one additional gene or genetic element to be cotransformed into the organism. Where additional genes or elements are included, the components are operably linked. The term "operably linked" is intended to mean a functional linkage between two or more elements. For example, an operable linkage between a promoter and a coding region of interest (e.g., region coding for an RGN, crRNA, tracrRNAs, and/or sgRNAs) is a functional link that allows for expression of the coding region of interest. Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein coding regions, by operably linked is intended that the coding regions are in the same reading frame. Alternatively, the additional gene(s) or element(s) can be provided on multiple expression cassettes. For example, the nucleotide sequence encoding a presently disclosed RGN can be present on one expression cassette, whereas the nucleotide sequence encoding a crRNA, tracrRNA, or complete guide RNA can be on a separate expression cassette. Such an expression cassette is provided with a plurality of restriction sites and/or recombination sites for insertion of the polynucleotides to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain a selectable marker gene.

[0074] The expression cassette will include in the 5'-3' direction of transcription, a transcriptional (and, in some embodiments, translational) initiation region (*i.e.*, a promoter), an RGN-, crRNA-, tracrRNA-and/or sgRNA- encoding polynucleotide in accordance with aspects of the invention, and a transcriptional (and in some embodiments, translational) termination region (*i.e.*, termination region) functional in the organism of interest. The promoters are capable of directing or driving expression of a coding sequence in a host cell. The regulatory regions (e.g., promoters, transcriptional regulatory regions, and translational termination regions) may be endogenous or heterologous to the host cell or to each other. As used herein, "heterologous" in reference to a sequence is a sequence that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

[0075] Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthase and nopaline synthase termination regions. See also Guerinneau et al. (1991) *Mol. Gen. Genet.* 262: 141-144; Proudfoot (1991) *Cell* 64:671-674; Sanfacon et al. (1991) *Genes Dev.* 5: 141-149; Mogen et al. (1990) *Plant Cell* 2:1261-1272; Munroe et al. (1990) *Gene* 91: 151-158; Ballas et al. (1989) *Nucleic Acids Res.* 17:7891-7903; and Joshi et al. (1987) *Nucleic Acids Res.* 15:9627-9639.

[0076] Additional regulatory signals include, but are not limited to, transcriptional initiation start sites, operators, activators, enhancers, other regulatory elements, ribosomal binding sites, an initiation codon, termination signals, and the like. See, for example, U.S. Pat. Nos.

5,039,523 and 4,853,331; EPO 0480762A2; Sambrook et al. (1992) *Molecular Cloning: A Laboratory Manual*, ed. Maniatis et al. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), hereinafter "Sambrook 11"; Davis et al., eds. (1980) *Advanced Bacterial Genetics* (Cold Spring Harbor Laboratory Press), Cold Spring Harbor, N.Y., and the references cited therein.

[0077] In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, *in vitro* mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.

[0078] A number of promoters can be used in the practice of the aspects of the invention. The promoters can be selected based on the desired outcome. The nucleic acids can be combined with constitutive, inducible, growth stage-specific, cell type-specific, tissue-preferred, tissue-specific, or other promoters for expression in the organism of interest. See, for example, promoters set forth in WO 99/43838 and in US Patent Nos: 8,575,425; 7,790,846; 8,147,856; 8,586,832; 7,772,369; 7,534,939; 6,072,050; 5,659,026; 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.

[0079] For expression in plants, constitutive promoters also include CaMV 35S promoter (Odell et al. (1985) *Nature* 313:810-812); rice actin (McElroy et al. (1990) *Plant Cell* 2:163-171); ubiquitin (Christensen et al. (1989) *Plant Mol. Biol.* 12:619-632 and Christensen et al. (1992) *Plant Mol. Biol.* 18:675-689); pEMU (Last et al. (1991) *Theor. Appl. Genet.* 81:581-588); and MAS (Velten et al. (1984) *EMBO J.* 3:2723-2730).

[0080] Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, the PDK promoter and the pepcarboxylase promoter which are both inducible by light. Also useful are promoters which are chemically inducible, such as the In2-2 promoter which is safener induced (U.S. Pat. No. 5,364,780), the Axig1 promoter which is auxin induced and tapetum specific but also active in callus (PCT US01/22169), the steroid-responsive promoters (see, for example, the ERE promoter which is estrogen induced, and the glucocorticoid-inducible promoter in Schena et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:10421-10425 and McNellis et al. (1998) *Plant J.* 14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz et al. (1991) *Mol. Gen. Genet.* 227:229-237, and U.S. Pat. Nos. 5,814,618 and 5,789,156).

[0081] Tissue-specific or tissue-preferred promoters can be utilized to target expression of an expression construct within a particular tissue. In certain embodiments, the tissue-specific or tissue-preferred promoters are active in plant tissue. Examples of promoters under developmental control in plants include promoters that initiate transcription preferentially in certain tissues, such as leaves, roots, fruit, seeds, or flowers. A "tissue specific" promoter is a promoter that initiates transcription only in certain tissues. Unlike constitutive expression of genes, tissue-specific expression is the result of several interacting levels of gene regulation. As such, promoters from homologous or closely related plant species can be preferable to use to achieve efficient and reliable expression of transgenes in particular tissues. In some embodiments, the expression comprises a tissue-preferred promoter. A "tissue preferred" promoter is a promoter that initiates transcription preferentially, but not necessarily entirely or solely in certain tissues.

[0082] In some embodiments, the nucleic acid molecules encoding an RGN, crRNA, and/or tracrRNA comprise a cell type-specific promoter. A "cell type specific" promoter is a promoter that primarily drives expression in certain cell types in one or more organs. Some examples of plant cells in which cell type specific promoters functional in plants may be primarily active include, for example, BETL cells, vascular cells in roots, leaves, stalk cells, and stem cells. The nucleic acid molecules can also include cell type preferred promoters. A "cell type preferred" promoter is a promoter that primarily drives expression mostly, but not necessarily entirely or solely in certain cell types in one or more organs. Some examples of plant cells in which cell type preferred promoters functional in plants may be preferentially active include, for example, BETL cells, vascular cells in roots, leaves, stalk cells, and stem cells.

[0083] The nucleic acid sequences encoding the RGNs, crRNAs, tracrRNAs, and/or sgRNAs can be operably linked to a promoter sequence that is recognized by a phage RNA polymerase for example, for *in vitro* mRNA synthesis. In such embodiments, the *in vitro*-transcribed RNA can be purified for use in the methods described herein. For example, the promoter sequence can be a T7, T3, or SP6 promoter sequence or a variation of a T7, T3, or SP6 promoter sequence. In such embodiments, the expressed protein and/or RNAs can be purified for use in the methods of genome modification described herein.

[0084] In certain embodiments, the polynucleotide encoding the RGN, crRNA, tracrRNA, and/or sgRNA also can be linked to a polyadenylation signal (e.g., SV40 polyA signal and other signals functional in plants) and/or at least one transcriptional termination sequence. Additionally, the sequence encoding the RGN also can be linked to sequence(s) encoding at least one nuclear localization signal, at least one cell-penetrating domain, and/or at least one signal peptide capable of trafficking proteins to particular subcellular locations, as described elsewhere herein.

[0085] The polynucleotide encoding the RGN, crRNA, tracrRNA, and/or sgRNA can be present in a vector or multiple vectors. A "vector" refers to a polynucleotide composition for transferring, delivering, or introducing a nucleic acid into a host cell. Suitable vectors include plasmid vectors, phagemids, cosmids, artificial/mini-chromosomes, transposons, and viral vectors (e.g., lentiviral vectors, adeno-associated viral vectors, baculoviral vector). The vector can comprise additional expression control sequences (e.g., enhancer

sequences, Kozak sequences, polyadenylation sequences, transcriptional termination sequences), selectable marker sequences (e.g., antibiotic resistance genes), origins of replication, and the like. Additional information can be found in "Current Protocols in Molecular Biology" Ausubel et al., John Wiley & Sons, New York, 2003 or "Molecular Cloning: A Laboratory Manual" Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 3rd edition, 2001.

[0086] The vector can also comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D).

[0087] In some embodiments, the expression cassette or vector comprising the sequence encoding the RGN polypeptide can further comprise a sequence encoding a crRNA and/or a tracrRNA, or the crRNA and tracrRNA combined to create a guide RNA. The sequence(s) encoding the crRNA and/or tracrRNA can be operably linked to at least one transcriptional control sequence for expression of the crRNA and/or tracrRNA in the organism or host cell of interest. For example, the polynucleotide encoding the crRNA and/or tracrRNA can be operably linked to a promoter sequence that is recognized by RNA polymerase III (Pol III). Examples of suitable Pol III promoters include, but are not limited to, mammalian U6, U3, H1, and 7SL RNA promoters and rice U6 and U3 promoters.

[0088] As indicated, expression constructs comprising nucleotide sequences encoding the RGNs, crRNA, tracrRNA, and/or sgRNA can be used to transform organisms of interest. Methods for transformation involve introducing a nucleotide construct into an organism of interest. By "introducing" is intended to introduce the nucleotide construct to the host cell in such a manner that the construct gains access to the interior of the host cell. The methods of the invention do not require a particular method for introducing a nucleotide construct to a host organism, only that the nucleotide construct gains access to the interior of at least one cell of the host organism. The host cell can be a eukaryotic or prokaryotic cell. In particular embodiments, the eukaryotic host cell is a plant cell, a mammalian cell, an avian cell, or an insect cell. In some embodiments, the eukaryotic cell that comprises or expresses a presently disclosed RGN or that has been modified by a presently disclosed RGN is a human cell. In some embodiments, the eukaryotic cell that comprises or expresses a presently disclosed RGN or that has been modified by a presently disclosed RGN is a cell of hematopoietic origin, such as an immune cell (i.e., a cell of the innate or adaptive immune system) including but not limited to a B cell, a T cell, a natural killer (NK) cell, a pluripotent stem cell, an induced pluripotent stem cell, a chimeric antigen receptor T (CAR-T) cell, a monocyte, a macrophage, and a dendritic cell.

[0089] Methods for introducing nucleotide constructs into plants and other host cells are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.

[0090] The methods result in a transformed organism, such as a plant, including whole plants, as well as plant organs (e.g., leaves, stems, roots, etc.), seeds, plant cells, propagules, plant embryos and progeny of the same. Plant cells can be differentiated or undifferentiated (e.g. callus, suspension culture cells, protoplasts, leaf cells, root cells, phloem cells, pollen).

[0091] "Transgenic organisms" or "transformed organisms" or "stably transformed" organisms or cells or tissues refers to organisms that have incorporated or integrated a polynucleotide encoding an RGN, crRNA, and/or tracrRNA in accordance with aspects of the invention. It is recognized that other exogenous or endogenous nucleic acid sequences or DNA fragments may also be incorporated into the host cell. *Agrobacterium*-and biolistic-mediated transformation remain the two predominantly employed approaches for transformation of plant cells. However, transformation of a host cell may be performed by infection, transfection, microinjection, electroporation, microprojection, biolistics or particle bombardment, electroporation, silica/carbon fibers, ultrasound mediated, PEG mediated, calcium phosphate co-precipitation, polycation DMSO technique, DEAE dextran procedure, and viral mediated, liposome mediated and the like. Viral-mediated introduction of a polynucleotide encoding an RGN, crRNA, and/or tracrRNA includes retroviral, lentiviral, adenoviral, and adeno-associated viral mediated introduction and expression, as well as the use of Caulimoviruses, Geminiviruses, and RNA plant viruses.

[0092] Transformation protocols as well as protocols for introducing polypeptides or polynucleotide sequences into plants may vary depending on the type of host cell (e.g., monocot or dicot plant cell) targeted for transformation. Methods for transformation are known in the art and include those set forth in US Patent Nos: 8,575,425; 7,692,068; 8,802,934; 7,541,517. See, also, Rakoczy-Trojanowska, M. (2002) Cell Mol Biol Lett. 7:849-858; Jones et al. (2005) Plant Methods 1:5; Rivera et al. (2012) Physics of Life Reviews 9:308-345; Bartlett et al. (2008) Plant Methods 4:1-12; Bates, G.W. (1999) Methods in Molecular Biology 111:359-366; Binns and Thomashow (1988) Annual Reviews in Microbiology 42:575-606; Christou, P. (1992) The Plant Journal 2:275-281; Christou, P. (1995) Euphytica 85:13-27; Tzfira et al. (2004) TRENDS in Genetics 20:375-383; Yao et al. (2006) Journal of Experimental Botany 57:3737-3746; Zupan and Zambryski (1995) Plant Physiology 107:1041-1047; Jones et al. (2005) Plant Methods 1:5;

[0093] Transformation may result in stable or transient incorporation of the nucleic acid into the cell. "Stable transformation" is intended to mean that the nucleotide construct introduced into a host cell integrates into the genome of the host cell and is capable of being inherited by the progeny thereof. "Transient transformation" is intended to mean that a polynucleotide is introduced into the host cell and does not integrate into the genome of the host cell.

[0094] Methods for transformation of chloroplasts are known in the art. See, for example, Svab et al. (1990) Proc. Natl. Acad. Sci. USA 87:8526-8530; Svab and Maliga (1993) Proc. Natl. Acad. Sci. USA 90:913-917; Svab and Maliga (1993) EMBO J. 12:601-606. The method relies on particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through

homologous recombination. Additionally, plastid transformation can be accomplished by transactivation of a silent plastid-borne transgene by tissue-preferred expression of a nuclear-encoded and plastid-directed RNA polymerase. Such a system has been reported in McBride et al. (1994) Proc. Natl. Acad. Sci. USA 91:7301-7305.

[0095] The cells that have been transformed may be grown into a transgenic organism, such as a plant, in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the present invention enables transformed seed (also referred to as "transgenic seed") having a nucleotide construct in accordance with aspects of the invention, for example, an expression cassette, stably incorporated into their genome.

[0096] Alternatively, cells that have been transformed may be introduced into an organism. These cells could have originated from the organism, wherein the cells are transformed in an *ex vivo* approach.

[0097] The sequences provided herein may be used for transformation of any plant species, including, but not limited to, monocots and dicots. Examples of plants of interest include, but are not limited to, corn (maize), sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape, Brassica sp., alfalfa, rye, millet, safflower, peanuts, sweet potato, cassava, coffee, coconut, pineapple, citrus trees, cocoa, tea, banana, avocado, fig, guava, mango, olive, papaya, cashew, macadamia, almond, oats, vegetables, ornamentals, and conifers.

[0098] Vegetables include, but are not limited to, tomatoes, lettuce, green beans, lima beans, peas, and members of the genus *Curcumis* such as cucumber, cantaloupe, and musk melon. Ornamentals include, but are not limited to, azalea, hydrangea, hibiscus, roses, tulips, daffodils, petunias, carnation, poinsettia, and chrysanthemum. Preferably, plants of the present invention are crop plants (for example, maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, oilseed rape, etc.).

[0099] As used herein, the term plant includes plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps, and plant cells that are intact in plants or parts of plants such as plant embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers, and the like. Grain is intended to mean the mature seed produced by commercial growers for purposes other than growing or reproducing the species. Progeny, variants, and mutants of the regenerated plants are also enabled by aspects of the invention, provided that these parts comprise the introduced polynucleotides. Further provided is a processed plant product or byproduct that retains the sequences disclosed herein, including for example, soymeal.

[0100] The polynucleotides encoding the RGNs, crRNAs, and/or tracrRNAs can also be used to transform any prokaryotic species, including but not limited to, archaea and bacteria (e.g., *Bacillus* sp., *Klebsiella* sp., *Streptomyces* sp., *Rhizobium* sp., *Escherichia* sp., *Pseudomonas* sp., *Salmonella* sp., *Shigella* sp., *Vibrio* sp., *Yersinia* sp., *Mycoplasma* sp., *Agrobacterium*, *Lactobacillus* sp.).

[0101] The polynucleotides encoding the RGNs, crRNAs, and/or tracrRNAs can be used to transform any eukaryotic species, including but not limited to animals (e.g., mammals, insects, fish, birds, and reptiles), fungi, amoeba, algae, and yeast.

[0102] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian, insect, or avian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of an RGN system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256: 808- 813 (1992); Nabel & Feigner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10): 1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and Immunology, Doerfler and Bohm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0103] Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam[™] and Lipofectin[™]). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration). The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291- 297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[0104] The use of RNA or DNA viral based systems for the delivery of nucleic acids takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

[0105] The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Viral. 66:2731-2739 (1992); Johann et al., J. Viral. 66: 1635-1640 (1992); Sommerfelt et al., Viral. 176:58-59 (1990); Wilson et al., J. Viral. 63:2374-2378 (1989); Miller et al., 1. Viral. 65:2220-2224 (1991); PCT/US94/05700).

[0106] In applications where transient expression is preferred, adenoviral based systems may be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus ("AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641; Katin, Human Gene Therapy 5:793-801 (1994); Muzyczka, 1. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., 1. Viral. 63:03822-3828 (1989). Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ 2 cells or PA317 cells, which package retrovirus.

[0107] Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide(s) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.

[0108] The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817.

[0109] In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. In some embodiments, the cell line may be mammalian, insect, or avian cells. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLaS3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panel, PC-3, TFI, CTLL-2, CIR, Rat6, CVI, RPTE, AIO, T24, 182, A375, ARH-77, Calul, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI- 231, HB56, TIB55, lurkat, 145.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial, BALB/3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-I cells, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C3H-10T1/2, C6/36, Cal-27, CHO, CHO-7, CHO-IR, CHO-KI, CHO-K2, CHO-T, CHO Dhfr-/-, COR-L23, COR-L23/CPR, COR-L235010, CORL23/ R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1, EMT6/AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepalcl7, HL-60, HMEC, HT-29, lurkat, /Y cells, K562 cells, Ku812, KCL22, KGI, KYOI, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCKII, MDCKII, MOR/ 0.2R, MONO-MAC 6, MTD-IA, MyEnd, NCI-H69/CPR, NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1, NW-145, OPCN/OPCT cell lines, Peer, PNT-IA/ PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THPI cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassas, Va.)).

[0110] In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of an RGN system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of

an RGN system, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells are used in assessing one or more test compounds.

[0111] In some embodiments, one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat, hamster, rabbit, cow, or pig. In some embodiments, the transgenic animal is a bird, such as a chicken or a duck. In some embodiments, the transgenic animal is an insect, such as a mosquito or a tick.

IV. Variants and Fragments of Polypeptides and Polynucleotides

[0112] The present disclosure provides, in accordance with aspects of the invention, active variants and fragments of a naturally-occurring (i.e., wild-type) RNA-guided nuclease, the amino acid sequence of which is set forth as SEQ ID NO: 83, as well as active variants and fragments of naturally-occurring CRISPR repeats, such as the sequence set forth as SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, and active variant and fragments of naturally-occurring tracrRNAs, such as the sequence set forth as SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, and polynucleotides encoding the same.

[0113] While the activity of a variant or fragment may be altered compared to the polynucleotide or polypeptide of interest, the variant and fragment should retain the functionality of the polynucleotide or polypeptide of interest. For example, a variant or fragment may have increased activity, decreased activity, different spectrum of activity or any other alteration in activity when compared to the polynucleotide or polypeptide of interest.

[0114] Fragments and variants of naturally-occurring RGN polypeptides, such as those disclosed herein, will retain sequence-specific, RNA-guided DNA-binding activity. In particular embodiments, fragments and variants of naturally-occurring RGN polypeptides, such as those disclosed herein, will retain nuclease activity (single-stranded or double-stranded).

[0115] Fragments and variants of naturally-occurring CRISPR repeats, such as those disclosed herein, will retain the ability, when part of a guide RNA (comprising a tracrRNA), to bind to and guide an RNA-guided nuclease (complexed with the guide RNA) to a target nucleotide sequence in a sequence-specific manner.

[0116] Fragments and variants of naturally-occurring tracrRNAs, such as those disclosed herein, will retain the ability, when part of a guide RNA (comprising a CRISPR RNA), to guide an RNA-guided nuclease (complexed with the guide RNA) to a target nucleotide sequence in a sequence-specific manner.

[0117] The term "fragment" refers to a portion of a polynucleotide or polypeptide sequence of the invention. "Fragments" or "biologically active portions" include polynucleotides comprising a sufficient number of contiguous nucleotides to retain the biological activity (i.e., binding to and directing an RGN in a sequence-specific manner to a target nucleotide sequence when comprised within a guideRNA). "Fragments" or "biologically active portions" include polypeptides comprising a sufficient number of contiguous amino acid residues to retain the biological activity (i.e., binding to a target nucleotide sequence in a sequence-specific manner when complexed with a guide RNA). Fragments of the RGN proteins include those that are shorter than the full-length sequences due to the use of an alternate downstream start site. A biologically active portion of an RGN protein can be a polypeptide that comprises, for example, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700 or more contiguous amino acid residues of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 43, 50, 56, 63, 70, 76, 83, 89, 96, 103, 110, 117, 123, or 570-579. Such biologically active portions can be prepared by recombinant techniques and evaluated for sequence-specific, RNA-guided DNA-binding activity. A biologically active fragment of a CRISPR repeat sequence can comprise at least 8 contiguous amino acids of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124. A biologically active portion of a CRISPR repeat sequence can be a polynucleotide that comprises, for example, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 contiguous nucleotides of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124. A biologically active portion of a tracrRNA can be a polynucleotide that comprises, for example, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110 or more contiguous nucleotides of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125.

[0118] In general, "variants" is intended to mean substantially similar sequences. For polynucleotides, a variant comprises a deletion and/or addition of one or more nucleotides at one or more internal sites within the native polynucleotide and/or a substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a "native" or "wild type" polynucleotide or polypeptide comprises a naturally occurring nucleotide sequence or amino acid sequence, respectively. For polynucleotides, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the native amino acid sequence of the gene of interest. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis but which still encode the polypeptide or the polynucleotide of interest. Generally, variants of a particular polynucleotide disclosed herein will have at least about

40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein.

[0119] Variants of a particular polynucleotide disclosed herein (*i.e.*, the reference polynucleotide) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide. Percent sequence identity between any two polypeptides can be calculated using sequence alignment programs and parameters described elsewhere herein. Where any given pair of polynucleotides disclosed herein is evaluated by comparison of the percent sequence identity shared by the two polypeptides they encode, the percent sequence identity between the two encoded polypeptides is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity.

[0120] In particular embodiments, the presently disclosed polynucleotides encode an RNA-guided nuclease polypeptide comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater identity to an amino acid sequence of SEQ ID NO: 83. An amino acid position of a first amino acid sequence "corresponding to" a particular position of a second amino acid sequence refers to the position in the first amino acid sequence when the first and second amino acid sequences are optimally aligned that lines up with the specified amino acid residue position in the second sequence.

[0121] A biologically active variant of an RGN polypeptide in accordance with aspects of the invention may differ by as few as about 1-15 amino acid residues, as few as about 1-10, such as about 6-10, as few as 5, as few as 4, as few as 3, as few as 2, or as few as 1 amino acid residue. In specific embodiments, the polypeptides can comprise an N-terminal or a C-terminal truncation, which can comprise at least a deletion of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700 amino acids or more from either the N or C terminus of the polypeptide.

[0122] In certain embodiments, the presently disclosed polynucleotides comprise or encode a CRISPR repeat comprising a nucleotide sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater identity to the nucleotide sequence set forth as SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124.

[0123] The presently disclosed polynucleotides can comprise or encode a tracrRNA comprising a nucleotide sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater identity to the nucleotide sequence set forth as SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125.

[0124] Biologically active variants of a CRISPR repeat or tracrRNA may differ by as few as about 1-15 nucleotides, as few as about 1-10, such as about 6-10, as few as 5, as few as 4, as few as 3, as few as 2, or as few as 1 nucleotide. In specific embodiments, the polynucleotides can comprise a 5' or 3' truncation, which can comprise at least a deletion of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 95, 100, 105, 110 nucleotides or more from either the 5' or 3' end of the polynucleotide.

[0125] It is recognized that modifications may be made to the RGN polypeptides, CRISPR repeats, and tracrRNAs provided herein creating variant proteins and polynucleotides. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques. Alternatively, native, as yet-unknown or as yet unidentified polynucleotides and/or polypeptides structurally and/or functionally-related to the sequences disclosed herein may also be identified that fall within the scope of the aspects of the present invention. Conservative amino acid substitutions may be made in nonconserved regions that do not alter the function of the RGN proteins. Alternatively, modifications may be made that improve the activity of the RGN.

[0126] Variant polynucleotides and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different RGN proteins disclosed herein (*e.g.*, SEQ ID NOs: 83) is manipulated to create a new RGN protein possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined *in vitro* or *in vivo*. For example, using this approach, sequence motifs encoding a domain of interest may be shuffled between the RGN sequences provided herein and other known RGN genes to obtain a new gene coding for a protein with an improved property of interest, such as an increased K_m in the case of an enzyme. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994) *Proc. Natl. Acad. Sci. USA* 91:10747-10751; Stemmer (1994) *Nature* 370:389-391; Cramer et al. (1997) *Nature Biotech.* 15:436-438; Moore et al. (1997) *J. Mol. Biol.* 272:336-347; Zhang et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:4504-4509; Cramer et al. (1998) *Nature* 391:288-291; and U.S. Patent Nos. 5,605,793 and 5,837,458. A "shuffled" nucleic acid is a nucleic acid produced by a shuffling procedure such as any shuffling procedure set forth herein. Shuffled nucleic acids are produced by recombining (physically or virtually) two or more nucleic acids (or character strings), for example in an artificial, and optionally recursive, fashion. Generally, one or more screening steps are used in shuffling processes to identify nucleic acids of interest; this screening step can be performed before or after any recombination step. In some (but not all) shuffling embodiments, it is desirable to perform multiple rounds of recombination prior to selection to increase the diversity of the pool to be screened. The overall process of recombination and selection are optionally repeated recursively. Depending on context, shuffling can refer to an overall process of recombination and selection, or, alternately, can simply refer to the recombinational portions of the overall process.

[0127] As used herein, "sequence identity" or "identity" in the context of two polynucleotides or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically, this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).

[0128] As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

[0129] Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity and % similarity for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nws gapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. By "equivalent program" is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.

[0130] Two sequences are "optimally aligned" when they are aligned for similarity scoring using a defined amino acid substitution matrix (e.g., BLOSUM62), gap existence penalty and gap extension penalty so as to arrive at the highest score possible for that pair of sequences. Amino acid substitution matrices and their use in quantifying the similarity between two sequences are well-known in the art and described, e.g., in Dayhoff et al. (1978) "A model of evolutionary change in proteins." In "Atlas of Protein Sequence and Structure," Vol. 5, Suppl. 3 (ed. M. O. Dayhoff), pp. 345-352. Natl. Biomed. Res. Found., Washington, D.C. and Henikoff et al. (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919. The BLOSUM62 matrix is often used as a default scoring substitution matrix in sequence alignment protocols. The gap existence penalty is imposed for the introduction of a single amino acid gap in one of the aligned sequences, and the gap extension penalty is imposed for each additional empty amino acid position inserted into an already opened gap. The alignment is defined by the amino acids positions of each sequence at which the alignment begins and ends, and optionally by the insertion of a gap or multiple gaps in one or both sequences, so as to arrive at the highest possible score. While optimal alignment and scoring can be accomplished manually, the process is facilitated by the use of a computer-implemented alignment algorithm, e.g., gapped BLAST 2.0, described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402, and made available to the public at the National Center for Biotechnology Information Website (www.ncbi.nlm.nih.gov). Optimal alignments, including multiple alignments, can be prepared using, e.g., PSI-BLAST, available through www.ncbi.nlm.nih.gov and described by Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402.

[0131] With respect to an amino acid sequence that is optimally aligned with a reference sequence, an amino acid residue "corresponds to" the position in the reference sequence with which the residue is paired in the alignment. The "position" is denoted by a number that sequentially identifies each amino acid in the reference sequence based on its position relative to the N-terminus. Owing to deletions, insertion, truncations, fusions, etc., that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence as determined by simply counting from the N-terminal will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where there is a deletion in an aligned test sequence, there will be no amino acid that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to any amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

V. Antibodies

[0132] Antibodies to the RGN polypeptides or ribonucleoproteins comprising the RGN polypeptides of the fourth aspect of the present invention, including those having the amino acid sequence set forth as SEQ ID NO: 83 or active variants or fragments thereof, are also enabled. Methods for producing antibodies are well known in the art (see, for example, Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; and U.S. Pat. No. 4,196,265). These antibodies can be used in kits for the detection and isolation of RGN polypeptides or ribonucleoproteins. Thus, this disclosure provides kits comprising antibodies that specifically bind to the polypeptides or ribonucleoproteins described herein, including, for example, polypeptides having the sequence of SEQ ID NO: 83.

VI. Systems and Ribonucleoprotein Complexes for Binding a Target Sequence of Interest and Methods of Making the Same

[0133] The present disclosure provides a system in accordance with the fifth aspect of the invention for binding a target sequence of interest, wherein the system comprises at least one guide RNA or a nucleotide sequence encoding the same, and at least one RNA-guided nuclease or a nucleotide sequence encoding the same. The guide RNA hybridizes to the target sequence of interest and also forms a complex with the RGN polypeptide, thereby directing the RGN polypeptide to bind to the target sequence. The RGN comprises an amino acid sequence of SEQ ID NO: 83, or an active variant or fragment thereof in accordance with the fourth aspect of the invention. In various embodiments, the guide RNA comprises a CRISPR repeat sequence comprising the nucleotide sequence of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, or an active variant or fragment thereof. In particular embodiments, the guide RNA comprises a tracrRNA comprising a nucleotide sequence of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, or an active variant or fragment thereof. The guide RNA of the system can be a single guide RNA or a dual-guide RNA. In particular embodiments, the system comprises an RNA-guided nuclease that is heterologous to the guideRNA, wherein the RGN and guideRNA are not found complexed to one another (i.e., bound to one another) in nature.

[0134] The system for binding a target sequence of interest provided herein can be a ribonucleoprotein complex, which is at least one molecule of an RNA bound to at least one protein. The ribonucleoprotein complexes provided herein comprise at least one guide RNA as the RNA component and an RNA-guided nuclease as the protein component. Such ribonucleoprotein complexes can be purified from a cell or organism that naturally expresses an RGN polypeptide and has been engineered to express a particular guide RNA that is specific for a target sequence of interest. Alternatively, the ribonucleoprotein complex can be purified from a cell or organism that has been transformed with polynucleotides that encode an RGN polypeptide and a guide RNA and cultured under conditions to allow for the expression of the RGN polypeptide and guide RNA. Thus, methods are provided for making an RGN polypeptide or an RGN ribonucleoprotein complex. Such methods comprise culturing a cell comprising a nucleotide sequence encoding an RGN polypeptide, and in some embodiments a nucleotide sequence encoding a guide RNA, under conditions in which the RGN polypeptide (and in some embodiments, the guide RNA) is expressed. The RGN polypeptide or RGN ribonucleoprotein can then be purified from a lysate of the cultured cells.

[0135] Methods for purifying an RGN polypeptide or RGN ribonucleoprotein complex from a lysate of a biological sample are known in the art (e.g., size exclusion and/or affinity chromatography, 2D-PAGE, HPLC, reversed-phase chromatography, immunoprecipitation). In particular methods, the RGN polypeptide is recombinantly produced and comprises a purification tag to aid in its purification, including but not limited to, glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, HA, nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, 6xHis, 10xHis, biotin carboxyl carrier protein (BCCP), and calmodulin. Generally, the tagged RGN polypeptide or RGN ribonucleoprotein complex is purified using immobilized metal affinity chromatography. It will be appreciated that other similar methods known in the art may be used, including other forms of chromatography or for example immunoprecipitation, either alone or in combination.

[0136] An "isolated" or "purified" polypeptide, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the polypeptide as found in its naturally occurring environment. Thus, an isolated or purified polypeptide is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of contaminating protein. When the protein of the fourth aspect of the invention or biologically active portion thereof is recombinantly produced, optimally culture medium represents less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.

[0137] Particular methods provided herein for binding and/or cleaving a target sequence of interest involve the use of an *in vitro* assembled RGN ribonucleoprotein complex. *In vitro* assembly of an RGN ribonucleoprotein complex can be performed using any method known in the art in which an RGN polypeptide is contacted with a guide RNA under conditions to allow for binding of the RGN polypeptide to the guide RNA. As used herein, "contact", "contacting", "contacted," refer to placing the components of a desired reaction together under conditions suitable for carrying out the desired reaction. The RGN polypeptide can be purified from a biological sample, cell lysate, or culture medium, produced via *in vitro* translation, or chemically synthesized. The guide RNA can be purified from a biological sample, cell lysate, or culture medium, transcribed *in vitro*, or chemically synthesized. The RGN polypeptide and guide RNA can be brought into contact in solution (e.g., buffered saline solution) to allow for *in vitro* assembly of the RGN ribonucleoprotein complex.

VII. Methods of Binding, Cleaving, or Modifying a Target Sequence

[0138] The present disclosure provides *in vitro* and *ex vivo* methods for binding, cleaving, and/or modifying a target nucleotide sequence of interest in accordance with aspects of the invention. The methods include delivering a system comprising at least one guide RNA or a polynucleotide encoding the same, and at least one RGN polypeptide or a polynucleotide encoding the same to the target sequence or a cell, organelle, or non-human embryo comprising the target sequence, wherein the method is not a process for modifying the germ line identity of a human being. The RGN comprises the amino acid sequence of SEQ ID NO: 83, or an active variant or fragment thereof in

accordance with the fourth aspect of the invention. In various embodiments, the guide RNA comprises a CRISPR repeat sequence comprising the nucleotide sequence of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, or an active variant or fragment thereof. In particular embodiments, the guide RNA comprises a tracrRNA comprising the nucleotide sequence of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, or an active variant or fragment thereof. The guide RNA of the system can be a single guide RNA or a dual-guide RNA. The RGN of the system may be nuclease dead RGN, have nickase activity, or may be a fusion polypeptide. In some embodiments, the fusion polypeptide comprises a base-editing polypeptide, for example a cytidine deaminase or an adenosine deaminase. In other embodiments, the RGN fusion protein comprises a reverse transcriptase. In other embodiments, the RGN fusion protein comprises a polypeptide that recruits members of a functional nucleic acid repair complex, such as a member of the nucleotide excision repair (NER) or transcription coupled-nucleotide excision repair (TC-NER) pathway (Wei et al., 2015, PNAS USA 112(27):E3495-504 ; Troelstra et al., 1992, Cell 71:939-953; Marnef et al., 2017, J Mol Biol 429(9):1277-1288), as described in U.S. Provisional Application No. 62/966,203, which was filed on January 27, 2020, and is incorporated by reference in its entirety. In some embodiments, the RGN fusion protein comprises CSB (van den Boom et al., 2004, J Cell Biol 166(1):27-36; van Gool et al., 1997, EMBO J 16(19):5955-65; an example of which is set forth as SEQ ID NO: 608), which is a member of the TC-NER (nucleotide excision repair) pathway and functions in the recruitment of other members. In further embodiments, the RGN fusion protein comprises an active domain of CSB, such as the acidic domain of CSB which comprises amino acid residues 356-394 of SEQ ID NO: 608 (Teng et al., 2018, Nat Commun 9(1):4115).

[0139] In particular embodiments, the RGN and/or guide RNA is heterologous to the cell, organelle, or non-human embryo to which the RGN and/or guide RNA (or polynucleotide(s) encoding at least one of the RGN and guide RNA) are introduced.

[0140] In those embodiments wherein the method comprises delivering a polynucleotide encoding a guide RNA and/or an RGN polypeptide, the cell or non-human embryo can then be cultured under conditions in which the guide RNA and/or RGN polypeptide are expressed. In various embodiments, the method comprises contacting a target sequence with an RGN ribonucleoprotein complex. The RGN ribonucleoprotein complex may comprise an RGN that is nuclease dead or has nickase activity. In some embodiments, the RGN of the ribonucleoprotein complex is a fusion polypeptide comprising a base-editing polypeptide. In certain embodiments, the method comprises introducing into a cell, organelle, or non-human embryo comprising a target sequence an RGN ribonucleoprotein complex. The RGN ribonucleoprotein complex can be one that has been purified from a biological sample, recombinantly produced and subsequently purified, or *in vitro*-assembled as described herein. In those embodiments wherein the RGN ribonucleoprotein complex that is contacted with the target sequence or a cell organelle, or non-human embryo has been assembled *in vitro*, the method can further comprise the *in vitro* assembly of the complex prior to contact with the target sequence, cell, organelle, or non-human embryo.

[0141] A purified or *in vitro* assembled RGN ribonucleoprotein complex can be introduced into a cell, organelle, or non-human embryo using any method known in the art, including, but not limited to electroporation. Alternatively, an RGN polypeptide and/or polynucleotide encoding or comprising the guide RNA can be introduced into a cell, organelle, or non-human embryo using any method known in the art (e.g., electroporation).

[0142] Upon delivery to or contact with the target sequence or cell, organelle, or non-human embryo comprising the target sequence, the guide RNA directs the RGN to bind to the target sequence in a sequence-specific manner. In those embodiments wherein the RGN has nuclease activity, the RGN polypeptide cleaves the target sequence of interest upon binding. The target sequence can subsequently be modified via endogenous repair mechanisms, such as non-homologous end joining, or homology-directed repair with a provided donor polynucleotide.

[0143] Methods to measure binding of an RGN polypeptide to a target sequence are known in the art and include chromatin immunoprecipitation assays, gel mobility shift assays, DNA pull-down assays, reporter assays, microplate capture and detection assays. Likewise, methods to measure cleavage or modification of a target sequence are known in the art and include *in vitro* or *in vivo* cleavage assays wherein cleavage is confirmed using PCR, sequencing, or gel electrophoresis, with or without the attachment of an appropriate label (e.g., radioisotope, fluorescent substance) to the target sequence to facilitate detection of degradation products. Alternatively, the nicking triggered exponential amplification reaction (NTEPAR) assay can be used (see, e.g., Zhang et al. (2016) Chem. Sci. 7:4951-4957). *In vivo* cleavage can be evaluated using the Surveyor assay (Guschin et al. (2010) Methods Mol Biol 649:247-256).

[0144] In some embodiments, the methods involve the use of a single type of RGN complexed with more than one guide RNA. The more than one guide RNA can target different regions of a single gene or can target multiple genes.

[0145] In those embodiments wherein a donor polynucleotide is not provided, a double-stranded break introduced by an RGN polypeptide can be repaired by a non-homologous end-joining (NHEJ) repair process. Due to the error-prone nature of NHEJ, repair of the double-stranded break can result in a modification to the target sequence. As used herein, a "modification" in reference to a nucleic acid molecule refers to a change in the nucleotide sequence of the nucleic acid molecule, which can be a deletion, insertion, or substitution of one or more nucleotides, or a combination thereof. Modification of the target sequence can result in the expression of an altered protein product or inactivation of a coding sequence.

[0146] In those embodiments wherein a donor polynucleotide is present, the donor sequence in the donor polynucleotide can be integrated into or exchanged with the target nucleotide sequence during the course of repair of the introduced double-stranded break, resulting in the introduction of the exogenous donor sequence. A donor polynucleotide thus comprises a donor sequence that is desired to be introduced into a target sequence of interest. In some embodiments, the donor sequence alters the original target nucleotide

sequence such that the newly integrated donor sequence will not be recognized and cleaved by the RGN. Integration of the donor sequence can be enhanced by the inclusion within the donor polynucleotide of flanking sequences, referred to herein as "homology arms" that have substantial sequence identity with the sequences flanking the target nucleotide sequence, allowing for a homology-directed repair process. In some embodiments, homology arms have a length of at least 50 base pairs, at least 100 base pairs, and up to 2000 base pairs or more, and have at least 90%, at least 95%, or more, sequence homology to their corresponding sequence within the target nucleotide sequence.

[0147] In those embodiments wherein the RGN polypeptide introduces double-stranded staggered breaks, the donor polynucleotide can comprise a donor sequence flanked by compatible overhangs, allowing for direct ligation of the donor sequence to the cleaved target nucleotide sequence comprising overhangs by a non-homologous repair process during repair of the double-stranded break.

[0148] In those embodiments wherein the method involves the use of an RGN that is a nickase (*i.e.*, is only able to cleave a single strand of a double-stranded polynucleotide), the method can comprise introducing two RGN nickases that target identical or overlapping target sequences and cleave different strands of the polynucleotide. For example, an RGN nickase that only cleaves the positive (+) strand of a double-stranded polynucleotide can be introduced along with a second RGN nickase that only cleaves the negative (-) strand of a double-stranded polynucleotide.

[0149] In various embodiments, a method is enabled for binding a target nucleotide sequence and detecting the target sequence, wherein the method comprises introducing into a cell, organelle, or non-human embryo at least one guide RNA or a polynucleotide encoding the same, and at least one RGN polypeptide or a polynucleotide encoding the same, expressing the guide RNA and/or RGN polypeptide (if coding sequences are introduced), wherein the RGN polypeptide is a nuclease-dead RGN and further comprises a detectable label, and the method further comprises detecting the detectable label. The detectable label may be fused to the RGN as a fusion protein (*e.g.*, fluorescent protein) or may be a small molecule conjugated to or incorporated within the RGN polypeptide that can be detected visually or by other means.

[0150] Also enabled herein are methods for modulating the expression of a target sequence or a gene of interest under the regulation of a target sequence. The methods comprise introducing into a cell, organelle, or non-human embryo at least one guide RNA or a polynucleotide encoding the same, and at least one RGN polypeptide or a polynucleotide encoding the same, expressing the guide RNA and/or RGN polypeptide (if coding sequences are introduced), wherein the RGN polypeptide is a nuclease-dead RGN. In some of these embodiments, the nuclease-dead RGN is a fusion protein comprising an expression modulator domain (*i.e.*, epigenetic modification domain, transcriptional activation domain or a transcriptional repressor domain) as described herein.

[0151] The present disclosure also enables methods for binding and/or modifying a target nucleotide sequence of interest. The methods include delivering a system comprising at least one guide RNA or a polynucleotide encoding the same, and at least one fusion polypeptide comprising an RGN of the invention and a base-editing polypeptide, for example a cytidine deaminase or an adenosine deaminase, or a polynucleotide encoding the fusion polypeptide, to the target sequence or a cell, organelle, or non-human embryo comprising the target sequence.

[0152] One of ordinary skill in the art will appreciate that any of the presently disclosed methods can be used to target a single target sequence or multiple target sequences. Thus, methods comprise the use of a single RGN polypeptide in combination with multiple, distinct guide RNAs, which can target multiple, distinct sequences within a single gene and/or multiple genes. Also encompassed herein are methods wherein multiple, distinct guide RNAs are introduced in combination with multiple, distinct RGN polypeptides. These guide RNAs and guide RNA/RGN polypeptide systems can target multiple, distinct sequences within a single gene and/or multiple genes.

[0153] In one aspect, the invention enables kits containing any one or more of the elements disclosed in the above methods and compositions. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a DNA sequence encoding the crRNA sequence and one or more insertion sites for inserting a guide sequence upstream of the encoded crRNA sequence, wherein when expressed, the guide sequence directs sequence-specific binding of an RGN complex to a target sequence in a eukaryotic cell, wherein the RGN complex comprises an RGN enzyme complexed with the guide RNA polynucleotide; and/or (b) a second regulatory element operably linked to an enzyme coding sequence encoding said RGN enzyme comprising a nuclear localization sequence. Elements may be provided individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube.

[0154] In some embodiments, the kit includes instructions in one or more languages. In some embodiments, a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein. Reagents may be provided in any suitable container. For example, a kit may provide one or more reaction or storage buffers. Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (*e.g.* in concentrate or lyophilized form). A buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10.

[0155] In some embodiments, the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element. In some embodiments, the kit comprises a homologous recombination template polynucleotide. In one aspect, the invention provides methods for using one or more elements of an RGN

system. The RGN system of the invention provides an effective means for modifying a target polynucleotide. The RGN system of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating, base editing) a target polynucleotide in a multiplicity of cell types. As such the RGN system of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis. An exemplary RGN system, or RGN complex, comprises an RGN enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide.

VIII. Target Polynucleotides

[0156] In accordance with aspects of the invention, the invention provides for *in vitro* or *ex vivo* methods of modifying a target polynucleotide in a eukaryotic cell, wherein the methods are not processes for modifying the germ line genetic identity of human beings. In some embodiments, the method comprises sampling a cell or population of cells from a human or non-human animal or plant (including microalgae) and modifying the cell or cells. Culturing may occur at any stage *ex vivo*. The cell or cells may even be re-introduced into the non-human animal or plant (including microalgae).

[0157] Using natural variability, plant breeders combine most useful genes for desirable qualities, such as yield, quality, uniformity, hardiness, and resistance against pests. These desirable qualities also include growth, day length preferences, temperature requirements, initiation date of floral or reproductive development, fatty acid content, insect resistance, disease resistance, nematode resistance, fungal resistance, herbicide resistance, tolerance to various environmental factors including drought, heat, wet, cold, wind, and adverse soil conditions including high salinity. The sources of these useful genes include native or foreign varieties, heirloom varieties, wild plant relatives, and induced mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome for sources of useful genes, and in varieties having desired characteristics or traits employ the present invention to induce the rise of useful genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.

[0158] The target polynucleotide of an RGN system can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA). Without wishing to be bound by theory, the target sequence should be associated with a PAM (protospacer adjacent motif); that is, a short sequence recognized by the RGN system. The precise sequence and length requirements for the PAM differ depending on the RGN used, but PAMs are typically 2-5 base pair sequences adjacent the protospacer (that is, the target sequence).

[0159] The target polynucleotide of an RGN system may include a number of disease-associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides. Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non-disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease (e.g., a causal mutation). The transcribed or translated products may be known or unknown, and further may be at a normal or abnormal level. In some embodiments, the disease may be an animal disease. In some embodiments, the disease may be an avian disease. In other embodiments, the disease may be a mammalian disease. In further embodiments, the disease may be a human disease. Examples of disease-associated genes and polynucleotides in humans are available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World Wide Web.

[0160] Although RGN systems are particularly useful for their relative ease in targeting to genomic sequences of interest, there still remains an issue of what the RGN can do to address a causal mutation. One approach is to produce a fusion protein between an RGN (preferably an inactive or nickase variant of the RGN) and a base-editing enzyme or the active domain of a base editing enzyme, such as a cytidine deaminase or an adenosine deaminase base editor (U.S. Patent No. 9,840,699). In some embodiments, the methods comprise contacting a DNA molecule with (a) a fusion protein comprising an RGN in accordance with aspects of the invention and a base-editing polypeptide such as a deaminase; and (b) a gRNA targeting the fusion protein of (a) to a target nucleotide sequence of the DNA strand; wherein the DNA molecule is contacted with the fusion protein and the gRNA in an amount effective and under conditions suitable for the deamination of a nucleobase. In some embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder, and wherein the deamination of the nucleobase results in a sequence that is not associated with a disease or disorder. In some embodiments, the target DNA sequence resides in an allele of a crop plant, wherein the particular allele of the trait of interest results in a plant of lesser agronomic value. The deamination of the nucleobase results in an allele that improves the trait and increases the agronomic value of the plant.

[0161] In some embodiments, the DNA sequence comprises a T→C or A→G point mutation associated with a disease or disorder, and wherein the deamination of the mutant C or G base results in a sequence that is not associated with a disease or disorder. In some

embodiments, the deamination corrects a point mutation in the sequence associated with the disease or disorder.

[0162] In some embodiments, the sequence associated with the disease or disorder encodes a protein, and wherein the deamination introduces a stop codon into the sequence associated with the disease or disorder, resulting in a truncation of the encoded protein. In some embodiments, the contacting is performed *in vivo* in a subject susceptible to having, having, or diagnosed with the disease or disorder. In some embodiments, the disease or disorder is a disease associated with a point mutation, or a single-base mutation, in the genome. In some embodiments, the disease is a genetic disease, a cancer, a metabolic disease, or a lysosomal storage disease.

IX. Pharmaceutical Compositions and Methods of Treatment

[0163] Pharmaceutical compositions comprising the presently disclosed RGN polypeptides and active variants and fragments thereof, as well as polynucleotides encoding the same, the presently disclosed gRNAs or polynucleotides encoding the same, the presently disclosed systems, or cells comprising any of the RGN polypeptides or RGN-encoding polynucleotides, gRNA or gRNA-encoding polynucleotides, or the RGN systems, and a pharmaceutically acceptable carrier are enabled.

[0164] A pharmaceutical composition is a composition that is employed to prevent, reduce in intensity, cure or otherwise treat a target condition or disease that comprises an active ingredient (i.e., RGN polypeptides, RGN-encoding polynucleotides, gRNA, gRNA-encoding polynucleotides, RGN systems, or cells comprising any one of these) and a pharmaceutically acceptable carrier.

[0165] As used herein, a "pharmaceutically acceptable carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the activity and properties of the active ingredient (i.e., RGN polypeptides, RGN-encoding polynucleotides, gRNA, gRNA-encoding polynucleotides, RGN systems, or cells comprising any one of these). Carriers must be of sufficiently high purity and of sufficiently low toxicity to render them suitable for administration to a subject being treated. The carrier can be inert, or it can possess pharmaceutical benefits. In some embodiments, a pharmaceutically acceptable carrier comprises one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal. In some embodiments, the pharmaceutically acceptable carrier is not naturally-occurring. In some embodiments, the pharmaceutically acceptable carrier and the active ingredient are not found together in nature.

[0166] Pharmaceutical compositions used in the presently disclosed methods can be formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations are known to those skilled in the art. See, e.g., Remington, *The Science and Practice of Pharmacy* (21st ed. 2005). Suitable formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN vesicles), lipid nanoparticles, DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Pharmaceutical compositions for oral or parenteral use may be prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.

[0167] In some embodiments wherein cells comprising or modified with the presently disclosed RGN, gRNAs, RGN systems or polynucleotides encoding the same are administered to a subject, the cells are administered as a suspension with a pharmaceutically acceptable carrier. One of skill in the art will recognize that a pharmaceutically acceptable carrier to be used in a cell composition will not include buffers, compounds, cryopreservation agents, preservatives, or other agents in amounts that substantially interfere with the viability of the cells to be delivered to the subject. A formulation comprising cells can include e.g., osmotic buffers that permit cell membrane integrity to be maintained, and optionally, nutrients to maintain cell viability or enhance engraftment upon administration. Such formulations and suspensions are known to those of skill in the art and/or can be adapted for use with the cells described herein using routine experimentation.

[0168] A cell composition can also be emulsified or presented as a liposome composition, provided that the emulsification procedure does not adversely affect cell viability. The cells and any other active ingredient can be mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient, and in amounts suitable for use in the therapeutic methods described herein.

[0169] Additional agents included in a cell composition can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

[0170] Physiologically tolerable and pharmaceutically acceptable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are

glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions. The amount of an active compound used in the cell compositions that is effective in the treatment of a particular disorder or condition can depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.

[0171] The presently disclosed RGN polypeptides, guide RNAs, RGN systems or polynucleotides encoding the same can be formulated with pharmaceutically acceptable excipients such as carriers, solvents, stabilizers, adjuvants, diluents, etc., depending upon the particular mode of administration and dosage form. In some embodiments, these pharmaceutical compositions are formulated to achieve a physiologically compatible pH, and range from a pH of about 3 to a pH of about 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In some embodiments, the pH can be adjusted to a range from about pH 5.0 to about pH 8. In some embodiments, the compositions can comprise a therapeutically effective amount of at least one compound as described herein, together with one or more pharmaceutically acceptable excipients. In some embodiments, the compositions comprise a combination of the compounds described herein, or include a second active ingredient useful in the treatment or prevention of bacterial growth (for example and without limitation, anti-bacterial or anti-microbial agents), or include a combination of reagents of the present disclosure.

[0172] Suitable excipients include, for example, carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Other exemplary excipients can include antioxidants (for example and without limitation, ascorbic acid), chelating agents (for example and without limitation, EDTA), carbohydrates (for example and without limitation, dextrin, hydroxyalkylcellulose, and hydroxyalkylmethylcellulose), stearic acid, liquids (for example and without limitation, oils, water, saline, glycerol and ethanol), wetting or emulsifying agents, pH buffering substances, and the like.

[0173] In some embodiments, the formulations are provided in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring the addition of the sterile liquid carrier, for example, saline, water-for-injection, a semiliquid foam, or gel, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. In some embodiments, the active ingredient is dissolved in a buffered liquid solution that is frozen in a unit-dose or multi-dose container and later thawed for injection or kept/stabilized under refrigeration until use.

[0174] The therapeutic agent(s) may be contained in controlled release systems. In order to prolong the effect of a drug, it often is desirable to slow the absorption of the drug from subcutaneous, intrathecal, or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. In some embodiments, the use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term sustained release implants are well-known to those of ordinary skill in the art.

[0175] Methods of treating a disease in a subject in need thereof are enabled. The methods comprise administering to a subject in need thereof an effective amount of a presently disclosed RGN polypeptide or active variant or fragment thereof or a polynucleotide encoding the same, a presently disclosed gRNA or a polynucleotide encoding the same, a presently disclosed RGN system, or a cell modified by or comprising any one of these compositions.

[0176] In some embodiments, the treatment comprises *in vivo* gene editing by administering a presently disclosed RGN polypeptide, gRNA, or RGN system or polynucleotide(s) encoding the same, wherein the treatment is not a process for modifying the germ line genetic identity of a human being. In some embodiments, the treatment comprises *ex vivo* gene editing wherein cells are genetically modified *ex vivo* with a presently disclosed RGN polypeptide, gRNA, or RGN system or polynucleotide(s) encoding the same and then the modified cells are administered to a subject. In some embodiments, the genetically modified cells originate from the subject that is then administered the modified cells, and the transplanted cells are referred to herein as autologous. In some embodiments, the genetically modified cells originate from a different subject (i.e., donor) within the same species as the subject that is administered the modified cells (i.e., recipient), and the transplanted cells are referred to herein as allogeneic. In some examples described herein, the cells can be expanded in culture prior to administration to a subject in need thereof.

[0177] In some embodiments, the disease to be treated with the presently disclosed compositions is one that can be treated with immunotherapy, such as with a chimeric antigen receptor (CAR) T cell. Such diseases include but are not limited to cancer. In some embodiments, the disease to be treated with the presently disclosed compositions is associated with a causal mutation. As used herein, a "causal mutation" refers to a particular nucleotide, nucleotides, or nucleotide sequence in the genome that contributes to the severity or presence of a disease or disorder in a subject. The correction of the causal mutation leads to the improvement of at least one symptom resulting from a disease or disorder. In some embodiments, the causal mutation is adjacent to a PAM site recognized by an RGN disclosed herein. The causal mutation can be corrected with a presently disclosed RGN or a fusion polypeptide comprising a presently disclosed RGN and a base-editing polypeptide (i.e., a base editor). Non-limiting examples of diseases associated with a causal mutation include cystic fibrosis, Hurler syndrome, Friedreich's Ataxia, Huntington's Disease, and sickle cell disease. In some embodiments, the disease to be treated with the presently disclosed RGNs is a disease listed in Table 11. Additional non-limiting examples of disease-associated genes and mutations are available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World Wide Web.

[0178] As used herein, "treatment" or "treating," or "palliating" or "ameliorating" are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. For prophylactic benefit, the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.

[0179] The term "effective amount" or "therapeutically effective amount" refers to the amount of an agent that is sufficient to effect beneficial or desired results. The therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, and the delivery system in which it is carried.

[0180] The term "administering" refers to the placement of an active ingredient into a subject, by a method or route that results in at least partial localization of the introduced active ingredient at a desired site, such as a site of injury or repair, such that a desired effect(s) is produced. In those embodiments wherein cells are administered, the cells can be administered by any appropriate route that results in delivery to a desired location in the subject where at least a portion of the implanted cells or components of the cells remain viable. The period of viability of the cells after administration to a subject can be as short as a few hours, e.g., twenty-four hours, to a few days, to as long as several years, or even the life time of the patient, i.e., long-term engraftment. For example, in some aspects described herein, an effective amount of photoreceptor cells or retinal progenitor cells is administered via a systemic route of administration, such as an intraperitoneal or intravenous route.

[0181] In some embodiments, the administering comprises administering by viral delivery. In some embodiments, the administering comprises administering by electroporation. In some embodiments, the administering comprises administering by nanoparticle delivery. In some embodiments, the administering comprises administering by liposome delivery. Any effective route of administration can be used to administer an effective amount of a pharmaceutical composition described herein. In some embodiments, the administering comprises administering by a method selected from the group consisting of: intravenously, subcutaneously, intramuscularly, orally, rectally, by aerosol, parenterally, ophthalmically, pulmonarily, transdermally, vaginally, otically, nasally, and by topical administration, or any combination thereof. In some embodiments, for the delivery of cells, administration by injection or infusion is used.

[0182] As used herein, the term "subject" refers to any individual for whom diagnosis, treatment or therapy is desired. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human being.

[0183] The efficacy of a treatment can be determined by the skilled clinician. However, a treatment is considered an "effective treatment," if any one or all of the signs or symptoms of a disease or disorder are altered in a beneficial manner (e.g., decreased by at least 10%), or other clinically accepted symptoms or markers of disease are improved or ameliorated. Efficacy can also be measured by failure of an individual to worsen as assessed by hospitalization or need for medical interventions (e.g., progression of the disease is halted or at least slowed). Methods of measuring these indicators are known to those of skill in the art. Treatment includes: (1) inhibiting the disease, e.g., arresting, or slowing the progression of symptoms; or (2) relieving the disease, e.g., causing regression of symptoms; and (3) preventing or reducing the likelihood of the development of symptoms.

A. Modifying causal mutations using base-editing

[0184] An example of a genetically inherited disease which could be corrected using an approach that relies on an RGN-base editor fusion protein of the invention is Hurler Syndrome. Hurler Syndrome, also known as MPS-1, is the result of a deficiency of α -L-iduronidase (IDUA) resulting in a lysosomal storage disease characterized at the molecular level by the accumulation of dermatan sulfate and heparan sulfate in lysosomes. This disease is generally an inherited genetic disorder caused by mutations in the IDUA gene encoding α -L-iduronidase. Common IDUA mutations are W402X and Q70X, both nonsense mutations resulting in premature termination of translation. Such mutations are well addressed by precise genome editing (PGE) approaches, since reversion of a single nucleotide, for example by a base-editing approach, would restore the wild-type coding sequence and result in protein expression controlled by the endogenous regulatory mechanisms of the genetic locus. Additionally, since heterozygotes are known to be asymptomatic, a PGE therapy that targets one of these mutations would be useful to a large proportion of patients with this disease, as only one of the mutated alleles needs to be corrected (Bunge et al. (1994) Hum. Mol. Genet. 3(6): 861-866).

[0185] Current treatments for Hurler Syndrome include enzyme replacement therapy and bone marrow transplants (Vellodi et al. (1997) Arch. Dis. Child. 76(2): 92-99; Peters et al. (1998) Blood 91(7): 2601-2608). While enzyme replacement therapy has had a dramatic effect on the survival and quality of life of Hurler Syndrome patients, this approach requires costly and time-consuming weekly infusions. Additional approaches include the delivery of the IDUA gene on an expression vector or the insertion of the gene into a highly expressed locus such as that of serum albumin (U.S. Patent No. 9,956,247). However, these approaches do not restore the original IDUA locus to

the correct coding sequence. A genome-editing strategy would have a number of advantages, most notably that regulation of gene expression would be controlled by the natural mechanisms present in healthy individuals. Additionally, using base editing does not necessitate causing a double stranded DNA breaks, which could lead to large chromosomal rearrangements, cell death, or oncogenicity by the disruption of tumor suppression mechanisms. A general strategy may be directed toward using RGN-base editor fusion proteins of the invention to target and correct certain disease-causing mutations in the human genome. It will be appreciated that similar approaches to target diseases that can be corrected by base-editing may also be pursued. It will be further appreciated that similar approaches to target disease-causing mutations in other species, particularly common household pets or livestock, can also be deployed using the RGNs of the invention. Common household pets and livestock include dogs, cats, horses, pigs, cows, sheep, chickens, donkeys, snakes, ferrets, and fish including salmon and shrimp.

B. Modifying causal mutations by targeted deletion

[0186] RGNs of the invention could also be useful in human therapeutic approaches where the causal mutation is more complicated. For example, some diseases such as Friedreich's Ataxia and Huntington's Disease are the result of a significant increase in repeats of a three nucleotide motif at a particular region of a gene, which affects the ability of the expressed protein to function or to be expressed. Friedreich's Ataxia (FRDA) is an autosomal recessive disease resulting in progressive degeneration of nervous tissue in the spinal cord. Reduced levels of the frataxin (FXN) protein in the mitochondria cause oxidative damages and iron deficiencies at the cellular level. The reduced FXN expression has been linked to a GAA triplet expansion within the intron 1 of the somatic and germline FXN gene. In FRDA patients, the GAA repeat frequently consists of more than 70, sometimes even more than 1000 (most commonly 600-900) triplets, whereas unaffected individuals have about 40 repeats or less (Pandolfo et al. (2012) Handbook of Clinical Neurology 103: 275-294; Campuzano et al. (1996) Science 271: 1423-1427; Pandolfo (2002) Adv. Exp. Med. Biol. 516: 99-118).

[0187] The expansion of the trinucleotide repeat sequence causing Friedreich's Ataxia (FRDA) occurs in a defined genetic locus within the FXN gene, referred to as the FRDA instability region. RNA guided nucleases (RGNs) may be used for excising the instability region in FRDA patient cells. This approach requires 1) an RGN and guide RNA sequence that can be programmed to target the allele in the human genome; and 2) a delivery approach for the RGN and guide sequence. Many nucleases used for genome editing, such as the commonly used Cas9 nuclease from *S. pyogenes* (SpCas9), are too large to be packaged into adeno-associated viral (AAV) vectors, especially when considering the length of the SpCas9 gene and the guide RNA in addition to other genetic elements required for functional expression cassettes. This makes an approach using SpCas9 more difficult.

[0188] Certain RNA guided nucleases of the invention are well suited for packaging into an AAV vector along with a guide RNA. Packing two guide RNAs would likely require a second vector, but this approach still compares favorably to what would be required of a larger nuclease such as SpCas9, which may require splitting the protein sequence between two vectors. The present invention encompasses a strategy using RGNs of the invention in which a region of genomic instability is removed. Such a strategy is applicable to other diseases and disorders which have a similar genetic basis, such as Huntington's Disease. Similar strategies using RGNs of the invention may also be applicable to similar diseases and disorders in non-human animals of agronomic or economic importance, including dogs, cats, horses, pigs, cows, sheep, chickens, donkeys, snakes, ferrets, and fish including salmon and shrimp.

C. Modifying causal mutations by targeted mutagenesis

[0189] RGNs of the invention could also be to introduce disruptive mutations that may result in a beneficial effect. Genetic defects in the genes encoding hemoglobin, particularly the beta globin chain (the HBB gene), can be responsible for a number of diseases known as hemoglobinopathies, including sickle cell anemia and thalassemias.

[0190] In adult humans, hemoglobin is a heterotetramer comprising two alpha (α)-like globin chains and two beta (β)-like globin chains and 4 heme groups. In adults the $\alpha_2\beta_2$ tetramer is referred to as Hemoglobin A (HbA) or adult hemoglobin. Typically, the alpha and beta globin chains are synthesized in an approximate 1:1 ratio and this ratio seems to be critical in terms of hemoglobin and red blood cell (RBC) stabilization. In a developing fetus, a different form of hemoglobin, fetal hemoglobin (HbF), is produced which has a higher binding affinity for oxygen than Hemoglobin A such that oxygen can be delivered to the baby's system via the mother's blood stream. Fetal hemoglobin also contains two α globin chains, but in place of the adult β -globin chains, it has two fetal gamma (γ)-globin chains (i.e., fetal hemoglobin is $\alpha_2\gamma_2$). The regulation of the switch from production of gamma- to beta-globin is quite complex, and primarily involves a down-regulation of gamma globin transcription with a simultaneous up-regulation of beta globin transcription. At approximately 30 weeks of gestation, the synthesis of gamma globin in the fetus starts to drop while the production of beta globin increases. By approximately 10 months of age, the newborn's hemoglobin is nearly all $\alpha_2\beta_2$ although some HbF persists into adulthood (approximately 1-3% of total hemoglobin). In the majority of patients with hemoglobinopathies, the genes encoding gamma globin remain present, but expression is relatively low due to normal gene repression occurring around parturition as described above.

[0191] Sickle cell disease is caused by a V6E mutation in the β globin gene (HBB) (a GAG to GTG at the DNA level), where the resultant hemoglobin is referred to as "hemoglobins" or "HbS." Under lower oxygen conditions, HbS molecules aggregate and form fibrous precipitates. These aggregates cause the abnormality or 'sickling' of the RBCs, resulting in a loss of flexibility of the cells. The sickling RBCs are no longer able to squeeze into the capillary beds and can result in vaso-occlusive crisis in sickle cell patients. In addition,

sickled RBCs are more fragile than normal RBCs, and tend towards hemolysis, eventually leading to anemia in the patient.

[0192] Treatment and management of sickle cell patients is a life-long proposition involving antibiotic treatment, pain management and transfusions during acute episodes. One approach is the use of hydroxyurea, which exerts its effects in part by increasing the production of gamma globin. Long term side effects of chronic hydroxyurea therapy are still unknown, however, and treatment gives unwanted side effects and can have variable efficacy from patient to patient. Despite an increase in the efficacy of sickle cell treatments, the life expectancy of patients is still only in the mid to late 50's and the associated morbidities of the disease have a profound impact on a patient's quality of life.

[0193] Thalassemias (alpha thalassemias and beta thalassemia) are also diseases relating to hemoglobin and typically involve a reduced expression of globin chains. This can occur through mutations in the regulatory regions of the genes or from a mutation in a globin coding sequence that results in reduced expression or reduced levels or functional globin protein. Treatment of thalassemias usually involves blood transfusions and iron chelation therapy. Bone marrow transplants are also being used for treatment of people with severe thalassemias if an appropriate donor can be identified, but this procedure can have significant risks.

[0194] One approach that has been proposed for the treatment of both sickle cell disease (SCD) and beta thalassemias is to increase the expression of gamma globin so that HbF functionally replaces the aberrant adult hemoglobin. As mentioned above, treatment of SCD patients with hydroxyurea is thought to be successful in part due to its effect on increasing gamma globin expression (DeSimone (1982) Proc Nat'l Acad Sci USA 79(14):4428-31; Ley, et al., (1982) N. Engl. J. Medicine, 307: 1469-1475; Ley, et al., (1983) Blood 62: 370-380; Constantoulakis et al., (1988) Blood 72(6):1961-1967). Increasing the expression of HbF involves identification of genes whose products play a role in the regulation of gamma globin expression. One such gene is BCL11A. BCL11A encodes a zinc finger protein that expressed in adult erythroid precursor cells, and down-regulation of its expression leads to an increase in gamma globin expression (Sankaran et al (2008) Science 322: 1839, herein incorporated by reference). Use of an inhibitory RNA targeted to the BCL11A gene has been proposed (e.g., U.S. Patent Publication 2011/0182867) but this technology has several potential drawbacks, including that complete knock down may not be achieved, delivery of such RNAs may be problematic, and the RNAs must be present continuously, requiring multiple treatments for life.

[0195] RGNs of the invention may be used to target the BCL11A enhancer region to disrupt expression of BCL11A, thereby increasing gamma globin expression. This targeted disruption can be achieved by non-homologous end joining (NHEJ), whereby an RGN of the invention targets to a particular sequence within the BCL11A enhancer region, makes a double-stranded break, and the cell's machinery repairs the break, typically simultaneously introducing deleterious mutations. Similar to what is described for other disease targets, RGNs of the invention may have advantages over other known RGNs due to their relatively small size, which enables packaging expression cassettes for the RGN and its guide RNA into a single AAV vector for *in vivo* delivery. Similar strategies using RGNs of the invention may also be applicable to similar diseases and disorders in both humans and in non-human animals of agronomic or economic importance.

X. Cells Comprising a Polynucleotide Genetic Modification

[0196] Enabled herein are cells and non-human organisms comprising a target sequence of interest that has been modified using a process mediated by an RGN, crRNA, and/or tracrRNA as described herein, which process is not a process for modifying the germ line genetic identity of human beings. The RGN comprises the amino acid sequence of SEQ ID NO: 83, or an active variant or fragment thereof in accordance with aspects of the invention. In various embodiments, the guide RNA comprises a CRISPR repeat sequence comprising the nucleotide sequence of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 44, 51, 57, 64, 71, 77, 84, 90, 97, 104, 111, 118, or 124, or an active variant or fragment thereof. In particular embodiments, the guide RNA comprises a tracrRNA comprising the nucleotide sequence of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 45, 52, 58, 65, 72, 78, 85, 91, 98, 105, 112, 119, or 125, or an active variant or fragment thereof. The guide RNA of the system can be a single guide RNA or a dual-guide RNA.

[0197] The modified cells can be eukaryotic (e.g., mammalian, plant, insect cell) or prokaryotic. Also enabled are organelles and non-human embryos comprising at least one nucleotide sequence that has been modified by a process utilizing an RGN, crRNA, and/or tracrRNA as described herein. The genetically modified cells, organisms, organelles, and non-human embryos can be heterozygous or homozygous for the modified nucleotide sequence.

[0198] The chromosomal modification of the cell, organism, organelle, or non-human embryo can result in altered expression (up-regulation or down-regulation), inactivation, or the expression of an altered protein product or an integrated sequence. In those embodiments wherein the chromosomal modification results in either the inactivation of a gene or the expression of a non-functional protein product, the genetically modified cell, organism, organelle, or non-human embryo is referred to as a "knock out". The knock out phenotype can be the result of a deletion mutation (i.e., deletion of at least one nucleotide), an insertion mutation (i.e., insertion of at least one nucleotide), or a nonsense mutation (i.e., substitution of at least one nucleotide such that a stop codon is introduced).

[0199] Alternatively, the chromosomal modification of a cell, organism, organelle, or non-human embryo can produce a "knock in", which results from the chromosomal integration of a nucleotide sequence that encodes a protein. In some of these examples, the coding sequence is integrated into the chromosome such that the chromosomal sequence encoding the wild-type protein is inactivated, but the exogenously introduced protein is expressed.

[0200] In other examples, the chromosomal modification results in the production of a variant protein product. The expressed variant protein product can have at least one amino acid substitution and/or the addition or deletion of at least one amino acid. The variant protein product encoded by the altered chromosomal sequence can exhibit modified characteristics or activities when compared to the wild-type protein, including but not limited to altered enzymatic activity or substrate specificity.

[0201] In yet other examples, the chromosomal modification can result in an altered expression pattern of a protein. As a non-limiting example, chromosomal alterations in the regulatory regions controlling the expression of a protein product can result in the overexpression or downregulation of the protein product or an altered tissue or temporal expression pattern.

[0202] The cells that have been modified can be grown into an organism, such as a plant, in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same modified strain or different strains, and the resulting hybrid having the genetic modification. The present invention enables genetically modified seed. Progeny, variants, and mutants of the regenerated plants are also enabled, provided that these parts comprise the genetic modification. Further provided is a processed plant product or byproduct that retains the genetic modification, including for example, soymeal.

[0203] The methods provided herein may be used for modification of any plant species, including, but not limited to, monocots and dicots. Examples of plants of interest include, but are not limited to, corn (maize), sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape, Brassica sp., alfalfa, rye, millet, safflower, peanuts, sweet potato, cassava, coffee, coconut, pineapple, citrus trees, cocoa, tea, banana, avocado, fig, guava, mango, olive, papaya, cashew, macadamia, almond, oats, vegetables, ornamentals, and conifers.

[0204] Vegetables include, but are not limited to, tomatoes, lettuce, green beans, lima beans, peas, and members of the genus *Curcumis* such as cucumber, cantaloupe, and musk melon. Ornamentals include, but are not limited to, azalea, hydrangea, hibiscus, roses, tulips, daffodils, petunias, carnation, poinsettia, and chrysanthemum. Preferably, plants of the present invention are crop plants (for example, maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, oilseed rape, etc.).

[0205] The methods provided herein can also be used to genetically modify any prokaryotic species, including but not limited to, archaea and bacteria (e.g., *Bacillus* sp., *Klebsiella* sp., *Streptomyces* sp., *Rhizobium* sp., *Escherichia* sp., *Pseudomonas* sp., *Salmonella* sp., *Shigella* sp., *Vibrio* sp., *Yersinia* sp., *Mycoplasma* sp., *Agrobacterium*, *Lactobacillus* sp.).

[0206] The methods provided herein can be used to genetically modify any eukaryotic species or cells therefrom, including but not limited to animals (e.g., mammals, insects, fish, birds, and reptiles), fungi, amoeba, algae, and yeast. In some embodiments, the cell that is modified by the presently disclosed methods include cells of hematopoietic origin, such as cells of the immune system including but not limited to B cells, T cells, natural killer (NK) cells, pluripotent stem cells, induced pluripotent stem cells, chimeric antigen receptor T (CAR-T) cells, monocytes, macrophages, and dendritic cells.

[0207] Cells that have been modified may be introduced into an organism. These cells could have originated from the same organism (e.g., person) in the case of autologous cellular transplants, wherein the cells are modified in an *ex vivo* approach. Alternatively, the cells originated from another organism within the same species (e.g., another person) in the case of allogeneic cellular transplants.

[0208] The article "a" and "an" are used herein to refer to one or more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, "a polypeptide" means one or more polypeptides.

[0209] All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this disclosure pertains.

[0210] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

[0211] The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1. Identification of RNA-guided nuclease

[0212] Nineteen distinct CRISPR-associated RNA-guided nucleases (RGNs) were identified and are described in Table 1 below. Table 1 provides the name of each RGN, its amino acid sequence, the source from which it was derived, and processed crRNA and tracrRNA sequences (see Example 2 for methods of identification). Table 1 further provides a generic single guide RNA (sgRNA) sequence, where the poly-N indicates the location of the spacer sequence which determines the nucleic acid target sequence of the sgRNA. For RGN

systems APG06622, APG02787, and APG06248, the conserved sequence in the base of the hairpin stem of the tracrRNA is UNANNA (SEQ ID NO: 129). For APG06007, APG09344, and APG07991, the sequence in the same location is UNANNU (SEQ ID NO: 130). For APG02874, APG03850, and APG07553, the sequence in the same location is UNANNG (SEQ ID NO: 131). For RGN systems APG03031, APG09208, APG05586, APG08770, APG03021, APG06015, APG01868, and APG02998, the conserved sequence in the base of the hairpin stem of the tracrRNA is UNANNC (SEQ ID NO: 132). For APG08167 and APG01604, the sequence in the same location is CNANNC (SEQ ID NO: 133).

Table 1: Summary of SEQ IDs and CRISPR associated systems

RGN ID	SEQ ID NO.	Source	crRNA repeat seq (SEQ ID NO.)	tracrRNA (SEQ ID NO.)	sgRNA backbone (SEQ ID NO)
APG06622	1	<i>Pedobacter</i> sp.	2	3	4
APG02787	8	<i>Chitinophaga</i> sp.	9	10	11
APG06248	15	<i>Mucilaginibacter</i> sp.	16	17	18
APG06007	22	<i>Acidovorax</i> sp.	23	24	25
APG02874	29	<i>Bacillus</i> sp.	30	31	32
APG03850	36	<i>Bacillus</i> sp.	37	38	39
APG07553	43	<i>Bacillus</i> sp.	44	45	46
APG03031	50	<i>Chryseobacterium</i> sp.	51	52	53
APG09208	56	<i>Bacillus</i> sp.	57	58	59
APG05586	63	<i>Enterococcus</i> sp.	64	65	66
APG08770	70	<i>Enterococcus</i> sp.	71	72	73
APG08167	76	<i>Staphylococcus</i> sp.	77	78	79
APG01604	83	<i>Staphylococcus</i> sp.	84	85	86
APG03021	89	<i>Streptococcus</i> sp.	90	91	92
APG06015	96	<i>Pediococcus</i> sp.	97	98	99
APG09344	103	<i>Weissella</i> sp.	104	105	106
APG07991	110	<i>Enterococcus</i> sp.	111	112	113
APG01868	117	<i>Enterococcus</i> sp.	118	119	120
APG02998	123	<i>Enterococcus</i> sp.	124	125	126

Example 2: Guide RNA identification and sgRNA construction

[0213] Cultures of bacteria that natively express the RNA-guided nuclease system under investigation were grown to mid-log phase (OD₆₀₀ of ~0.600), pelleted, and flash frozen. RNA was isolated from the pellets using a mirVANA miRNA Isolation Kit (Life Technologies, Carlsbad, CA), and sequencing libraries were prepared from the isolated RNA using an NEBNext Small RNA Library Prep kit (NEB, Beverly, MA). The library prep was fractionated on a 6% polyacrylamide gel to capture the RNA species less than 200nt to detect crRNAs and tracrRNAs, respectively. Deep sequencing (75 bp paired-end) was performed on a Next Seq 500 (High Output kit) by a service provider (MoGene, St. Louis, MO). Reads were quality trimmed using Cutadapt and mapped to reference genomes using Bowtie2. A custom RNAseq pipeline was written in python to detect the crRNA and tracrRNA transcripts. Processed crRNA boundaries were determined by sequence coverage of the native repeat spacer array. The anti-repeat portion of the tracrRNA was identified using permissive BLASTn parameters. RNA sequencing depth confirmed the boundaries of the processed tracrRNA by identifying the transcript containing the anti-repeat. Manual curation of RNAs was performed using secondary structure prediction by NUPACK, an RNA folding software. sgRNA cassettes were prepared by DNA synthesis and were generally designed as follows (5'→3'): 20-30 bp spacer sequence, operably linked at its 3' end to the processed repeat portion of the crRNA, operably linked to a 4 bp noncomplementary linker (AAAG; SEQ ID NO: 249), operably linked at its 3' end to the processed tracrRNA. Other 4 bp noncomplementary linkers may also be used.

[0214] For *in vitro* assays, sgRNAs were synthesized by *in vitro* transcription of the sgRNA cassettes with a GeneArt™ Precision gRNA Synthesis Kit (ThermoFisher). Processed crRNA and tracrRNA sequences for each of the RGN polypeptides are identified and are set forth in Table 1. See below for the sgRNAs constructed for PAM libraries 1 and 2.

Example 3: Determination of PAM requirements for each RGN

[0215] PAM requirements for each RGN were determined using a PAM depletion assay essentially adapted from Kleinstiver et al. (2015) Nature 523:481-485 and Zetsche et al. (2015) Cell 163:759-771. Briefly, two plasmid libraries (L1 and L2) were generated in a pUC18 backbone (ampR), with each containing a distinct 30bp protospacer (target) sequence flanked by 8 random nucleotides (i.e., the PAM region). The target sequence and flanking PAM region of library 1 and library 2 for each RGN are set forth in Table 2.

[0216] The libraries were separately electroporated into *E. coli* BL21(DE3) cells harboring pRSF-1b expression vectors containing an RGN of the invention (codon optimized for *E. coli*) along with a cognate sgRNA containing a spacer sequence corresponding to the protospacer in L1 or L2. Sufficient library plasmid was used in the transformation reaction to obtain $>10^6$ CFU. Both the RGN and sgRNA in the pRSF-1b backbone were under the control of T7 promoters. The transformation reaction was allowed to recover for 1 hr after which it was diluted into LB media containing carbenicillin and kanamycin and grown overnight. The following day, the mixture was diluted into self-inducing Overnight Express™ Instant TB Medium (Millipore Sigma) to allow expression of the RGN and sgRNA, and grown for an additional 4h or 20h after which the cells were spun down and plasmid DNA was isolated with a Mini-prep kit (Qiagen, Germantown, MD). In the presence of the appropriate sgRNA, plasmids containing a PAM that is recognizable by the RGN will be cleaved resulting in their removal from the population. Plasmids containing PAMs that are not recognizable by the RGN, or that are transformed into bacteria not containing an appropriate sgRNA, will survive and replicate. The PAM and protospacer regions of uncleaved plasmids were PCR-amplified and prepared for sequencing following published protocols (16s-metagenomic library prep guide 15044223B, Illumina, San Diego, CA). Deep sequencing (75bp single end reads) was performed on a MiSeq (Illumina) by a service provider (MoGene, St. Louis, MO). Typically, 1-4M reads were obtained per amplicon. PAM regions were extracted, counted, and normalized to total reads for each sample. PAMs that lead to plasmid cleavage were identified by being underrepresented when compared to controls (i.e., when the library is transformed into *E. coli* containing the RGN but lacking an appropriate sgRNA). To represent PAM requirements for a novel RGN, the depletion ratios (frequency in sample/frequency in control) for all sequences in the region in question were converted to enrichment values with a -log base 2 transformation. Sufficient PAMs were defined as those with enrichment values >2.3 (which corresponds to depletion ratios $< \sim 0.2$). PAMs above this threshold in both libraries were collected and used to generate web logos, which for example can be generated using a web-based service on the internet known as "weblogo". PAM sequences were identified and reported when there was a consistent pattern in the top enriched PAMs. A consensus PAM (having an enrichment factor (EF) >2.3) for each RGN is provided in Table 2. The PAM orientation is also indicated in Table 2.

Table 2: PAM or PAM-like determination

[0217]

RGN ID	sgRNA L1 (SEQ ID NO.)	sgRNA L2 (SEQ ID NO.)	PAM (SEQ ID NO.)	PAM orientation
APG06622	5	6	7	5'-target-PAM-3'
APG02787	12	13	14	5'-target-PAM-3'
APG06248	19	20	21	5'-target-PAM-3'
APG06007	26	27	28	5'-target-PAM-3'
APG02874	33	34	35	5'-target-PAM-3'
APG03850	40	41	42	5'-target-PAM-3'
APG07553	47	48	49	5'-target-PAM-3'
APG03031	54	55	35	5'-target-PAM-3'
APG09208	60	61	62	5'-target-PAM-3'
APG05586	67	68	69	5'-target-PAM-3'
APG08770	74	75	69	5'-target-PAM-3'
APG08167	80	81	82	5'-target-PAM-3'
APG01604	87	88	82	5'-target-PAM-3'
APG03021	93	94	95	5'-target-PAM-3'
APG06015	100	101	102	5'-target-PAM-3'
APG09344	107	108	109	5'-target-PAM-3'
APG07991	114	115	116	5'-target-PAM-3'
APG01868	121	122	116	5'-target-PAM-3'
APG02998	127	128	116	5'-target-PAM-3'

Example 4: Demonstration of gene editing activity in mammalian cells

[0218] RGN expression cassettes were produced and introduced into vectors for mammalian expression. Each RGN was codon-optimized for human expression (SEQ ID NOs: 134-152), and operably fused at the 5' end to an SV40 nuclear localization sequence (NLS; SEQ ID NO: 251) and to 3xFLAG tags (SEQ ID NO: 252), and operably fused at the 3' end to nucleoplasmin NLS sequences (SEQ ID NO: 253). Two copies of the NLS sequence were used, operably fused in tandem. Each expression cassette was under control of a cytomegalovirus (CMV) promoter (SEQ ID NO: 258). It is known in the art that the CMV transcription enhancer (SEQ ID NO: 259) may also be included in constructs comprising the CMV promoter. Guide RNA expression constructs encoding a single gRNA each under the

control of a human RNA polymerase III U6 promoter (SEQ ID NO: 260) were produced and introduced into the pTwist High Copy Amp vector. Sequences for the target sequences for each guide are in Table 3.

[0219] Several of the constructs described above were introduced into mammalian cells. One day prior to transfection, 1×10^5 HEK293T cells (Sigma) were plated in 24-well dishes in Dulbecco's modified Eagle medium (DMEM) plus 10% (vol/vol) fetal bovine serum (Gibco) and 1% Penicillin-Streptomycin (Gibco). The next day when the cells were at 50-60% confluency, 500 ng of an RGN expression plasmid plus 500 ng of a single gRNA expression plasmid were co-transfected using 1.5 μ L of Lipofectamine 3000 (Thermo Scientific) per well, following the manufacturer's instructions. After 48 hours of growth, total genomic DNA was harvested using a genomic DNA isolation kit (Machery-Nagel) according to the manufacturer's instructions.

[0220] The total genomic DNA was then analyzed to determine the rate of editing for each RGN for each genomic target. First, oligonucleotides were produced to be used for PCR amplification and subsequent analysis of the amplified genomic target site. Oligonucleotide sequences used are listed in Table 4.

[0221] All PCR reactions were performed using 10 μ L of 2X Master Mix Phusion High-Fidelity DNA polymerase (Thermo Scientific) in a 20 μ L reaction including 0.5 μ M of each primer. Large genomic regions encompassing each target gene were first amplified using PCR#1 primers, using a program of: 98°C., 1 min; 30 cycles of [98°C., 10 sec; 62°C., 15 sec; 72°C., 5 min]; 72°C., 5 min; 12°C., forever. One microliter of this PCR reaction was then further amplified using primers specific for each guide (PCR#2 primers), using a program of: 98°C., 1 min; 35 cycles of [98°C., 10 sec; 67°C., 15 sec; 72°C., 30 sec]; 72°C., 5 min; 12°C., forever. Primers for PCR#2 include Nextera Read 1 and Read 2 Transposase Adapter overhang sequences for Illumina sequencing.

[0222] For RGNs APG02874, APG03850, and APG09208, methods were carried out as described above. A number of different genes in the human genome were targeted for RNA-guided cleavage. These loci are included in Table 3 below, along with the reference to the SEQ ID NO of the sgRNA. The indel percentage, which is an indication of RGN activity, is also shown.

Table 3: Target and sgRNA sequences for guide RNAs used to test gene editing activity in mammalian cells

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG02874, APG09208	RelA	SGN000973, SGN000778	153	188, 206
APG02874	RelA	SGN000974	154	189
APG02874	RelA	SGN000975, SGN000780	155	190, 208
APG02874, APG09208	AurkB	SGN000976, SGN000775	156	191, 204
APG02874, APG09208	AurkB	SGN000977, SGN000776	157	192, 205
APG02874	AurkB	SGN000978	158	193
APG02874	VEGFA	SGN000979	159	194
APG02874	VEGFA	SGN000981	160	195
APG03850	RelA	SGN000982	161	196
APG03850	RelA	SGN000983	162	197
APG03850	RelA	SGN000984	163	198
APG03850	AurkB	SGN000985	164	199
APG03850	AurkB	SGN000986	165	200
APG03850	AurkB	SGN000987	166	201
APG03850	VEGFA	SGN000988	167	202
APG03850	VEGFA	SGN000990	168	203
APG09208	RelA	SGN000779	169	207
APG09208	AurkB	SGN000793	170	209
APG09208	AurkB	SGN000794	171	210
APG05586	TRA	SGN001163	553	557
APG05586	TRA	SGN001164	554	558
APG05586	VEGFA	SGN001165	555	559
APG05586	VEGFA	SGN001166	556	560
APG09208	RelA	SGN000778	153	206
APG09208	AurkB	SGN000793	609	811
APG05586, APG08770, APG09298	EMX1	SGN001159	610	812
APG05586, APG08770, APG09298	TRA	SGN001162	611	813
APG05586, APG08770, APG09298	TRA	SGN001163	612	814
APG05586, APG08770, APG09298	TRA	SGN001164	613	815

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG05586, APG08770, APG09298	VEGFA	SGN001165	614	816
APG05586, APG08770, APG09298	VEGFA	SGN001166	615	817
APG05586, APG09298	VEGFA	SGN001167	616	818
APG09208	RelA	SGN001213	617	819
APG08167, APG01604	VEGFA	SGN001245	618	820
APG08167, APG01604	VEGFA	SGN001246	619	821
APG08167, APG01604	VEGFA	SGN001247	620	822
APG08167, APG01604	RelA	SGN001248	621	823
APG08167, APG01604	RelA	SGN001249	622	824
APG08167, APG01604	RelA	SGN001250	623	825
APG08167, APG01604	AurkB	SGN001251	624	826
APG08167, APG01604	AurkB	SGN001252	625	827
APG08167, APG01604	AurkB	SGN001253	626	828
APG07991	RelA	SGN001312	627	829
APG07991	RelA	SGN001313	628	830
APG07991	RelA	SGN001314	629	831
APG01868	RelA	SGN001315	630	832
APG01868	RelA	SGN001316	631	833
APG01868	RelA	SGN001317	632	834
APG02998	RelA	SGN001318	633	835
APG02998	RelA	SGN001319	634	836
APG02998	RelA	SGN001320	635	837
APG09344	RelA	SGN001321	636	838
APG06015	RelA	SGN001322	637	839
APG03021	RelA	SGN001323	638	840
APG09344	RelA	SGN001324	639	841
APG06015	RelA	SGN001325	640	842
APG03021	RelA	SGN001326	641	843
APG06015	RelA	SGN001327	642	844
APG03021	RelA	SGN001328	643	845
APG09344	RelA	SGN001329	644	846
APG03021	TRA	SGN001330	645	847
APG03021	TRA	SGN001331	646	848
APG03021	TRA	SGN001332	647	849
APG06015	TRA	SGN001333	648	850
APG06015	TRA	SGN001334	649	851
APG06015	TRA	SGN001335	650	852
APG09344	TRA	SGN001336	651	853
APG09344	TRA	SGN001337	652	854
APG09344	TRA	SGN001338	653	855
APG07991	TRA	SGN001339	654	856
APG07991	TRA	SGN001340	655	857
APG07991	TRA	SGN001341	656	858
APG01868	TRA	SGN001342	657	859
APG01868	TRA	SGN001343	658	860
APG01868	TRA	SGN001344	659	861
APG01868	TRA	SGN001692	660	862
APG02998	TRA	SGN001345	661	863
APG02998	TRA	SGN001346	662	864
APG02998	TRA	SGN001347	663	865

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG03021	HAO1	SGN001348	664	866
APG03021	HAO1	SGN001349	665	867
APG03021	HAO1	SGN001350	666	868
APG06015	HAO1	SGN001351	667	869
APG06015	HAO1	SGN001352	668	870
APG06015	HAO1	SGN001353	669	871
APG09344	HAO1	SGN001354	670	872
APG09344	HAO1	SGN001355	671	873
APG09344	HAO1	SGN001356	672	874
APG07991	HAO1	SGN001357	673	875
APG07991	HAO1	SGN001358	674	876
APG07991	HAO1	SGN001359	675	877
APG01868	HAO1	SGN001360	676	878
APG01868	HAO1	SGN001361	677	879
APG01868	HAO1	SGN001362	678	880
APG02998	HAO1	SGN001363	679	881
APG02998	HAO1	SGN001364	680	882
APG02998	HAO1	SGN001365	681	883
APG05586, APG09298	TRA	SGN001371	682	884
APG05586, APG09298	TRA	SGN001372	683	885
APG05586, APG09298	TRA	SGN001373	684	886
APG05586, APG09298	TRA	SGN001374	685	887
APG05586, APG09298	TRA	SGN001375	686	888
APG05586, APG09298	TRA	SGN001376	687	889
APG05586, APG09298	TRA	SGN001377	688	890
APG05586, APG09298	TRA	SGN001378	689	891
APG05586, APG09298	TRA	SGN001379	690	892
APG05586, APG09298	TRA	SGN001380	691	893
APG05586, APG09298	TRA	SGN001381	692	894
APG05586, APG09298	TRA	SGN001382	693	895
APG05586, APG09298	B2M	SGN001383	694	896
APG05586, APG09298	B2M	SGN001384	695	897
APG05586, APG09298	B2M	SGN001385	696	898
APG05586, APG09298	B2M	SGN001386	697	899
APG05586, APG09298	B2M	SGN001387	698	900
APG05586, APG09298	B2M	SGN001388	699	901
APG05586, APG09298	B2M	SGN001389	700	902
APG05586, APG09298	B2M	SGN001390	701	903
APG05586, APG09298	B2M	SGN001391	702	904
APG05586, APG09298	B2M	SGN001392	703	905
APG05586, APG09298	B2M	SGN001393	704	906
APG05586, APG09298	B2M	SGN001394	705	907
APG05586, APG09298	LDHA	SGN001395	706	908
APG05586, APG09298	LDHA	SGN001396	707	909
APG05586, APG09298	LDHA	SGN001397	708	910
APG05586, APG09298	LDHA	SGN001399	709	911
APG05586, APG09298	LDHA	SGN001400	710	912
APG05586, APG09298	LDHA	SGN001401	711	913
APG05586, APG09298	LDHA	SGN001402	712	914
APG05586, APG09298	LDHA	SGN001403	713	915

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG05586, APG09298	LDHA	SGN001404	714	916
APG05586, APG09298	LDHA	SGN001405	715	917
APG05586, APG09298	HAO1	SGN001406	716	918
APG05586, APG09298	HAO1	SGN001407	717	919
APG05586, APG09298	HAO1	SGN001408	718	920
APG05586, APG09298	HAO1	SGN001409	719	921
APG05586, APG09298	HAO1	SGN001410	720	922
APG05586, APG09298	HAO1	SGN001411	721	923
APG05586, APG09298	HAO1	SGN001412	722	924
APG05586, APG09298	HAO1	SGN001413	723	925
APG05586, APG09298	HAO1	SGN001414	724	926
APG05586, APG09298	HAO1	SGN001415	725	927
APG05586, APG09298	HAO1	SGN001416	726	928
APG01604	B2M	SGN001592	727	929
APG01604	B2M	SGN001593	728	930
APG01604	B2M	SGN001594	729	931
APG01604	B2M	SGN001595	730	932
APG01604	B2M	SGN001596	731	933
APG01604	B2M	SGN001597	732	934
APG01604	B2M	SGN001598	733	935
APG01604	B2M	SGN001599	734	936
APG01604	B2M	SGN001600	735	937
APG01604	B2M	SGN001601	736	938
APG01604	B2M	SGN001602	737	939
APG01604	B2M	SGN001603	738	940
APG01604	HAO1	SGN001616	739	941
APG01604	HAO1	SGN001617	740	942
APG01604	HAO1	SGN001618	741	943
APG01604	HAO1	SGN001619	742	944
APG01604	HAO1	SGN001620	743	945
APG01604	HAO1	SGN001621	744	946
APG01604	HAO1	SGN001622	745	947
APG01604	HAO1	SGN001623	746	948
APG01604	HAO1	SGN001624	747	949
APG01604	HAO1	SGN001625	748	950
APG01604	HAO1	SGN001626	749	951
APG01604	HAO1	SGN001627	750	952
APG01604	LDHA	SGN001640	751	953
APG01604	LDHA	SGN001641	752	954
APG01604	LDHA	SGN001642	753	955
APG01604	LDHA	SGN001643	754	956
APG01604	LDHA	SGN001644	755	957
APG01604	LDHA	SGN001645	756	958
APG01604	LDHA	SGN001646	757	959
APG01604	LDHA	SGN001647	758	960
APG01604	LDHA	SGN001648	759	961
APG01604	LDHA	SGN001649	760	962
APG01604	LDHA	SGN001650	761	963
APG01604	LDHA	SGN001651	762	964
APG01604	TRA	SGN001664	763	965

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG01604	TRA	SGN001665	764	966
APG01604	TRA	SGN001666	765	967
APG01604	TRA	SGN001667	766	968
APG01604	TRA	SGN001668	767	969
APG01604	TRA	SGN001669	768	970
APG01604	TRA	SGN001670	769	971
APG01604	TRA	SGN001671	770	972
APG01604	TRA	SGN001672	771	973
APG01604	TRA	SGN001673	772	974
APG01604	TRA	SGN001674	773	975
APG01604	TRA	SGN001675	774	976
APG01868	TRA	SGN001684	775	977
APG01868	TRA	SGN001685	776	978
APG01868	TRA	SGN001686	777	979
APG01868	TRA	SGN001687	778	980
APG01868	TRA	SGN001688	779	981
APG01868	TRA	SGN001689	780	982
APG01868	TRA	SGN001690	781	983
APG01868	TRA	SGN001691	782	984
APG01868	EMX1	SGN001697	783	985
APG01868	EMX1	SGN001698	784	986
APG01868	EMX1	SGN001699	785	987
APG01868	EMX1	SGN001700	786	988
APG01868	EMX1	SGN001701	787	989
APG01868	EMX1	SGN001702	788	990
APG01868	EMX1	SGN001703	789	991
APG01868	EMX1	SGN001704	1176	992
APG01868	EMX1	SGN001705	1177	993
APG01868	EMX1	SGN001706	1178	994
APG01868	EMX1	SGN001707	1179	995
APG01868	EMX1	SGN001708	1180	996
APG01868	EMX1	SGN001709	1181	997
APG01868	EMX1	SGN001710	1182	998
APG01868	EMX1	SGN001711	1183	999
APG01868	HAO1	SGN001713	1184	1000
APG01868	HAO1	SGN001714	1185	1001
APG01868	HAO1	SGN001715	790	1002
APG01868	HAO1	SGN001716	791	1003
APG01868	HAO1	SGN001717	792	1004
APG01868	HAO1	SGN001718	793	1005
APG01868	HAO1	SGN001719	794	1006
APG01868	HAO1	SGN001721	795	1007
APG01868	HAO1	SGN001722	796	1008
APG01868	HAO1	SGN001723	797	1009
APG01868	HAO1	SGN001724	798	1010
APG01868	LDHA	SGN001725	799	1011
APG01868	LDHA	SGN001726	800	1012
APG01868	LDHA	SGN001727	801	1013
APG01868	LDHA	SGN001728	802	1014

RGN ID	Gene	Guide ID	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
APG01868	LDHA	SGN001729	803	1015
APG01868	LDHA	SGN001730	804	1016
APG01868	LDHA	SGN001731	805	1017
APG01868	LDHA	SGN001732	806	1018
APG01868	LDHA	SGN001733	807	1019
APG01868	LDHA	SGN001734	808	1020
APG01868	LDHA	SGN001735	809	1021
APG01868	VEGFA	SGN001785	810	1022

Table 4: Oligonucleotides for detection of gene editing activity in mammalian cells

Description	Primer Sequence	SEQ ID NO
SGN000977 FWD	CTTG TAGCTGGAGGTCCATC	172
SGN000977 REV	TGTTGGCAAATCTAGTCTCG	173
SGN000978 FWD	ACATTTGACGAGCAGCGAA	174
SGN000978 REV	GGCCCTGGAGAGGTTTTAA	175
SGN000979, SGN000982, SGN000988, SGN000990 FWD	ACACAGCTTCCCGTTCTCAG	176
SGN000979, SGN000982, SGN000988, SGN000990 REV	ATTCACCCAGCTTCCCTGTG	177
SGN000981 FWD	GGCGTCGCACTGAACTTTT	178
SGN000981 REV	AGTTCATGGTTTCGGAGGCC	179
SGN000983 FWD	CGACCAAACAAGTGCAAAGG	180
SGN000983 REV	GGGTTGTTGTTGGTCTGGAT	181
SGN000775, SGN000776, SGN000793, SGN000794, SGN000976, SGN000985, SGN000986, SGN000987 FWD	ACTGCCATGGGAAGAAGGTG	182
SGN000775, SGN000776, SGN000793, SGN000794, SGN000976, SGN000985, SGN000986, SGN000987 REV	ACAATTCTCCTGCCTCAGCC	183
SGN000778, SGN000973, SGN000984 FWD	TGGCCCCCTATGTGGAGATCA	184
SGN000778, SGN000973, SGN000984 REV	GGCAGAGCTCAGCCTCATAG	185
SGN000779, SGN000780, SGN000974, SGN000975 FWD	ATATCCCCACTTCCCCTGCT	186
SGN000779, SGN000780, SGN000974, SGN000975 REV	CACCTCAAGGACAGCTCTGG	187
SGN001163, SGN001164 FWD	TTGATAGCTTGTGCCTGTCC	561
SGN001163, SGN001164 REV	AGAGTCTCTCAGCTGGTACA	562
SGN001165, SGN001166 FWD	GCGACAGGGGCAAAGTGAGT	563
SGN001165, SGN001166 REV	CTAGCACTTCTCGCGGCTCC	564
SGN001382 FWD	AACTCATGCCTGCTGCTCTT	1023
SGN001382 REV	CAGTCTCACGCAGTCACTCA	1024
SGN001371, SGN001372, SGN001373, SGN001689, SGN001690 FWD	AAGTGAAGCCAGGCAAGAGCA	1025
SGN001371, SGN001372, SGN001373, SGN001689, SGN001690 REV	TGGGACATGCAAGCCCATAA	1026
SGN001730 FWD	AAGATGTTGACATGCTCTTCC	1027
SGN001730 REV	TATGCAGTCAAAAGCCTCA	1028
SGN001353, SGN001356, SGN001359, SGN001362, SGN001365, SGN001406, SGN001407, SGN001412, SGN001413, SGN001414, SGN001622, SGN001623, SGN001624, SGN001625, SGN001626, SGN001627 FWD	AAGTCATTTGCTTGTTTGA	1029
SGN001353, SGN001356, SGN001359, SGN001362, SGN001365, SGN001406, SGN001407, SGN001412, SGN001413, SGN001414, SGN001622, SGN001623, SGN001624, SGN001625, SGN001626, SGN001627 REV	TGGTGCATTCAGAGAAGGAG	1030
SGN001375, SGN001376, SGN001377 FWD	AATGAAGCCAGGCAAGAGCA	1031
SGN001375, SGN001376, SGN001377 REV	CTGTGCAAACCCAGGCTAGA	1032
SGN001251, SGN001252 FWD	ACATTTGACGAGCAGCGAA	1033
SGN001251, SGN001252 REV	GGCCCTGGAGAGGTTTTAA	1034

Description	Primer Sequence	SEQ ID NO
SGN001380 FWD	ACCCGGCCTGCTTTTCTTAA	1035
SGN001380 REV	GGCAGCGAGGCATACATAGT	1036
SGN001731,SGN001732,SGN001733,SGN001734, SGN001735 FWD	ACCCTGCTTTTTCTGCCTTT	1037
SGN001731,SGN001732,SGN001733,SGN001734, SGN001735 REV	CAGGCCTAATGGACATTAATC CT	1038
SGN001374,SGN001688 FWD	ACTACTAAGGGGCCCATCT	1039
SGN001374,SGN001688 REV	CAGGAGGAGGATTCGGAACC	1040
SGN001726,SGN001727,SGN001728,SGN001729 FWD	AGGAAAATGAATCACAATTAC T	1041
SGN001726,SGN001727,SGN001728,SGN001729 REV	GTGCGAAAGGGCAAGATTCT	1042
SGN001397 FWD	AGGCCTTTCAACTCTCTTTTGG CA	1043
SGN001397 REV	GGATGGGGTCAAGGTATGGGC	1044
SGN001213,SGN001248,SGN001249,SGN001321, SGN001322,SGN001323 FWD	ATGACATTCAAGCCACAGTG	1045
SGN001213,SGN001248,SGN001249,SGN001321, SGN001322,SGN001323 REV	CTTCCTCCTATTCAAGCCCA	1046
SGN001725 FWD	CAGCTTTTGAAATGGGGTGC	1047
SGN001725 REV	CAACAAATGGAGACCATCTGG A	1048
SGN001381 FWD	CAGTATTCTAAGGACGCCAGA AA	1049
SGN001381 REV	GCACTTTGGGAGGCTGAA	1050
SGN001390,SGN001391,SGN001392,SGN001393, SGN001394,SGN001592,SGN001593,SGN001594, SGN001595,SGN001596,SGN001597,SGN001598, SGN001599,SGN001600,SGN001601,SGN001602, SGN001603 FWD	CGGGCATTCTGAAGCTG	1051
SGN001390,SGN001391,SGN001392,SGN001393, SGN001394,SGN001592,SGN001593,SGN001594, SGN001595,SGN001596,SGN001597,SGN001598, SGN001599,SGN001600,SGN001601,SGN001602, SGN001603 REV	GTAGGCCAAAGGTCTCCCC	1052
SGN001383,SGN001384,SGN001385,SGN001386, SGN001387,SGN001388,SGN001389 FWD	CTTGACACCAAGTTAGCCCC	1053
SGN001383,SGN001384,SGN001385,SGN001386, SGN001387,SGN001388,SGN001389 REV	TCATACACAACCTTCAGCAGC	1054
SGN000793,SGN001253 FWD	CTTGTAGCTGGAGGTCCATC	1055
SGN000793,SGN001253 REV	TGTTGGCAAATCTAGTCTCG	1056
SGN001379 FWD	GAGCAGCTGAGTCAATGATAG T	1057
SGN001379 REV	GGAGAGATCTGGAGGGAAGTT A	1058
SGN001165,SGN001166,SGN001245 FWD	GCAAAGTGAGTGACCTGCTT	1059
SGN001165,SGN001166,SGN001245 REV	GAGCTAGCACTTCTCGCG	1060
SGN001738 FWD	GCTGTTTGGGAGGTCAGAAA	1061
SGN001738 REV	GAATATTGAAGGGGGCAGGG	1062
SGN001167,SGN001246,SGN001247,SGN001785 FWD	GGACACTTCCCAAAGGACC	1063

Description	Primer Sequence	SEQ ID NO
SGN001167,SGN001246,SGN001247,SGN001785 REV	CACGTCCTCACTCTCGAAGA	1064
SGN001399,SGN001402,SGN001403,SGN001646,SGN001647,SGN001648,SGN001649,SGN001650,SGN001651 FWD	GGCCTTCACTCTTCACAGACCC	1065
SGN001399,SGN001402,SGN001403,SGN001646,SGN001647,SGN001648,SGN001649,SGN001650,SGN001651 REV	GGATGGGGTCAAGGTATGGGC	1066
SGN001162,SGN001163,SGN001164,SGN001330,SGN001331,SGN001332,SGN001333,SGN001334,SGN001335,SGN001336,SGN001337,SGN001338,SGN001339,SGN001340,SGN001341,SGN001342,SGN001343,SGN001344,SGN001345,SGN001346,SGN001347,SGN001664,SGN001665,SGN001666,SGN001667,SGN001668,SGN001669,SGN001670,SGN001671,SGN001672,SGN001673,SGN001674,SGN001675,SGN001684,SGN001685,SGN001686,SGN001687,SGN001691,SGN001692 FWD	GGGCAAAGAGGGAAATGAGA	1067
SGN001162,SGN001163,SGN001164,SGN001330,SGN001331,SGN001332,SGN001333,SGN001334,SGN001335,SGN001336,SGN001337,SGN001338,SGN001339,SGN001340,SGN001341,SGN001342,SGN001343,SGN001344,SGN001345,SGN001346,SGN001347,SGN001664,SGN001665,SGN001666,SGN001667,SGN001668,SGN001669,SGN001670,SGN001671,SGN001672,SGN001673,SGN001674,SGN001675,SGN001684,SGN001685,SGN001686,SGN001687,SGN001691,SGN001692 REV	GAACCTGGCCATTCTCTGAAG	1068
SGN001714,SGN001722 FWD	GGTTTTTGGAGGTGGAGTTGA	1069
SGN001714,SGN001722 REV	CCCCCTAACCAAGTGAAAAGA	1070
SGN001716,SGN001717,SGN001721 FWD	TAGATAAATGAGCAGTGAACA GCC	1071
SGN001716,SGN001717,SGN001721 REV	TCCACAAAGGATCACAAAGTC A	1072
SGN001313,SGN001316,SGN001319 FWD	TGAGAGACAGTGGGACAGAC	1073
SGN001313,SGN001316,SGN001319 REV	AGTCCTAGAGGAGGCAGAAC	1074
SGN001702,SGN001703,SGN001707,SGN001709,SGN001710,SGN001711 FWD	TGAGTCCGAGCAGAAGAAGA	1075
SGN001702,SGN001703,SGN001707,SGN001709,SGN001710,SGN001711 REV	GGAGATTGGAGACACGGAGA	1076
SGN001723 FWD	TGGAGGTGGAGTTGAATAACA	1077
SGN001723 REV	CTTTCTCCCCCTAACCAAGTG	1078
SGN001395,SGN001396 FWD	TGGATCTCCAACATGGCAGCC	1079
SGN001395,SGN001396 REV	CGGAAGGCTAAGGAGGGAGG A	1080
SGN000778,SGN001250,SGN001312,SGN001314,SGN001315,SGN001317,SGN001318,SGN001320,SGN001324,SGN001325,SGN001326,SGN001327,SGN001328,SGN001329 FWD	TGGCCCCCTATGTGGAGATCA	1081
SGN000778,SGN001250,SGN001312,SGN001314,SGN001315,SGN001317,SGN001318,SGN001320,SGN001324,SGN001325,SGN001326,SGN001327,SGN001328,SGN001329 REV	GGCAGAGCTCAGCCTCATAG	1082
SGN001159,SGN001697,SGN001698,SGN001699,SGN001700,SGN001701,SGN001704,SGN001705,SGN001706,SGN001708 FWD	TGTTAGACCCATGGGAGCAG	1083
SGN001159,SGN001697,SGN001698,SGN001699,SGN001700,SGN001701,SGN001704,SGN001705,SGN001706,SGN001708 REV	GTTGCCACCCCTAGTCATT	1084

Description	Primer Sequence	SEQ ID NO
SGN001400,SGN001401,SGN001404,SGN001405,SGN001640,SGN001641,SGN001642,SGN001643,SGN001644,SGN001645 FWD	TTCCACGCTAAGGTATGGGCC	1085
SGN001400,SGN001401,SGN001404,SGN001405,SGN001640,SGN001641,SGN001642,SGN001643,SGN001644,SGN001645 REV	GCCAACAGCACCAACCCCAA	1086
SGN001348,SGN001349,SGN001350,SGN001351,SGN001352,SGN001354,SGN001355,SGN001357,SGN001358,SGN001360,SGN001361,SGN001363,SGN001364,SGN001408,SGN001409,SGN001410,SGN001411,SGN001415,SGN001416,SGN001616,SGN001617,SGN001618,SGN001619,SGN001620,SGN001621,SGN001713,SGN001715,SGN001718,SGN001719,SGN001724 FWD	TTGCTCACTTGATGTAAGCAA	1087
SGN001348,SGN001349,SGN001350,SGN001351,SGN001352,SGN001354,SGN001355,SGN001357,SGN001358,SGN001360,SGN001361,SGN001363,SGN001364,SGN001408,SGN001409,SGN001410,SGN001411,SGN001415,SGN001416,SGN001616,SGN001617,SGN001618,SGN001619,SGN001620,SGN001621,SGN001713,SGN001715,SGN001718,SGN001719,SGN001724 REV	TTTGGTACGGTCTTTGTGT	1088

[0223] Purified genomic DNA was subjected to PCR# 1 and PCR#2 as above. Following the second PCR amplification, DNA was cleaned using a PCR cleanup kit (Zymo) according to the manufacturer's instructions and eluted in water. 200-500ng of purified PCR#2 product was combined with 2 μ L of 10X NEB Buffer 2 and water in a 20 μ L reaction and annealed to form heteroduplex DNA using a program of: 95°C., 5 min; 95-85°C, cooled at a rate of 2°C / sec; 85-25°C, cooled at a rate of 0.1°C / sec.; 12°C., forever. Following annealing 5 μ L of DNA was removed as a no enzyme control, and 1 μ L of T7 Endonuclease I (NEB) was added and the reaction incubated at 37°C for 1 hr. After incubation 5x FlashGel loading dye (Lonza) was added and 5 μ L of each reaction and controls were analyzed by a 2.2% agarose FlashGel (Lonza) using gel electrophoresis. Following visualization of the gel, the percentage of non-homologous end joining (NHEJ) was determined using the following equation: %NHEJ events = $100 \times [1 - (1 - \text{fraction cleaved})^{1/2}]$, where (fraction cleaved) is defined as: (density of digested products)/(density of digested products + undigested parental band).

[0224] For some samples, SURVEYOR® was used to analyze the results following expression in mammalian cells. Cells were incubated at 37° C for 72 h post-transfection before genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. The genomic region flanking the RGN target site was PCR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer's protocol. 200-500 ng total of the purified PCR products were mixed with 1 μ L 10x Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 10 μ L, and subjected to a re-annealing process to enable heteroduplex formation: 95° C for 10 min, 95° C to 85° C ramping at -2° C/s, 85° C to 25° C at -0.25° C/s, and 25° C hold for 1 min.

[0225] After reannealing, products were treated with SURVEYOR® nuclease and SURVEYOR® enhancer S (Integrated DNA Technologies) following the manufacturer's recommended protocol and analyzed on 4-20% Novex TBE polyacrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 10 min and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities. Indel percentage was determined by the formula, $100 \times (1 - (1 - (b+c)/(a+b+c))^{1/2})$, where a is the integrated intensity of the undigested PCR product, and b and c are the integrated intensities of each cleavage product.

[0226] Additionally, products from PCR#2 containing Illumina overhang sequences underwent library preparation following the Illumina 16S Metagenomic Sequencing Library protocol. Deep sequencing was performed on an Illumina Mi-Seq platform by a service provider (MOGene). Typically, 200,000 of 250 bp paired-end reads (2 $\times$ 100,000 reads) are generated per amplicon. The reads were analyzed using CRISPResso (Pinello, et al. 2016 Nature Biotech, 34:695-697) to calculate the rates of editing. Output alignments were hand-curated to confirm insertion and deletion sites as well as identify microhomology sites at the recombination sites. The rates of editing are shown in Table 5. All experiments were performed in human cells. The "target sequence" is the targeted sequence within the gene target. For each target sequence, the guide RNA comprised the complementary RNA target sequence and the appropriate sgRNA depending on the RGN used. A selected breakdown of experiments by guide RNA is shown in Tables 6.1-6.3.

Table 5: Activity of RGNs in mammalian cells

RGN	Guide ID	Gene target	Overall Editing Rate	Deletion Rate in Sample	Insertion Rate in Sample
APG02874	SGN000973	RelA	N.D.		
APG02874	SGN000974	RelA	0.10%	37.23%	62.77%

RGN	Guide ID	Gene target	Overall Editing Rate	Deletion Rate in Sample	Insertion Rate in Sample
APG02874	SGN000975	RelA	N.D.		
APG02874	SGN000976	AurkB	0.56%	35.17%	64.84%
APG02874	SGN000977	AurkB	0.30%	76.34%	23.65%
APG02874	SGN000978	AurkB	N.D.		
APG02874	SGN000979	VEGFA	0.17%	13.95%	86.05%
APG02874	SGN000981	VEGFA	N.D.		
APG03850	SGN000982	RelA	0.19%	40.55%	59.45%
APG03850	SGN000983	RelA	N.D.		
APG03850	SGN000984	RelA	0.05%	72.17%	27.84%
APG03850	SGN000985	AurkB	0.37%	66.62%	33.37%
APG03850	SGN000986	AurkB	N.D.		
APG03850	SGN000987	AurkB	N.D.		
APG03850	SGN000988	VEGFA	N.D.		
APG03850	SGN000990	VEGFA	N.D.		
APG09208	SGN000775	AurkB	N.D.		
APG09208	SGN000776	AurkB	N.D.		
APG09208	SGN000778	RelA	N.D.		
APG09208	SGN000779	RelA	N.D.		
APG09208	SGN000780	RelA	N.D.		
APG09208	SGN000793	AurkB	1.18%	59.97%	40.02%
APG09208	SGN000794	AurkB	N.D.		
APG05586	SGN001163	TRA	23.49%	95.03%	5.41%
APG05586	SGN001164	TRA	1.37%	95.65%	4.36%
APG05586	SGN001165	VEGFA	65.59%	98.58%	2.03%
APG05586	SGN001166	VEGFA	10.48%	94.98%	5.02%
APG06015	SGN001322	RelA	N.D.		
APG06015	SGN001325	RelA	N.D.		
APG06015	SGN001327	RelA	N.D.		
APG06015	SGN001333	TRA	N.D.		
APG06015	SGN001334	TRA	0.03	100%	0%
APG06015	SGN001335	TRA	N.D.		
APG06015	SGN001351	HAO1	N.D.		
APG06015	SGN001352	HAO1	N.D.		
APG06015	SGN001353	HAO1	N.D.		
APG09344	SGN001321	RelA	0.02	0%	100%
APG09344	SGN001324	RelA	N.D.		
APG09344	SGN001329	RelA	N.D.		
APG09344	SGN001336	TRA	N.D.		
APG09344	SGN001337	TRA	N.D.		
APG09344	SGN001338	TRA	N.D.		
APG09344	SGN001354	HAO1	N.D.		
APG09344	SGN001355	HAO1	N.D.		
APG09344	SGN001356	HAO1	N.D.		
APG07991	SGN001312	RelA	2.16	56.61%	43.39%
APG07991	SGN001313	RelA	2.64	80.6%	19.39%
APG07991	SGN001314	RelA	2.49	32.48%	67.51%
APG07991	SGN001339	TRA	6.75	76.47%	27.42%
APG07991	SGN001340	TRA	6.66	69.19%	33.89%
APG07991	SGN001341	TRA	2.84	60.63%	39.38%
APG07991	SGN001357	HAO1	13.34	79.66%	21.31%

RGN	Guide ID	Gene target	Overall Editing Rate	Deletion Rate in Sample	Insertion Rate in Sample
APG07991	SGN001358	HAO1	0.05	60.78%	39.22%
APG07991	SGN001359	HAO1	0.21	80.53%	19.48%
APG01868	SGN001315	RelA	10.78	64.07%	36.36%
APG01868	SGN001316	RelA	6.26	87.09%	13.73%
APG01868	SGN001317	RelA	19.42	62.57%	38.11%
APG01868	SGN001342	TRA	4.66	39.32%	60.68%
APG01868	SGN001343	TRA	41.39	60.13%	41.39%
APG01868	SGN001344	TRA	5.42	60.46%	39.53%
APG01868	SGN001360	HAO1	0.38	69.28%	30.72%
APG01868	SGN001361	HAO1	9.48	84.92%	17.07%
APG01868	SGN001362	HAO1	0.32	28.97%	71.03%
APG02998	SGN001318	RelA	1.13	72.78%	27.22%
APG02998	SGN001319	RelA	2.55	91.76%	8.22%
APG02998	SGN001320	RelA	3.48	43.97%	56.04%
APG02998	SGN001345	TRA	2.01	79.92%	26.06%
APG02998	SGN001346	TRA	5.87	40.14%	61.02%
APG02998	SGN001347	TRA	2.26	59.08%	40.89%
APG02998	SGN001363	HAO 1	0.4	16.34%	83.66%
APG02998	SGN001364	HAO 1	N.D.		
APG02998	SGN001365	HAO 1	1.14	65.98%	34.02%
APG09208	SGN000778	RelA	0.26	0%	100.00%
APG09208	SGN000793	AurkB	1.64	50.94%	49.06%
APG09208	SGN001213	RelA	0.05	100%	0.00%
APG05586	SGN001159	EMX1	40.13	83.86%	16.13%
APG05586	SGN001162	TRA	46.12	86.07%	14.45%
APG05586	SGN001163	TRA	43.77	93.38%	7.58%
APG05586	SGN001164	TRA	8	95.23%	4.80%
APG05586	SGN001165	VEGFA	65.59	98.58%	2.03%
APG05586	SGN001166	VEGFA	10.48	94.98%	5.02%
APG05586	SGN001167	VEGFA	43.8	92.97%	7.35%
APG08770	SGN001159	EMX1	11.9	80.98%	20.13%
APG08770	SGN001162	TRA	14.57	90.2%	10.24%
APG08770	SGN001163	TRA	12.78	95.47%	5.49%
APG08770	SGN001164	TRA	3.09	92.84%	9.00%
APG08770	SGN001165	VEGFA	23.12	92.75%	8.00%
APG08770	SGN001166	VEGFA	10.52	93.45%	6.92%
APG08167	SGN001245	VEGFA	N.D.		
APG08167	SGN001246	VEGFA	N.D.		
APG08167	SGN001247	VEGFA	N.D.		
APG08167	SGN001248	RelA	N.D.		
APG08167	SGN001249	RelA	N.D.		
APG08167	SGN001250	RelA	N.D.		
APG08167	SGN001251	AurkB	N.D.		
APG08167	SGN001252	AurkB	N.D.		
APG08167	SGN001253	AurkB	N.D.		
APG01604	SGN001245	VEGFA	69.13	96.82%	7.23%
APG01604	SGN001246	VEGFA	4.57	79.07%	24.78%
APG01604	SGN001247	VEGFA	18.49	96.17%	5.09%
APG01604	SGN001248	RelA	17.04	94.78%	5.61%
APG01604	SGN001249	RelA	5.53	87.88%	14.96%

RGN	Guide ID	Gene target	Overall Editing Rate	Deletion Rate in Sample	Insertion Rate in Sample
APG01604	SGN001250	RelA	21.18	81.7%	19.19%
APG01604	SGN001251	AurkB	8.38	84.67%	15.34%
APG01604	SGN001252	AurkB	24.74	90.49%	10.22%
APG01604	SGN001253	AurkB	0.32	86.44%	13.56%
APG03021	SGN001323	RelA	13.73	87.67%	12.31%
APG03021	SGN001326	RelA	1.03	78.9%	21.11%
APG03021	SGN001328	RelA	7.12	92.18%	9.68%
APG03021	SGN001330	TRA	N.D.		
APG03021	SGN001331	TRA	0.45	23.15%	76.85%
APG03021	SGN001332	TRA	0.25	49.44%	50.57%
APG03021	SGN001348	HAO1	0.08	30.16%	69.84%
APG03021	SGN001349	HAO1	0.03	58.33%	41.67%
APG03021	SGN001350	HAO1	0.36	70.53%	29.48%

[0227] Specific insertions and deletions for respective guides are shown in Tables 6.1-6.3. In these tables, the target sequence is identified by bold upper case letters. The 8mer PAM regions are double underlined, with the main recognized nucleotides in bold. Insertions are identified by lowercase letters. Deletions are indicated with dashes (-). The INDEL location is calculated from the PAM proximal edge of the target sequence, with the edge being location 0. The location is positive (+) if the location is on the target side of the edge; the location is negative (-) if the location is on the PAM side of the edge.

Table 6.1: Specific insertions and deletions for Guide 977 using RGN APG02874

Guide SGN000977 (SEQ ID NO: 157)	# Reads	% Reads	% of INDELS	Type	INDEL Location	Size
GGAGAGGTTTAAATGGCCAGCCTCACACCCAGG	218651	99.7				
GGAGAGGTTTAAATGGCCAG---ACACCCAGG	161	0.07	24.88	Deletion	-1	4
GGAGAGGTTTAAATGGCCAGtaacCCTCACACCC AGG	153	0.07	23.65	Insertion	+3	3
GGAGAGGTTTAAATGGCCAG-----G	137	0.06	21.17	Deletion	-9	12
GGAGAGGTTTAAATGGCCAGC ---ACCCAGG	130	0.06	20.09	Deletion	-3	5
GGAGAGGTTTAAATGGCCAGCCTCACACCCAGG	33	0.02	5.1	Deletion	+13	1
GGAGAGGTTTAAATGGCC-AGCCTCACACCCAGG	33	0.02	5.1	Deletion	+5	1

Table 6.2: Specific insertions and deletions for Guide 985 using RGN APG03850

Guide SGN000985 (SEQ ID NO: 164)	# Reads	% Reads	% of INDELS	Type	INDEL Location	Size
AGGCTGGGCCATTAAACCTCTCCAGGGGCCGTG	218367	99.63				
AGGCTGGGCCATTAAACCTCTCCaAGGGGCCGT G	268	0.12	33.37	Insertion	3	1
AGGCTGGGCCATTAAACCTCT-CAGGGGCCGTG	204	0.09	25.4	Deletion	4	1
AGGCTGGGCCATTAAACCTCT---CCGTG	140	0.06	17.43	Deletion	-2	7
AGGCTGGGCCATTAAACCTCTCC-GGGGCCGTG	137	0.06	17.06	Deletion	2	1
AGGCT-GGCCATTAAACCTCTCCAGGGGCCGTG	28	0.01	3.49	Deletion	21	1
C----- -----T	26	0.01	3.24	Deletion	-39	88

Table 6.3: Specific insertions and deletions for Guide 793 using RGN APG09208

Guide SGN000793 (SEQ ID NO: 170)	# Reads	% Reads	% of INDELS	Type	INDEL Location	Size
AGGTTTAAATGGCCAGCCTCACACCCAGGTCTG	169578	98.82				
C----- -----G	471	0.27	23.25	Deletion	-17	80

Guide SGN000793 (SEQ ID NO: 170)	# Reads	% Reads	% of INDELs	Type	INDEL Location	Size
CTGGAGAGGTTTAAATGGCCAGCCTCACAaCCCA GGTCTGGCCTCCC	398	0.23	19.64	Insertion	+3	1
CTGGAGAGGTTTAAATGGCCAGCCTCACA---- -----G	190	0.11	9.38	Deletion	-15	18
CTGGAGAGGTTTAAATGGCCAGCCTCACAC-- -----TCCC	133	0.08	6.56	Deletion	-10	12
CTGGAGAGGTTTAAATGGCCAGCCTCACACC-- AGGTCTGGCCTCCC	110	0.06	5.43	Deletion	0	1
CTGGAGAGGTTTAAATGGCCAG----- -GTCTGGCCTCCC	106	0.06	5.23	Deletion	-2	12
CTGGAGAGGTTTAAATGGCCAGCCTCACAaggCC CAGGTCTGGCCTCCC	102	0.06	5.03	Insertion	+3	2
CTGGAGAGGTTTAAATGGCCAGC----- CAGGTCTGGCCTCCC	92	0.05	4.54	Deletion	+1	7
CTGGAGAGGTTTAAATGGCCAGCCTCACAaCCC AGGTCTGGCCTCCC	82	0.05	4.05	Insertion	0	1
CTGGAGAGGTTTAAATGGCCAGCCTCACAactgt ttgacctggagccactctctgaccccgctgacc CCCAAGTCTGGCCTCCC	61	0.04	3.01	Insertion	+3	38
C----- -----TCCC	50	0.03	2.47	Deletion	-10	44
CTGGAGAGGTTTAAATGGCCAGCCTCACAacta ggtgtattataagaatcttataaacCCAGGTCT GGCCTCCC	48	0.03	2.37	Insertion	+3	29
CTGGAGAGGTTTAAATGGCCAGCCTCACAaccag ctttcgttcgcaactcgagtggaagattggactt gcctgCCAGGTCTGGCCTCCC	39	0.02	1.92	Insertion	+3	43
CTGGAGAGGTTTAAATGGCCAGCCTC----- -----CC	36	0.02	1.78	Deletion	-12	18
CTGGAGAGGTTTAAATGTCCCAGCCTCACAgcac tgttcaactggtgatcatacactgatcaagtga ttgateatCCAGGTCTGGCCTCCC	34	0.02	1.68	Insertion	+3	46
CTGGAGAGGTTTAAATGGCCCA----- -----T	27	0.02	1.33	Deletion	-23	34
CTGGAGAGGTTTAAATGGCCAGCCTCACAgatg cgacgctgcgcgtcttatactccacatattgcca gattcagaacggatacCCAGGTCTGGCCTCCC	24	0.01	1.18	Insertion	+3	55
CTGGAGAGGTTTAAATGGCCAgcctcacagqta gctggaactatgcattgatggtgctgctcaagc agccatcttgccctaagaagtgaagagccaggagc caaggatagCCAGGTCTGGCCTCCC	23	0.01	1.14	Insertion	+3	81

Table 6.4: Specific insertions and deletions for Guide 1166 using RGN APG005586

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
CGCGCGGACCACGGCTCCTCCGAAGCGAGACAG GCCCAGAAG	197148	89.52				
CGCGCGGACCACGGCTCCTCCGA-----GACAG GCCCAGAAG	3829	1.74	16.59	Deletion	5	0
CGCGCGGACCACGGCTCCTCCGAAG----ACAG GCCCAGAAG	1985	0.9	8.6	Deletion	4	-1
CGCGCGGACCACGGCTCCTCCGAA-----CA GCCCAGAAG	1300	0.59	5.63	Deletion	7	-3
CGCGCGGACCACGGCTCCTCCGAA-CGAGACAG GCCCAGAAG	1223	0.56	5.3	Deletion	1	3
CGCGCGGACCACGGCTCCTCCGAAG-AGACAG GCCCAGAAG	1221	0.55	5.29	Deletion	2	1
CGCGCGGACCACGGCTCCTCCGAA----- ----- ----- -----C	936	0.43	4.06	Deletion	117	-113
CGCGCGGACCACGGCTCCTCCGAAGC----- ---CCAGAAG	845	0.38	3.66	Deletion	9	-7
CGCGCGGACCACGGCTCCTCC----- ----- -----T	715	0.32	3.1	Deletion	64	-57
CGCGCGGACCACGGCTCCTCCGAAG----- ----- ----- -----G	615	0.28	2.66	Deletion	140	-137
CGCGCGGACCACGG----- ----- ----- -----T	610	0.28	2.64	Deletion	132	-118
CGCGCGGACCACGGCTCCTCC-----CGAGACAG GCCCAGAAG	551	0.25	2.39	Deletion	4	3
CGCGCGGACCACGGCTCCTCCGA-CGAGACAG GCCCAGAAG	497	0.23	2.15	Deletion	2	3
CGCGCGGACCACGGCTCCTCCGAAGTCGAGACAG GCCCAGAAG	438	0.2	1.9	Insertion	1	3
CGCGCGGACCACGGCTCCTCCGAAG-GAGACAG GCCCAGAAG	381	0.17	1.65	Deletion	1	2
G-----gaGGCgg----- -----G	334	0.15	1.45	Deletion	49	-13
CGCGCGGACCACGGCTCCTCCGAA----- -----A	328	0.15	1.42	Deletion	27	-23

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
CGCGCGGACCACGGCTCCTCCGAAGagGAGACA GCCCAGAAG	326	0.15	1.41	Insertion	2	2
CGCGCGGACCACGGCTCCTCCGAAGC----- ----AGAAG	321	0.15	1.39	Deletion	11	-9
CGCGCGGACCACGGCTCCTCCGAAGAG----- -----G	301	0.14	1.3	Deletion	18	-17
CGCGCGGACCACGGCTCCTCCGAAG----- -----AAG	290	0.13	1.26	Deletion	14	-11
CGCGCGGACCACGGCTCC-----GAGACA GCCCAGAAG	266	0.12	1.15	Deletion	8	2
CGCGCGGACCACGGCTCCTC-----GAGACA GCCCAGAAG	265	0.12	1.15	Deletion	6	2
CGCGCGGACCACGGCTC-----GAGACA GCCCAGAAG	232	0.11	1.01	Deletion	9	2
GCGCGGACCACGGCTCCTCCGAAGcCGAGACA GCCCAGAAG	217	0.1	0.94	Insertion	1	2
CGCGCGGACCACGGCTCC-----CGAGACA GCCCAGAAG	199	0.09	0.86	Deletion	7	3
CGCGCGGACCACGGCTCCTCCGAAG----- -----T	192	0.09	0.83	Deletion	17	-14
CGCGCGGACCACGGCTCCTCC----- ---CAGAAG	177	0.08	0.77	Deletion	15	-8
CGCGCGGACCACGGC-----GAGACA GCCCAGAAG	158	0.07	0.68	Deletion	11	2
CGCGCGGACCACGGCTCCTCC----- ----- -----T	149	0.07	0.65	Deletion	97	-90
CGCGCGGACCACGGC-----CGAGACA GCCCAGAAG	147	0.07	0.64	Deletion	10	3
CGCGCGGACCACGGCTCC----- ---CAGAAG	131	0.06	0.57	Deletion	18	-8
CGCGCGGACCACGGCTCCTCCGAAGC----- ---CAGAAG	127	0.06	0.55	Deletion	10	-8
CGCGCGGACCACGGCTCCTCCGAAG----- -----G	124	0.06	0.54	Deletion	53	-50
CGCGCGGACCACGGCCCTCCGA-----GAACA GCCCAGAAG	113	0.05	0.49	Deletion	5	0
CGCGCGGACCACGGCTCCTCC----- ----AGAAG	112	0.05	0.49	Deletion	16	-9

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
CGCGCGGACCACGGCTCC-----A GCCCAGAAG	104	0.05	0.45	Deletion	14	-4
CGCGCGGA-----GAACA GCCCAGAAG	102	0.05	0.44	Deletion	20	0
CGCGCGGACCACGGC----- --CCAGAAG	101	0.05	0.44	Deletion	20	-7
CGCGCG-----AGAACA GCCCAGAAG	98	0.04	0.42	Deletion	21	1
CGCGCGGACCACGGCTCCTCCG---CGAGAACA GCCCAGAAG	97	0.04	0.42	Deletion	3	3
CGCGCGGACCACGGCTCCTCCG----- ----- ----- -G	94	0.04	0.41	Deletion	78	-72
CGCGCGGACCACGGCTCCTCCGAAG---GAACA GCCCAGAAG	91	0.04	0.39	Deletion	3	0
CGCGCGGACCACGGCTCCTCCGAAG----- ----AGAAG	90	0.04	0.39	Deletion	12	-9
CGCGC----- --CCAGAAG	80	0.04	0.35	Deletion	30	-7
CGCGCGGACCACGGCTCCTCCGAAGcCCAGAACA GCCCAGAAG	74	0.03	0.32	Insertion	1	1
C----- -----AGAAG	73	0.03	0.32	Deletion	56	-9
CGCGCGGACCACGGCTCCTCCGAAG----- -----A	67	0.03	0.29	Deletion	47	-44
CGCGCGGACCACGGCTCCTCCGAA-CGAGAACA GCCCAGAG	66	0.03	0.29	Deletion	1	3
CGCGCGGACCACGGCTC----- ----AGAAG	63	0.03	0.27	Deletion	20	-9
CGCGCGGACC----- ----CAGAAG	63	0.03	0.27	Deletion	26	-8
CGCGCGGACCACGGCTCCTCCG----- ----- ----- ----- ---T	62	0.03	0.27	Deletion	179	-173
C----- -----AGAAG	60	0.03	0.26	Deletion	51	-9
CGCGCGGACCACGGCTCCTCC-----A	59	0.03	0.26	Deletion	11	-4

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
GCCCAGAAG						
CGCGCGGAC CCAC ----- ----AGAAG	56	0.03	0.24	Deletion	25	-9
CGCGCGGAC----- GAG AACA GCCCAGAAG	55	0.02	0.24	Deletion	17	2
CGCGCGGAC CCG GCTCCTCT---- CG AACA GCCCAGAAG	54	0.02	0.23	Deletion	4	3
CGCGCGGAC CCAC GGCTCCTCCGAAG----- GCCCAGAAG	54	0.02	0.23	Deletion	8	-5
G----- ----- AG AACAGCCCAAG	53	0.02	0.23	Deletion	39	1
CGCGCGGAC CCA ----- -----GAAG	52	0.02	0.23	Deletion	27	-10
CGCGCGGAC CCAC GGCTCC----- ----AGAAG	52	0.02	0.23	Deletion	19	-9
CGCGCGGAC CCAC GGCTCCTCCG---- GAG AACA GCCCAGAAG	50	0.02	0.22	Deletion	4	2
CGCGCGGAC CCAC GGCTCC----- -CCCAAG	48	0.02	0.21	Deletion	16	-6
CGCGCGGAC CCAC GGCTCCTCCGA----- -----GAAG	48	0.02	0.21	Deletion	15	-10
CGCGCGGA----- ACA GCCCAGAAG	47	0.02	0.2	Deletion	22	-2
CGCGCGGAC CCAC GGCTCCTCCGAAG---- ACA GCCCAGAAG	46	0.02	0.2	Deletion	5	-2
CGCGCGGAC CCAC GGCTCCT---- GCG AACA GCCCAGAAG	45	0.02	0.19	Deletion	5	4
CGCGCGGAC CC ----- CG AACA GCCCAGAAG	45	0.02	0.19	Deletion	15	3
CGCG----- AG AACA GCCCAGAAG	44	0.02	0.19	Deletion	23	1
CGCGCGGAC CCA ----- GA AACA GCCCAGAAG	44	0.02	0.19	Deletion	17	0
CG----- A GCCCAGAAG	44	0.02	0.19	Deletion	30	-4
CGCGCGGAC CCAC GGCTCCTCCGA---- GA AACA GCCCAGACG	44	0.02	0.19	Deletion	5	0
CGCGCGGAC CCAC GGCTCCTCCGA---- GA AACA GCCCAGAAG	42	0.02	0.18	Deletion	5	0

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
CGCGCGGACCACGGCTCCTCCTC-CGAGACAA GCCCAGAAG	42	0.02	0.18	Deletion	2	3
CGCGCGG-----GGAAGACAA GCCCAGAAG	41	0.02	0.18	Deletion	17	4
CGCGCGGACCACGGCTCCTCCGAAG----- -----GAAG	39	0.02	0.17	Deletion	13	-10
CGCGCGGACC-----GAGACAA GCCCAGAAG	39	0.02	0.17	Deletion	16	2
CGCGCGGACCACGGCTCCTCCGAAG----- -----GA-----G	39	0.02	0.17	Deletion	17	-16
GGGGAACCACGGCTCCTCCGAAGaagCGAGACAA GCCCAGAAG	38	0.02	0.16	Insertion	3	3
GGACCACGGCTCCTCCGAAGGAGagGAGACAA GCCCAGAAG	38	0.02	0.16	Insertion	5	2
CGCGCGGACCAC----- -----AAG	38	0.02	0.16	Deletion	27	-11
CGCGCGGACCACGGCTCCTCCGAAGC-----A GCCCAGAAG	38	0.02	0.16	Deletion	6	-4
T----- -----T	37	0.02	0.16	Deletion	47	-15
CGCGCGGACCACGGCTGTCTGA-----GACAA GCCCAGAAG	37	0.02	0.16	Deletion	5	0
C----- CGAGAACAGCCAGAAG	36	0.02	0.16	Deletion	31	3
CGCGCGGACCACGGC----- -----GAAG	36	0.02	0.16	Deletion	23	-10
CGCGCGGA----- -----AG	35	0.02	0.15	Deletion	32	-12
CGCGCGGACCACGG-----AACAA GCCCAGAAG	34	0.02	0.15	Deletion	15	-1
CGCGCGGACCACGGCTC-----AACAA GCCCAGAAG	34	0.02	0.15	Deletion	12	-1
CGCGCGGACCACGGCCCTCC----CGAGACAA GCCCAGAAG	33	0.01	0.14	Deletion	4	3
G----- -----A	33	0.01	0.14	Deletion	57	-21
CGCGCGGACCACGGCTCCTCCGA-GCGAGACAA GCCCAGAAG	32	0.01	0.14	Deletion	1	4

Guide SGN001166 (SEQ ID NO: 556)	#Reads	% Reads	% of INDELS	Type	INDEL Location	Size
CGCGCGGACCACGTT-----CGAGACA GCCCAGAAG	32	0.01	0.14	Deletion	10	3
CGCGA-----AGACA GCCCAGAAG	31	0.01	0.13	Deletion	22	1
CGCGCGGACCACGG----- -----AAG	31	0.01	0.13	Deletion	25	-11
CGCG-----ACA GCC-----G	30	0.01	0.13	Deletion	36	-20
CGCGCGGACCACGGCTCCTCCGAAG---ACA GCCCAGCAG	30	0.01	0.13	Deletion	4	-1
CGCGCGGACCACGGCTCCT-----GACA GCCCAGAAG	30	0.01	0.13	Deletion	9	0
CGCGGACCACGGCTCCTCCGAAGcGCGAGACA GCCCAGAAG	30	0.01	0.13	Insertion	2	1
CG----- AGACAGCCCAGAAG	29	0.01	0.13	Deletion	25	1
CGCGCGGACCACGGCCCTCCGAAG--- ACAGCCCAGAAG	29	0.01	0.13	Deletion	4	-1
CGCGCGGACCAC----- AGCCCAGAAG	29	0.01	0.13	Deletion	20	-4
CGCGCGGACCACGG----- ACAGCCCAGAAG	29	0.01	0.13	Deletion	16	-2
CGCGCGGACCACGGCTCCTC----- -----AGAAG	28	0.01	0.12	Deletion	17	-9

[0228] The robustness of several nucleases was tested by assaying their ability to edit at many different target sites across several genes. Over 40 targets were tested in the expanded guide panel. All proteins tested showed robust editing at the diverse sites. Results are shown in Table 7.

Table 7: Robustness of select RNA-guided nucleases

RGN	Gene	SGN Number	Overall Editing Rate (%)
APG01868	TRA	SGN001684	42.62
		SGN001685	1.43
		SGN001686	8.19
		SGN001687	8.83
		SGN001688	0.21
		SGN001689	0
		SGN001690	0
		SGN001691	20.86
		SGN001697	0.93
		SGN001698	0
		SGN001699	18.84
		SGN001700	21.8
		SGN001701	39.94

RGN	Gene	SGN Number	Overall Editing Rate (%)
	EMX1	SGN001702	2.16
		SGN001703	0.79
		SGN001704	3.49
		SGN001705	14.49
		SGN001706	1.04
		SGN001707	2.51
		SGN001708	1.75
		SGN001709	3.62
		SGN001710	0
		SGN001711	13.39
	HAO 1	SGN001713	22.29
		SGN001714	0.67
		SGN001715	0.23
		SGN001716	7.1
		SGN001717	0.68
		SGN001718	0.21
		SGN001719	0
		SGN001721	0.17
		SGN001722	1.36
		SGN001723	24.16
	LDHA	SGN001724	0.2
		SGN001725	4.92
		SGN001726	0
		SGN001727	1.32
		SGN001728	0.28
		SGN001729	1.94
		SGN001730	5.2
		SGN001731	11.28
		SGN001732	6.04
		SGN001733	1.12
	TRA	SGN001734	2.11
		SGN001735	7
		SGN001371	30.52
		SGN001372	26.01
		SGN001373	26.67
		SGN001374	22.94
		SGN001375	21.17
		SGN001376	0
		SGN001377	0
		SGN001378	30.04
		SGN001379	39.13
		SGN001380	4.93
		SGN001381	17.14
		SGN001382	5.6
		SGN001383	36.23
		SGN001384	44.28
		SGN001385	6.33
		SGN001386	5.55
		SGN001387	48.71

RGN	Gene	SGN Number	Overall Editing Rate (%)
APG05586	B2M	SGN001388	31.78
		SGN001389	41
		SGN001390	48.15
		SGN001391	46.19
		SGN001392	37.22
		SGN001393	31.62
		SGN001394	29.72
		SGN001396	32.88
	LDHA	SGN001397	41.45
		SGN001399	43.28
		SGN001400	2.52
		SGN001401	37.52
		SGN001402	0.37
		SGN001403	53.13
		SGN001404	44.06
		SGN001405	1.46
	HAO 1	SGN001406	21.98
		SGN001407	9.13
		SGN001408	25.06
		SGN001409	43.81
		SGN001410	37.6
		SGN001411	40.75
		SGN001412	18.2
		SGN001413	28.44
		SGN001414	29.39
		SGN001415	0.39
		SGN001416	43.59
		B2M	SGN001592
SGN001593	22.7		
SGN001594	23.6		
SGN001595	33.23		
SGN001596	20.88		
SGN001597	1.26		
SGN001598	26.7		
SGN001599	9.41		
SGN001600	28.88		
SGN001601	7.39		
SGN001602	27.8		
SGN001603	6.93		
APG01604	HAO 1	SGN001616	0
		SGN001617	2.55
		SGN001618	0.6
		SGN001619	6.29
		SGN001620	7.92
		SGN001621	13.03
		SGN001622	5.32
		SGN001623	18.58
		SGN001624	20.03
		SGN001625	1.65
		SGN001626	0.18

RGN	Gene	SGN Number	Overall Editing Rate (%)
		SGN001627	0.73
	LDHA	SGN001640	3.75
		SGN001641	1.13
		SGN001642	14.2
		SGN001643	12.16
		SGN001644	4.9
		SGN001645	4.78
		SGN001646	0.74
		SGN001647	2.89
		SGN001648	0
		SGN001649	0.15
		SGN001650	4.4
		SGN001651	7.26
		SGN001664	0.44
		SGN001665	3.4
	TRA	SGN001666	17.24
		SGN001667	2.33
		SGN001668	0.3
		SGN001669	13.68
		SGN001670	0.54
		SGN001671	5.09
		SGN001672	0.22
		SGN001673	12.22
		SGN001674	17.33
		SGN001675	11.69
APG09298	B2M	SGN001383	22.25
		SGN001384	9.5
		SGN001385	2.37
		SGN001386	0.4
		SGN001387	38.03
		SGN001388	17.66
		SGN001389	42.03
		SGN001390	42.88
		SGN001391	16.31
		SGN001392	16.5
		SGN001393	6.27
		SGN001394	17.15
	HAO 1	SGN001406	3.46
		SGN001407	1.87
		SGN001408	10.71
		SGN001409	18.79
		SGN001410	15.09
		SGN001411	14.81
		SGN001412	0.63
		SGN001413	5.92
		SGN001414	5.24
		SGN001415	0.03
		SGN001416	15.41
	LDHA	SGN001395	3.15
		SGN001396	28.53

RGN	Gene	SGN Number	Overall Editing Rate (%)
		SGN001397	11.69
		SGN001399	23.92
		SGN001400	0.89
		SGN001401	33.97
		SGN001402	0
		SGN001403	25.62
		SGN001404	16.96
		SGN001405	0.11
	TRA	SGN001162	44.26
		SGN001163	42.06
		SGN001164	8.1
		SGN001371	21.05
		SGN001372	3.95
		SGN001373	7.8
		SGN001374	9.04
		SGN001375	2.94
		SGN001376	0
		SGN001377	0
		SGN001378	22.14
		SGN001379	27.43
		SGN001380	0.16
		SGN001381	14.18
		SGN001382	2.78

Example 5: Protein engineering of APG05586

[0229] Conserved and variable residues of APG05586 were identified by comparison of APG05586 to closely related homologs, including APG08770 (SEQ ID NO: 70), APG09882 (set forth as SEQ ID NO: 568 and described in International Appl. No. PCT/US2020/045759, which is incorporated by reference in its entirety), and APG01658 (set forth as SEQ ID NO: 569 and described in International Appl. No. PCT/US2020/045759). Several variants were generated containing mutations at the nonconserved locations to identify critical residues in the APG05586 protein. In total, 132 residues were altered in ten APG05586 engineered variant RGNs (SEQ ID NOs: 570-579). These ten APG05586 variants and wild type APG05586 were then assayed for activity in mammalian cells. Using the guide RNA backbone for APG05586 (SEQ ID NO: 66), the RGNs were tested for activity at six targeted genomic locations (Table 8) following the methods described in Example 4. Mammalian codon-optimized coding sequences for each variant are provided as SEQ ID NOs: 580-589. 5' and 3' primer nucleotide sequences useful for detection of gene editing activity are also provided in Table 8. Editing rates are shown in Table 9.

Table 8: Target sequences

Guide ID	Gene	Target Sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)	5' Primer for amplification	3' Primer for amplification
SGN001159	EMX1	590	591	592	593
SGN001162	TRA	594	595	596	597
SGN001163	TRA	598	599	596	597
SGN001164	TRA	600	601	596	597
SGN001165	VEGFA	602	603	604	605
SGN001166	VEGFA	606	607	604	605

Table 9: Editing rates for APG05586 and variants thereof

RGN ID	RGN SEQ ID NO.	SGN001159	SGN001162	SGN001163	SGN001164	SGN001165	SGN001166
APG09298	570	33.40%	44.26%	42.06%	8.10%	33.94%	46.19%
APG06251	571	0%	43.59%	48.82%	5.90%	25.07%	35.08%
APG03066	572	0%	0%	0%	0%	0%	0%

RGN ID	RGN SEQ ID NO.	SGN001159	SGN001162	SGN001163	SGN001164	SGN001165	SGN001166
APG01560	573	15.12%	16.38%	17.59%	2.52%	44.99%	20.68%
APG02777	574	0%	0.08%	0%	0%	0%	0%
APG05761	575	24.25%	21.95%	21.86%	10.45%	23.72%	20.17%
APG02479	576	5.61%	9.25%	11.00%	1.45%	4.53%	6.34%
APG08385	577	31.16%	39.95%	35.42%	2.37%	31.41%	26.65%
APG09217	578	29.43%	41.12%	44.71%	4.79%	38.16%	31.76%
APG06657	579	36.81%	44.20%	41.54%	4.44%	16.29%	21.86%
APG05586	63	40.13%	46.12%	43.77%	8.00%	96.76%	77.38%

[0230] The relative activity of the variants suggests which locations in the protein tolerate mutations. Table 10 shown below is a summary of the activity of the variant RGN with the number of mutations introduced compared to APG005586. "-" is no activity; "+" is 1-15% editing in at least 4 out of 6 targets; "++" is 10-25% editing in at least 4 out of 6 targets; and "+++" is 20-50% editing in at least 4 out of 6 targets.

Table 10: Summary of protein engineering changes and editing rates

Protein	Activity Outcome	Number of mutations
APG09298	+++	10
APG06251	+++	12
APG03066	-	87
APG01560	++	10
APG02777	-	37
APG05761	++	10
APG02479	+	12
APG08385	+++	12
APG09217	+++	14
APG06657	+++	14
APG05586	+++	0

[0231] Variants APG03066 and APG02777 contained too many mutations to identify specific residues important for function, however, the low activity of these variants indicates that extensive changes to the bridge helix and recognition domain are not tolerated in this protein. All other variants contained 14 or fewer mutations, which enabled identification of specific residues important for activity. Based on these results, several residues were identified as important for function of the protein. I305L, V328A, L366I, T368S, and V405A mutations resulted in decreased activity in the assayed variants. All of these mutations are predicted to be in the recognition domain of the protein. The decrease in activity for APG01560 is a result of multiple changes that are not localized to a specific region within the protein.

Example 6: Identification of Disease Targets

[0232] A database of clinical variants was obtained from NCBI ClinVar database, which is available through the world wide web at the NCBI ClinVar website. Pathogenic Single Nucleotide Polymorphisms (SNPs) were identified from this list. Using the genomic locus information, CRISPR targets in the region overlapping and surrounding each SNP were identified. A selection of SNPs that can be corrected using base editing in combination with the RGNs of the invention to target the causal mutation ("Cas1 Mut.") is listed in Table 11. In Table 11, only one alias of each disease is listed. The "RS#" corresponds to the RS accession number through the SNP database at the NCBI website. The AlleleID corresponds to a causal allele accession number, and the Chromosome Accession number also provides accession reference information found through the NCBI website. Table 11 also provides genomic target sequence information suitable for the RGN listed for each disease. The target sequence information also provides protospacer sequence for the production of the necessary sgRNA for the corresponding RGN of the invention.

Table 11: Disease Targets for RGNs

Disease	RS#	RGN	Cas1 Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Stargardt disease 1	1800553	APG06622	C>T	22927	NC_000001.10,NC_000001.11	ABCA4	261
Stargardt disease 1	1800728	APG06622	A>G	98777	NC_000001.10,NC_000001.11	ABCA4	262

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Stargardt disease 1	61751374	APG06622	G>A	22933	NC_000001.10,NC_000001.11	ABCA4	263
Stargardt disease 1	61750641	APG02874, APG03031, APG09208	G>A	105317	NC_000001.10,NC_000001.11	ABCA4	264
Stargardt disease 1	1800553	APG02787	G>A	22927	NC_000001.10,NC_000001.11	ABCA4	265
Stargardt disease 1	1800553	APG06007	G>A	22927	NC_000001.10,NC_000001.11	ABCA4	266
Stargardt disease 1	1800553	APG03850	G>A	22927	NC_000001.10,NC_000001.11	ABCA4	267
Stargardt disease 1	1800553	APG05586	G>A	22927	NC_000001.10,NC_000001.11	ABCA4	268
Stargardt disease 1	1800553	APG08167, APG01604	C>T	22927	NC_000001.10,NC_000001.11	ABCA4	269
Familial hyperinsulinism	1.51E+08	APG02874, APG03031, APG09208	G>A	24127	NC_000011.9,NC_000011.10	ABCC8	270
Very long chain acyl-CoA dehydrogenase deficiency	1.14E+08	APG06622	T>C	33877	NC_000017.10,NC_000017.11	ACADVL	271
Very long chain acyl-CoA dehydrogenase deficiency	1.14E+08	APG06248	T>C	33877	NC_000017.10,NC_000017.11	ACADVL	272
Very long chain acyl-CoA dehydrogenase deficiency	3.7E+08	APG02874, APG03031, APG09208	G>A	98197	NC_000017.10,NC_000017.11	ACADVL	273
Baraitser-Winter syndrome 1	2.82E+08	APG02874, APG03031, APG09208	G>A	38553	NC_000007.13,NC_000007.14	ACTB	274
Severe immunodeficiency due to ADA deficiency	1.22E+08	APG02874, APG03031, APG09208	G>A	16996	NC_000020.10,NC_000020.11	ADA	275
Severe immunodeficiency due to ADA deficiency	1.22E+08	APG02874, APG03031, APG09208	T>C	17004	NC_000020.10,NC_000020.11	ADA	276
Primary hyperoxaluria	1.22E+08	APG06622	G>A	38436	NC_000002.11,NC_000002.12	AGXT	277
Congenital disorder of glycosylation	28939378	APG06622	C>T	19763	NC_000016.9,NC_000016.10	ALG1	278
Hypophosphatasia	1.22E+08	APG06622	G>A	28709	NC_000001.10,NC_000001.11	ALPL	279
Hypophosphatasia	1.22E+08	APG02874, APG03031, APG09208	G>A	28709	NC_000001.10,NC_000001.11	ALPL	280
Colorectal cancer	1.38E+08	APG06622	C>T	15837	NC_000005.9,NC_000005.10	APC	281
Metachromatic leukodystrophy	80338815	APG06622	C>T	18090	NC_000022.10,NC_000022.11	ARSA	282
Wilson disease	1.94E+08	APG02874, APG03031, APG09208	G>A	44393	NC_000013.10,NC_000013.11	ATP7B	283
Cardio-facio-cutaneous syndrome	1.8E+08	APG06622	T>C	29012	NC_000007.13,NC_000007.14	BRAF	284
Cardio-facio-cutaneous syndrome	1.8E+08	APG06248	T>C	29012	NC_000007.13,NC_000007.14	BRAF	285
Breast and/or ovarian cancer	41293455	APG06622	G>A	32714	NC_000017.10,NC_000017.11	BRCA1	286
Breast and/or ovarian cancer	41293465	APG06622	G>A	70268	NC_000017.10,NC_000017.11	BRCA1	287
Breast and colorectal cancer	55770810	APG06622	G>A	70063	NC_000017.10,NC_000017.11	BRCA1	288
Breast and/or ovarian cancer	62625307	APG06622	G>A	69596	NC_000017.10,NC_000017.11	BRCA1	289
Breast and/or ovarian cancer	62625308	APG06622	G>A	32710	NC_000017.10,NC_000017.11	BRCA1	290

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Breast and/or ovarian cancer	80356962	APG06622	C>T	70247	NC_000017.10,NC_000017.11	BRCA1	291
Breast and/or ovarian cancer	41293455	APG02787	C>T	32714	NC_000017.10,NC_000017.11	BRCA1	292
Breast and/or ovarian cancer	41293455	APG06007	C>T	32714	NC_000017.10,NC_000017.11	BRCA1	293
Breast and/or ovarian cancer	41293455	APG03850	C>T	32714	NC_000017.10,NC_000017.11	BRCA1	294
Breast and/or ovarian cancer	41293455	APG05586	C>T	32714	NC_000017.10,NC_000017.11	BRCA1	295
Breast and/or ovarian cancer	41293455	APG08167, APG01604	G>A	32714	NC_000017.10,NC_000017.11	BRCA1	296
Breast and/or ovarian cancer	80356962	APG08167, APG01604	C>T	70247	NC_000017.10,NC_000017.11	BRCA1	297
Breast and/or ovarian cancer	80358163	APG08167, APG01604	T>C	46006	NC_000017.10,NC_000017.11	BRCA1	298
Breast and/or ovarian cancer	45580035	APG06622	C>T	67431	NC_000013.10,NC_000013.11	BRCA2	299
Breast and/or ovarian cancer	80359212	APG06622	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	300
Breast and/or ovarian cancer	80359003	APG02874, APG03031, APG09208	G>A	67069	NC_000013.10,NC_000013.11	BRCA2	301
Breast and/or ovarian cancer	80359004	APG02874, APG03031, APG09208	G>A	46672	NC_000013.10,NC_000013.11	BRCA2	302
Breast and/or ovarian cancer	80359212	APG02787	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	303
Breast and/or ovarian cancer	80359212	APG06007	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	304
Breast and/or ovarian cancer	80359212	APG03850	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	305
Breast and/or ovarian cancer	80359212	APG05586	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	306
Breast and/or ovarian cancer	80359212	APG08167, APG01604	C>T	67494	NC_000013.10,NC_000013.11	BRCA2	307
Breast and/or ovarian cancer	80359071	APG08167, APG01604	G>A	67203	NC_000013.10,NC_000013.11	BRCA2	308
CAPN3-Related Disorders	1.21E+08	APG02874, APG03031, APG09208	G>A	32661	NC_000015.9,NC_000015.10	CAPN3;POMT1	309
CB S-deficiency	5742905	APG06622	A>G	15159	NC_000021.8,NC_000021.9	CBS	310
CB S-deficiency	5742905	APG02874, APG03031, APG09208	T>C	15159	NC_000021.8,NC_000021.9	CBS	311
CB S-deficiency	1.22E+08	APG02874, APG03031, APG09208	G>A	15156	NC_000021.8,NC_000021.9	CBS	312
Cystic fibrosis	77010898	APG06622	G>A	22168	NC_000007.13,NC_000007.14	CFTR	313
Cystic fibrosis	75096551	APG02874, APG03031, APG09208	G>A	33858	NC_000007.13,NC_000007.14	CFTR	314
Cystic fibrosis	75527207	APG02787	G>A	22159	NC_000007.13,NC_000007.14	CFTR	315
Cystic fibrosis	75527207	APG06007	G>A	22159	NC_000007.13,NC_000007.14	CFTR	316
Cystic fibrosis	75527207	APG03850	G>A	22159	NC_000007.13,NC_000007.14	CFTR	317
Cystic fibrosis	75527207	APG05586	G>A	22159	NC_000007.13,NC_000007.14	CFTR	318
Cystic fibrosis	78655421	APG02787	G>A	22148	NC_000007.13,NC_000007.14	CFTR	319

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Cystic fibrosis	78655421	APG06007	G>A	22148	NC_000007.13,NC_000007.14	CFTR	320
Cystic fibrosis	78655421	APG03850	G>A	22148	NC_000007.13,NC_000007.14	CFTR	321
Cystic fibrosis	78655421	APG05586	G>A	22148	NC_000007.13,NC_000007.14	CFTR	322
Cystic fibrosis	75527207	APG08167, APG01604	G>A	22159	NC_000007.13,NC_000007.14	CFTR	323
Congenital myotonia	80356701	APG02874, APG03031, APG09208	T>C	33902	NC_000007.13,NC_000007.14	CLCN1	324
Osteogenesis imperfecta type I	72645321	APG02874, APG03031, APG09208	G>A	414022	NC_000017.10,NC_000017.11	COL1A1	325
Osteogenesis imperfecta type I	72645321	APG02874, APG03031, APG09208	G>A	414022	NC_000017.10,NC_000017.11	COL1A1	326
Alport syndrome 1, X-linked recessive	1.05E+08	APG02874, APG03031, APG09208	G>A	35796	NC_000023.10,NC_000023.11	COL4A5	327
Carnitine palmitoyltransferase II deficiency	74315294	APG06622	C>T	23992	NC_000001.10,NC_000001.11	CPT2	328
Carnitine palmitoyltransferase II deficiency	74315294	APG06248	C>T	23992	NC_000001.10,NC_000001.11	CPT2	329
Carnitine palmitoyltransferase II deficiency	74315294	APG06007	C>T	23992	NC_000001.10,NC_000001.11	CPT2	330
Carnitine palmitoyltransferase II deficiency	74315294	APG03850	C>T	23992	NC_000001.10,NC_000001.11	CPT2	331
Carnitine palmitoyltransferase II deficiency	74315294	APG05586	C>T	23992	NC_000001.10,NC_000001.11	CPT2	332
Carnitine palmitoyltransferase II deficiency	74315294	APG08167, APG01604	C>T	23992	NC_000001.10,NC_000001.11	CPT2	333
Dopamine beta hydroxylase deficiency	74853476	APG02874, APG03031, APG09208	T>C	16789	NC_000009.11,NC_000009.12	DBH	334
Congenital microcephaly	11555217	APG06622	C>T	34125	NC_000011.9,NC_000011.10	DHCR7	335
Smith-Lemli-Opitz syndrome	80338853	APG06622	G>A	21822	NC_000011.9,NC_000011.10	DHCR7	336
Smith-Lemli-Opitz syndrome	80338857	APG02874, APG03031, APG09208	G>A	34128	NC_000011.9,NC_000011.10	DHCR7	337
Smith-Lemli-Opitz syndrome	11555217	APG06007	G>A	34125	NC_000011.9,NC_000011.10	DHCR7	338
Smith-Lemli-Opitz syndrome	11555217	APG03850	G>A	34125	NC_000011.9,NC_000011.10	DHCR7	339
Smith-Lemli-Opitz syndrome	11555217	APG05586	G>A	34125	NC_000011.9,NC_000011.10	DHCR7	340
Familial dysautonomia	1.11E+08	APG06248	A>G	21124	NC_000009.11,NC_000009.12	ELP1	341
Hypertyrosinemia	80338901	APG06622	G>A	26909	NC_000015.9,NC_000015.10	FAR	342
Hypertyrosinemia	80338901	APG06248	G>A	26909	NC_000015.9,NC_000015.10	FAR	343
Fanconi anemia	1.05E+08	APG06622	G>A	27086	NC_000009.11,NC_000009.12	FANCC	344
Marfan Syndrome	3.98E+08	APG06622	C>T	51454	NC_000015.9,NC_000015.10	FBN1	345
Marfan Syndrome	7.28E+08	APG06622	A>G	175979	NC_000015.9,NC_000015.10	FBN1	346

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Marfan Syndrome	1.38E+08	APG02874, APG03031, APG09208	G>A	31496	NC_000015.9,NC_000015.10	FBN1	347
Marfan Syndrome	1.38E+08	APG02874, APG03031, APG09208	G>A	31496	NC_000015.9,NC_000015.10	FBN1	348
Marfan Syndrome	3.88E+08	APG02874, APG03031, APG09208	G>A	38652	NC_000015.9,NC_000015.10	FBN1	349
FGFR3-Related Disorders	1.22E+08	APG06622	C>T	31371	NC_000004.11,NC_000004.12	FGFR3	350
Glycogen storage disease type 1A	1801175	APG08167, APG01604	C>T	27037	NC_000017.10,NC_000017.11	G6PC	351
Glycogen storage disease, type II	3.98E+08	APG02874, APG03031, APG09208	G>A	415590	NC_000017.10,NC_000017.11	GAA	352
Deficiency of UDPglucosehexose-1-phosphate uridylyltransferase	75391579	APG06622	A>G	18653	NC_000009.11,NC_000009.12	GALT	353
Glutaric aciduria, type 1	1.21E+08	APG02874, APG03031, APG09208	G>A	17127	NC_000019.9,NC_000019.10	GCDH	354
Deafness, X-linked	76434661	APG06622	C>T	53916	NC_000013.10,NC_000013.11	GJB2	355
Deafness, X-linked	80338945	APG06622	A>G	32055	NC_000013.10,NC_000013.11	GJB2	356
Deafness, X-linked	80338945	APG02874, APG03031, APG09208	T>C	32055	NC_000013.10,NC_000013.11	GJB2	357
Deafness, X-linked	80338945	APG02874, APG03031, APG09208	T>C	32055	NC_000013.10,NC_000013.11	GJB2	358
Deafness, X-linked	1.11E+08	APG02874, APG03031, APG09208	G>A	53902	NC_000013.10,NC_000013.11	GJB2	359
Deafness, X-linked	1.05E+08	APG06007	G>A	32041	NC_000013.10,NC_000013.11	GJB2	360
Deafness, X-linked	1.05E+08	APG03850	G>A	32041	NC_000013.10,NC_000013.11	GJB2	361
Deafness, X-linked	1.05E+08	APG08167, APG01604	C>T	32041	NC_000013.10,NC_000013.11	GJB2	362
Deafness, X-linked	80338945	APG08167, APG01604	A>G	32055	NC_000013.10,NC_000013.11	GJB2	363
Inclusion body myopathy 2	28937594	APG06622	A>G	21064	NC_000009.11,NC_000009.12	GNE	364
Inclusion body myopathy 2	28937594	APG06248	A>G	21064	NC_000009.11,NC_000009.12	GNE	365
beta Thalassemia	33930165	APG02874, APG03031, APG09208	G>A	30165	NC_000011.9,NC_000011.10	HBB	366
Mucopolysaccharidosis type I	1.22E+08	APG06622	G>A	26947	NC_000004.11,NC_000004.12	IDUA	367
Mucopolysaccharidosis type I	1.22E+08	APG06622	C>T	26948	NC_000004.11,NC_000004.12	IDUA	368
Mucopolysaccharidosis type I	1.22E+08	APG02874, APG03031, APG09208	G>A	26947	NC_000004.11,NC_000004.12	IDUA	369
Congenital long QT syndrome	1.99E+08	APG02874, APG03031, APG09208	G>A	67758	NC_000011.9,NC_000011.10	KCNQ1	370
Congenital long QT syndrome	1.99E+08	APG02874, APG03031,	T>C	67776	NC_000011.9,NC_000011.10	KCNQ1	371

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
		APG09208					
Familial hypercholesterolemia	28942080	APG06622	G>A	18735	NC_000019.9,NC_000019.10	LDLR	372
Familial hypercholesterolemia	1.22E+08	APG06622	C>T	18725	NC_000019.9,NC_000019.10	LDLR	373
Familial hypercholesterolemia	1.38E+08	APG06622	G>A	171217	NC_000019.9,NC_000019.10	LDLR	374
Familial hypercholesterolemia	7.46E+08	APG06622	C>T	228192	NC_000019.9,NC_000019.10	LDLR	375
Familial hypercholesterolemia	7.66E+08	APG06622	G>A	228162	NC_000019.10,NC_000019.9	LDLR	376
Familial hypercholesterolemia	7.69E+08	APG06622	G>A	228176	NC_000019.10,NC_000019.9	LDLR	377
Familial hypercholesterolemia	7.46E+08	APG06248	C>T	228192	NC_000019.9,NC_000019.10	LDLR	378
Familial hypercholesterolemia	7.69E+08	APG06248	G>A	228176	NC_000019.10,NC_000019.9	LDLR	379
Familial hypercholesterolemia	3.76E+08	APG02874, APG03031, APG09208	G>A	198012	NC_000019.10,NC_000019.9	LDLR	380
Familial hypercholesterolemia	7.69E+08	APG02874, APG03031, APG09208	G>A	228176	NC_000019.10,NC_000019.9	LDLR	381
Familial hypercholesterolemia	7.75E+08	APG02874, APG03031, APG09208	T>C	228197	NC_000019.9,NC_000019.10	LDLR	382
Familial hypercholesterolemia	7.76E+08	APG02874, APG03031, APG09208	G>A	246116	NC_000019.9,NC_000019.10	LDLR	383
Familial hypercholesterolemia	8.79E+08	APG02874, APG03031, APG09208	T>C	246008	NC_000019.10,NC_000019.9	LDLR	384
Familial hypercholesterolemia	1.38E+08	APG02787	G>A	171217	NC_000019.9,NC_000019.10	LDLR	385
Familial hypercholesterolemia	1.38E+08	APG06007	G>A	171217	NC_000019.9,NC_000019.10	LDLR	386
Familial hypercholesterolemia	1.38E+08	APG03850	G>A	171217	NC_000019.9,NC_000019.10	LDLR	387
Familial hypercholesterolemia	1.38E+08	APG05586	G>A	171217	NC_000019.9,NC_000019.10	LDLR	388
Familial hypercholesterolemia	1.38E+08	APG08167, APG01604	G>A	171217	NC_000019.9,NC_000019.10	LDLR	389
Familial hypercholesterolemia	1.22E+08	APG08167, APG01604	C>T	18725	NC_000019.9,NC_000019.10	LDLR	390
Cardio-facio-cutaneous syndrome	1.22E+08	APG06622	A>G	28390	NC_000015.9,NC_000015.10	MAP2K1	391
MECP2-Related Disorders	28934906	APG06622	G>A	26850	NC_000023.10,NC_000023.11	MECP2	392
MECP2-Related Disorders	28935468	APG06622	G>A	26863	NC_000023.10,NC_000023.11	MECP2	393
MECP2-Related Disorders	61749721	APG06622	G>A	26868	NC_000023.10,NC_000023.11	MECP2	394
MECP2-Related Disorders	61750240	APG06622	G>A	26854	NC_000023.10,NC_000023.11	MECP2	395
MECP2-Related Disorders	28935468	APG06248	G>A	26863	NC_000023.10,NC_000023.11	MECP2	396
MECP2-Related Disorders	28934906	APG06007	C>T	26850	NC_000023.10,NC_000023.11	MECP2	397

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
MECP2-Related Disorders	28934906	APG03850	C>T	26850	NC_000023.10,NC_000023.11	MECP2	398
MECP2-Related Disorders	61750240	APG02787	C>T	26854	NC_000023.10,NC_000023.11	MECP2	399
MECP2-Related Disorders	61750240	APG06007	C>T	26854	NC_000023.10,NC_000023.11	MECP2	400
MECP2-Related Disorders	61750240	APG03850	C>T	26854	NC_000023.10,NC_000023.11	MECP2	401
MECP2-Related Disorders	61750240	APG05586	C>T	26854	NC_000023.10,NC_000023.11	MECP2	402
Angelman syndrome	61751362	APG02787	C>T	26858	NC_000023.10,NC_000023.11	MECP2	403
Angelman syndrome	61751362	APG06007	C>T	26858	NC_000023.10,NC_000023.11	MECP2	404
Angelman syndrome	61751362	APG03850	C>T	26858	NC_000023.10,NC_000023.11	MECP2	405
Angelman syndrome	61751362	APG05586	C>T	26858	NC_000023.10,NC_000023.11	MECP2	406
Angelman syndrome	28934906	APG08167, APG01604	G>A	26850	NC_000023.10,NC_000023.11	MECP2	407
Familial Mediterranean fever	28940579	APG06622	A>G	17579	NC_000016.9,NC_000016.10	MEFV	408
Familial Mediterranean fever	61752717	APG06622	T>C	17577	NC_000016.9,NC_000016.10	MEFV	409
Familial Mediterranean fever	1.05E+08	APG06622	C>T	17588	NC_000016.9,NC_000016.10	MEFV	410
Familial Mediterranean fever	61752717	APG06248	T>C	17577	NC_000016.9,NC_000016.10	MEFV	411
Familial Mediterranean fever	1.05E+08	APG06248	C>T	17588	NC_000016.9,NC_000016.10	MEFV	412
Familial Mediterranean fever	1.05E+08	APG02874, APG03031, APG09208	G>A	17588	NC_000016.9,NC_000016.10	MEFV	413
Familial Mediterranean fever	28940579	APG08167, APG01604	A>G	17579	NC_000016.9,NC_000016.10	MEFV	414
Charcot-Marie-Tooth disease, type 2	28940293	APG02874, APG03031, APG09208	T>C	17309	NC_000001.10,NC_000001.11	MFN2	415
Hereditary nonpolyposis colon cancer	63751657	APG02874, APG03031, APG09208	G>A	95331	NC_000003.11,NC_000003.12	MLH1	416
Hereditary nonpolyposis colon cancer	63751711	APG02874, APG03031, APG09208	G>A	95792	NC_000003.11,NC_000003.12	MLH1	417
Methylmalonic acidemia	1.22E+08	APG06622	C>T	16462	NC_000001.10,NC_000001.11	MMACHC	418
Methylmalonic acidemia	1.22E+08	APG06248	C>T	16462	NC_000001.10,NC_000001.11	MMACHC	419
Methylmalonic acidemia	1.22E+08	APG02874, APG03031, APG09208	G>A	16464	NC_000001.10,NC_000001.11	MMACHC	420
Hereditary cancerpredisposing syndrome	63750636	APG06622	C>T	96378	NC_000002.11,NC_000002.12	MSH2	421
Hereditary cancerpredisposing syndrome	63749843	APG06622	C>T	94826	NC_000002.11,NC_000002.12	MSH6	422
Hereditary cancerpredisposing syndrome	7.86E+08	APG06622	C>T	181998	NC_000002.12,NC_000002.11	MSH6	423
Hereditary cancerpredisposing syndrome	63750741	APG02874, APG03031, APG09208	T>C	94663	NC_000002.11,NC_000002.12	MSH6	424
Hereditary	63749843	APG02787	C>T	94826	NC_000002.11,NC_000002.12	MSH6	425

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
cancerpredisposing syndrome							
Hereditary cancerpredisposing syndrome	63749843	APG06007	C>T	94826	NC_000002.11,NC_000002.12	MSH6	426
Hereditary cancerpredisposing syndrome	63749843	APG03850	C>T	94826	NC_000002.11,NC_000002.12	MSH6	427
Hereditary cancerpredisposing syndrome	63749843	APG05586	C>T	94826	NC_000002.11,NC_000002.12	MSH6	428
Hereditary cancerpredisposing syndrome	63751017	APG02787	C>T	94786	NC_000002.11,NC_000002.12	MSH6	429
Hereditary cancerpredisposing syndrome	63751017	APG06007	C>T	94786	NC_000002.11,NC_000002.12	MSH6	430
Hereditary cancerpredisposing syndrome	63751017	APG03850	C>T	94786	NC_000002.11,NC_000002.12	MSH6	431
Hereditary cancerpredisposing syndrome	63751017	APG05586	C>T	94786	NC_000002.11,NC_000002.12	MSH6	432
Hereditary cancerpredisposing syndrome	63751017	APG08167, APG01604	C>T	94786	NC_000002.11,NC_000002.12	MSH6	433
MUTYH-associated polyposis	34612342	APG06622	T>C	20332	NC_000001.10,NC_000001.11	MUTYH	434
MUTYH-associated polyposis	36053993	APG06622	C>T	20333	NC_000001.10,NC_000001.11	MUTYH	435
MUTYH-associated polyposis	36053993	APG02787	G>A	20333	NC_000001.10,NC_000001.11	MUTYH	436
MUTYH-associated polyposis	36053993	APG06007	G>A	20333	NC_000001.10,NC_000001.11	MUTYH	437
MUTYH-associated polyposis	36053993	APG03850	G>A	20333	NC_000001.10,NC_000001.11	MUTYH	438
MUTYH-associated polyposis	36053993	APG05586	G>A	20333	NC_000001.10,NC_000001.11	MUTYH	439
MUTYH-associated polyposis	36053993	APG08167, APG01604	C>T	20333	NC_000001.10,NC_000001.11	MUTYH	440
MUTYH-associated polyposis	34612342	APG08167, APG01604	T>C	20332	NC_000001.10,NC_000001.11	MUTYH	441
Hyperimmunoglobulin D with periodic fever	28934897	APG06622	G>A	26968	NC_000012.11,NC_000012.12	MVK	442
MYBPC3-Related Disorders	2E+08	APG06622	C>T	174776	NC_000011.9,NC_000011.10	MYBPC3	443
MYBPC3-Related Disorders	3.88E+08	APG06622	G>A	45725	NC_000011.9,NC_000011.10	MYBPC3	444
MYBPC3-Related Disorders	3.98E+08	APG06622	C>T	51962	NC_000011.9,NC_000011.10	MYBPC3	445
MYBPC3-Related Disorders	2E+08	APG06248	C>T	174776	NC_000011.9,NC_000011.10	MYBPC3	446
MYBPC3-Related Disorders	1.88E+08	APG02874, APG03031, APG09208	T>C	45267	NC_000011.9,NC_000011.10	MYBPC3	447
MYBPC3-Related Disorders	2E+08	APG02874, APG03031, APG09208	G>A	174776	NC_000011.9,NC_000011.10	MYBPC3	448
MYBPC3-Related Disorders	3.98E+08	APG02874,	G>A	51820	NC_000011.9,NC_000011.10	MYBPC3	449

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
Disorders		APG03031, APG09208					
MYBPC3-Related Disorders	3.98E+08	APG02874, APG03031, APG09208	G>A	51962	NC_000011.9,NC_000011.10	MYBPC3	450
Cardiomyopathy	3218716	APG06622	C>T	52071	NC_000014.8,NC_000014.9	MYH7	451
Cardiomyopathy	36211715	APG06622	C>T	29159	NC_000014.8,NC_000014.9	MYH7	452
Cardiomyopathy	1.22E+08	APG06622	G>A	29128	NC_000014.8,NC_000014.9	MYH7	453
Cardiomyopathy	3.72E+08	APG06622	C>T	52045	NC_000014.8,NC_000014.9	MYH7	454
Cardiomyopathy	3.98E+08	APG02874, APG03031, APG09208	T>C	52276	NC_000014.8,NC_000014.9	MYH7	455
Cardiomyopathy	3.72E+08	APG06007	G>A	52045	NC_000014.8,NC_000014.9	MYH7	456
Cardiomyopathy	3.72E+08	APG03850	G>A	52045	NC_000014.8,NC_000014.9	MYH7	457
Deafness, autosomal recessive	1.11E+08	APG02874, APG03031, APG09208	G>A	52388	NC_000011.9,NC_000011.10	MYO7A	458
Inborn genetic diseases	80358259	APG06622	A>G	18006	NC_000018.9,NC_000018.10	NPC1	459
Inborn genetic diseases	80358259	APG02874, APG03031, APG09208	T>C	18006	NC_000018.9,NC_000018.10	NPC1	460
Inborn genetic diseases	1.2E+08	APG02874, APG03031, APG09208	G>A	18010	NC_000018.9,NC_000018.10	NPC1	461
Phenylketonuria	5030851	APG06622	G>A	15628	NC_000012.11,NC_000012.12	PAH	462
Phenylketonuria	5030858	APG06622	G>A	15616	NC_000012.11,NC_000012.12	PAH	463
Hyperphenylalaninemia	5030860	APG06622	T>C	15632	NC_000012.11,NC_000012.12	PAH	464
Phenylketonuria	62516101	APG02874, APG03031, APG09208	G>A	15658	NC_000012.11,NC_000012.12	PAH	465
Hyperphenylalaninemia, non-pku	62644499	APG02874, APG03031, APG09208	G>A	15656	NC_000012.11,NC_000012.12	PAH	466
Phenylketonuria	5030858	APG02787	C>T	15616	NC_000012.11,NC_000012.12	PAH	467
Phenylketonuria	5030858	APG06007	C>T	15616	NC_000012.11,NC_000012.12	PAH	468
Phenylketonuria	5030858	APG03850	C>T	15616	NC_000012.11,NC_000012.12	PAH	469
Phenylketonuria	5030858	APG05586	C>T	15616	NC_000012.11,NC_000012.12	PAH	470
Hyperphenylalaninemia, non-pku	5030860	APG08167, APG01604	T>C	15632	NC_000012.11,NC_000012.12	PAH	471
Hyperphenylalaninemia, non-pku	62642937	APG08167, APG01604	G>A	15667	NC_000012.11,NC_000012.12	PAH	472
Familial cancer of breast	1.8E+08	APG06622	G>A	132139	NC_000016.10,NC_000016.9	PALB2	473
Familial cancer of breast	1.8E+08	APG02874, APG03031, APG09208	G>A	132185	NC_000016.10,NC_000016.9	PALB2	474
Peroxisome biogenesis disorder 1B	61750420	APG08167, APG01604	C>T	22555	NC_000007.13,NC_000007.14	PEX1	475
Immunodeficiency 14	3.98E+08	APG06622	G>A	94255	NC_000001.10,NC_000001.11	PIK3CD	476
Polycystic kidney dysplasia	1.38E+08	APG06622	G>A	19147	NC_000006.11,NC_000006.12	PKHD1	477
Carbohydrate-deficient glycoprotein syndrome type I	28936415	APG02787	G>A	22745	NC_000016.9,NC_000016.10	PMM2	478
Carbohydrate-deficient glycoprotein syndrome	28936415	APG06007	G>A	22745	NC_000016.9,NC_000016.10	PMM2	479

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
type I							
Carbohydrate-deficient glycoprotein syndrome type I	28936415	APG03850	G>A	22745	NC_000016.9,NC_000016.10	PMM2	480
Carbohydrate-deficient glycoprotein syndrome type I	28936415	APG05586	G>A	22745	NC_000016.9,NC_000016.10	PMM2	481
Carbohydrate-deficient glycoprotein syndrome type I	28936415	APG08167, APG01604	G>A	22745	NC_000016.9,NC_000016.10	PMM2	482
POLG-related condition	1.14E+08	APG06622	C>T	28535	NC_000015.9,NC_000015.10	POLG	483
POLG-related condition	1.14E+08	APG06622	C>T	28541	NC_000015.9,NC_000015.10	POLG	484
POLG-related condition	1.14E+08	APG02874, APG03031, APG09208	G>A	28535	NC_000015.9,NC_000015.10	POLG	485
POLG-related condition	1.14E+08	APG06007	G>A	28535	NC_000015.9,NC_000015.10	POLG	486
POLG-related condition	1.14E+08	APG03850	G>A	28535	NC_000015.9,NC_000015.10	POLG	487
POLG-related condition	1.14E+08	APG08167, APG01604	C>T	28541	NC_000015.9,NC_000015.10	POLG	488
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG06622	G>A	23943	NC_000001.10,NC_000001.11	PPT1	489
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG02787	C>T	23943	NC_000001.10,NC_000001.11	PPT1	490
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG06007	C>T	23943	NC_000001.10,NC_000001.11	PPT1	491
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG03850	C>T	23943	NC_000001.10,NC_000001.11	PPT1	492
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG05586	C>T	23943	NC_000001.10,NC_000001.11	PPT1	493
Ceroid lipofuscinosis neuronal 1	1.38E+08	APG08167, APG01604	G>A	23943	NC_000001.10,NC_000001.11	PPT1	494
Cardiomyopathy	1.22E+08	APG06622	C>T	21885	NC_000007.13,NC_000007.14	PRKAG2	495
Cowden syndrome	1.22E+08	APG06622	C>T	22852	NC_000010.10,NC_000010.11	PTEN	496
PTPN11-related disorder	1.22E+08	APG06622	C>T	28370	NC_000012.11,NC_000012.12	PTPN 11	497
B lymphoblastic leukemia lymphoma, no ICD-O subtype	1.22E+08	APG06622	A>G	28372	NC_000012.11,NC_000012.12	PTPN 11	498
PTPN11-related disorder	3.98E+08	APG06622	A>G	49032	NC_000012.11,NC_000012.12	PTPN 11	499
PTPN11-related disorder	1.22E+08	APG06248	C>T	28370	NC_000012.11,NC_000012.12	PTPN 11	500
PTPN11-related disorder	1.22E+08	APG06248	A>G	28379	NC_000012.11,NC_000012.12	PTPN11	501
PTPN 11-related disorder	28933386	APG02787	A>G	28365	NC_000012.11,NC_000012.12	PTPN11	502
PTPN11-related disorder	28933386	APG06007	A>G	28365	NC_000012.11,NC_000012.12	PTPN11	503
PTPN11-related disorder	28933386	APG03850	A>G	28365	NC_000012.11,NC_000012.12	PTPN11	504
PTPN11-related disorder	28933386	APG05586	A>G	28365	NC_000012.11,NC_000012.12	PTPN11	505
PTPN11-related disorder	1.22E+08	APG02787	A>G	28372	NC_000012.11,NC_000012.12	PTPN11	506
PTPN11-related disorder	1.22E+08	APG06007	A>G	28372	NC_000012.11,NC_000012.12	PTPN11	507
PTPN11-related	1.22E+08	APG03850	A>G	28372	NC_000012.11,NC_000012.12	PTPN11	508

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
disorder							
PTPN11-related disorder	1.22E+08	APG05586	A>G	28372	NC_000012.11,NC_000012.12	PTPN11	509
PTPN11-related disorder	28933386	APG08167, APG01604	A>G	28365	NC_000012.11,NC_000012.12	PTPN11	510
Glycogen storage disease	1.17E+08	APG06622	G>A	17337	NC_000011.9,NC_000011.10	PYGM	511
Glycogen storage disease	1.17E+08	APG06248	G>A	17337	NC_000011.9,NC_000011.10	PYGM	512
Breast-ovarian cancer, familial 4	3.88E+08	APG06622	G>A	39241	NC_000017.10,NC_000017.11	RAD51D	513
Dilated cardiomyopathy 1DD	2.68E+08	APG02874, APG03031, APG09208	G>A	15310	NC_000010.10,NC_000010.11	RBM20	514
RET-Related Disorders	74799832	APG06622	T>C	28958	NC_000010.10,NC_000010.11	RET	515
RET-Related Disorders	74799832	APG02874, APG03031, APG09208	T>C	28958	NC_000010.10,NC_000010.11	RET	516
RYR1-Related Disorders	1.18E+08	APG06622	C>T	28003	NC_000019.9,NC_000019.10	RYR1	517
RYR1-Related Disorders	2.01E+08	APG06622	C>T	169564	NC_000019.9,NC_000019.10	RYR1	518
RYR1-Related Disorders	1.18E+08	APG02874, APG03031, APG09208	G>A	76888	NC_000019.9,NC_000019.10	RYR1	519
RYR1-Related Disorders	1.18E+08	APG02874, APG03031, APG09208	G>A	76888	NC_000019.9,NC_000019.10	RYR1	520
RYR1-Related Disorders	1.18E+08	APG02874, APG03031, APG09208	G>A	76835	NC_000019.9,NC_000019.10	RYR1	521
RYR1-Related Disorders	1.18E+08	APG02874, APG03031, APG09208	T>C	28014	NC_000019.9,NC_000019.10	RYR1	522
Shwachman syndrome	1.14E+08	APG06622	A>G	18235	NC_000007.13,NC_000007.14	SBDS	523
Brugada syndrome	1.38E+08	APG06622	C>T	24416	NC_000003.11,NC_000003.12	SCN5A	524
Brugada syndrome	28937316	APG02874, APG03031, APG09208	G>A	24408	NC_000003.11,NC_000003.12	SCN5A	525
Brugada syndrome	45546039	APG02874, APG03031, APG09208	G>A	48043	NC_000003.11,NC_000003.12	SCN5A	526
Brugada syndrome	72549410	APG02874, APG03031, APG09208	G>A	78547	NC_000003.11,NC_000003.12	SCN5A	527
Cowden syndrome 3	80338844	APG06622	C>T	21935	NC_000011.9,NC_000011.10	SDHD	528
Cowden syndrome 3	80338844	APG06248	C>T	21935	NC_000011.9,NC_000011.10	SDHD	529
Alpha-1 -antitrypsin deficiency	28929474	APG06622	C>T	33006	NC_000014.8,NC_000014.9	SERPINA1	530
Alpha-1 -antitrypsin deficiency	28929474	APG02787	G>A	33006	NC_000014.8,NC_000014.9	SERPINA1	531
Alpha-1 -antitrypsin deficiency	28929474	APG03850	G>A	33006	NC_000014.8,NC_000014.9	SERPINA1	532
Alpha-1 -antitrypsin deficiency	28929474	APG05586	G>A	33006	NC_000014.8,NC_000014.9	SERPINA1	533
Alpha-1 -antitrypsin deficiency	28929474	APG08167, APG01604	C>T	33006	NC_000014.8,NC_000014.9	SERPINA1	534
Limb-girdle muscular	28933693	APG06622	C>T	24476	NC_000017.10,NC_000017.11	SGCA	535

Disease	RS#	RGN	CasI Mut.	AlleleID	ChromosomeAccession	Gene Symbol	Target (SEQ ID NO.)
dystrophy, type 2D							
Mucopolysaccharidosis, MPS-III-A	1.05E+08	APG06622	C>T	20146	NC_000017.10,NC_000017.11	SGSH	536
Mucopolysaccharidosis, MPS-III-A	1.05E+08	APG02874, APG03031, APG09208	G>A	20146	NC_000017.10,NC_000017.11	SGSH	537
Noonan syndrome	2.68E+08	APG02787	A>G	21860	NC_000010.10,NC_000010.11	SHOC2	538
Noonan syndrome	2.68E+08	APG06007	A>G	21860	NC_000010.10,NC_000010.11	SHOC2	539
Noonan syndrome	2.68E+08	APG03850	A>G	21860	NC_000010.10,NC_000010.11	SHOC2	540
Noonan syndrome	2.68E+08	APG05586	A>G	21860	NC_000010.10,NC_000010.11	SHOC2	541
Noonan syndrome	2.68E+08	APG08167, APG01604	A>G	21860	NC_000010.10,NC_000010.11	SHOC2	542
SLC26A2-Related Disorders	1.05E+08	APG06622	C>T	19128	NC_000005.9,NC_000005.10	SLC26A2	543
SLC26A2-Related Disorders	1.11E+08	APG02874, APG03031, APG09208	G>A	52666	NC_000007.13,NC_000007.14	SLC26A4	544
Familial hypertrophic cardiomyopathy 2	7.28E+08	APG02874, APG03031, APG09208	G>A	172354	NC_000001.10,NC_000001.11	TNNT2	545
Charcot-Marie-Tooth disease type 2C	3.98E+08	APG02874, APG03031, APG09208	G>A	48018	NC_000012.11,NC_000012.12	TRPV4	546
Focal cortical dysplasia type II	28934872	APG06622	G>A	27436	NC_000016.9,NC_000016.10	TSC2	547
Amyloidogenic transthyretin amyloidosis	76992529	APG06622	G>A	28465	NC_000018.9,NC_000018.10	TTR	548
Amyloidogenic transthyretin amyloidosis	76992529	APG06248	G>A	28465	NC_000018.9,NC_000018.10	TTR	549
Oculocutaneous albinism	1.05E+08	APG06622	C>T	18816	NC_000011.9,NC_000011.10	TYR	550
Oculocutaneous albinism	1.22E+08	APG02874, APG03031, APG09208	G>A	18814	NC_000011.9,NC_000011.10	TYR	551
Von Willebrand disease	41276738	APG06622	C>T	15335	NC_000012.11,NC_000012.12	VWF	552

Example 7: Targeting mutations responsible for Hurler Syndrome

[0233] The following describes a potential treatment for Hurler Syndrome, also referred to as MPS-1, using an RNA directed base editing system that corrects a mutation responsible for Hurler syndrome in a large proportion of patients with the disease. This approach utilizes a base editing fusion protein that is RNA guided and that can be packaged into a single AAV vector for delivery to a wide range of tissue types. Depending on the exact regulatory elements and base editor domain used, it may also be possible to engineer a single vector that encodes for both the base editing fusion protein and a single guide RNA to target the diseased locus.

Example 7.7; Identifying RGN with ideal PAM

[0234] The genetic disease MPS-1 is a lysosomal storage disease characterized at the molecular level by the accumulation of dermatan sulfate and heparan sulfate in lysosomes. This disease is generally an inherited genetic disorder caused by mutations in the IDUA gene (NCBI Reference sequence NG_008103. 1), which encodes α -L-iduronidase. The disease is a result of a deficiency of α -L-iduronidase. The most common IDUA mutations found in studies of individuals of Northern European background are W402X and Q70X, both nonsense mutations resulting in premature termination of translation (Bunge et al. (1994), Hum. Mol. Genet., 3(6): 861-866, herein incorporated by reference). Reversion of a single nucleotide would restore the wild-type coding sequence and result in protein expression controlled by the endogenous regulatory mechanisms of the genetic locus.

[0235] The W402X mutation of the human *Idua* gene accounts for a high proportion of MPS-1H cases. Base editors can target a narrow sequence window relative to the binding site of the protospacer component of the guide RNA and thus the presence of a PAM sequence a specific distance from the target locus is essential for the success of the strategy. Given the constraints that the target mutation must be on the exposed non-target strand (NTS) during the interaction of the base editing protein and that the footprint of the RGN domain will block access to the region near the PAM, an accessible locus is thought to be 10-30 bp from the PAM. To avoid editing and mutagenesis of other nearby adenosine bases in this window, different linkers are screened. The ideal window is 12-16 bp from the PAM.

[0236] A PAM sequence compatible with APG02874, APG09208, and APG05586 is readily apparent at the genetic locus. These nucleases have a PAM sequence of 5'-nnnnCC-3' (SEQ ID NO: 35), 5'-nnnnC-3' (SEQ ID NO: 62) and 5'-nnRYA-3' (SEQ ID NO: 69), respectively, and are compact in size - potentially allowing delivery via a single AAV vector. This delivery approach bestows multiple advantages relative to others, such as access to a wide range of tissues (liver, muscle, CNS) and well established safety profile and manufacturing techniques.

[0237] Cas9 from *S. pyogenes* (SpyCas9) requires a PAM sequence of NGG (SEQ ID NO: 256), which is present near the W402X locus, but the size of SpyCas9 prevents packaging into a single AAV vector, and thus forgoes the aforementioned advantages of this approach. While a dual delivery strategy may be employed (for example, Ryu et al, (2018), Nat. Biotechnol., 36(6): 536-539, herein incorporated by reference), it would add significant manufacturing complexity and cost. Additionally, dual viral vector delivery significantly decreases the efficiency of gene correction, since a successful edit in a given cell requires infection with both vectors and assembly of the fusion protein in the cell.

[0238] A commonly used Cas9 ortholog from *S. aureus* (SauCas9) is considerably smaller in size relative to SpyCas9 but has a more complex PAM requirement - NGRRT (SEQ ID NO: 257). This sequence is not within a range expected to be useful for base editing of the causative locus.

Example 7.2: RGN fusion constructs and sgRNA sequences

[0239] A DNA sequence encoding a fusion protein with the following domains is produced using standard molecular biology techniques: 1) an RGN domain with mutations that inactivate the DNA cleavage activity ("dead" or "nickase"); 2) an adenosine deaminase useful for base editing. All constructs described in the table below comprise a fusion protein with the base editing active domain, in this example ADAT (SEQ ID NO: 211), operably fused to the N-terminal end of the a dead RGN APG02874 (SEQ ID NO: 214), APG09208 (SEQ ID NO: 216), and APG005586 (SEQ ID NO: 567). Other adenosine deaminases useful for base editing DNA may also be used (see for example PCT application PCT/US2019/068079). It is known in the art that a fusion protein could also be made with the base-editing enzyme at the C-terminal end of the RGN. Additionally, the RGN and the base editor of the fusion protein are typically separated by a linker amino sequence. It is known in the art that lengths of standard linkers range from 15-30 amino acids. Further, it is known in the art that certain fusion proteins between an RGN and a base-editing enzyme may also comprise at least one uracil glycosylase inhibitor (UGI) domain (SEQ ID NO: 212), which may increase base editing efficiency (U.S. Patent No. 10,167, 457, herein incorporated by reference). Therefore, a fusion protein may comprise RGN APG02874, APG09208, or a variant thereof, an adenosine deaminase, and optionally at least one UGI.

Table 12: Constructs for RNA-targeted base editing

SEQ ID NO.	Construct	RGN	Dead (D)or Nickase (N)	Base editor
213	Nuc-ADAT-Linker-d APG02874 - Linker-SV40	APG02874	D	ADAT
215	Nuc-ADAT-Linker-d APG09208-Linker-SV40	APG09208	D	ADAT
565	Nuc-ADAT-Linker-d APG05586-Linker-SV40	APG05586	D	ADAT

[0240] The accessible editing sites of an RGN are determined by the PAM sequence. When combining an RGN with a base editing domain, the target residue for editing must reside on the non-target strand (NTS), since the NTS is single stranded while the RGN is associated with the locus. Evaluating a number of nucleases and corresponding guide RNAs enables the selection of the most appropriate gene editing tool for this particular locus. Several potential PAM sequences that can be targeted by the constructs described above in the human *Idua* gene are in the proximity of the mutant nucleotide responsible for the W402X mutation. A sequence encoding a guide RNA transcript containing 1) a "spacer" that is complementary to the non-coding DNA strand at the disease locus; and 2) RNA sequence required for association of the guide RNA with the RGN is also produced. Such a sgRNA may be encoded by, for example, SEQ ID NO: 217 for the APG02874 RGN system, SEQ ID NO: 218 for the APG09208 RGN system, or SEQ ID NO: 566 for the APG005586 RGN system. These sgRNA molecules, and similar sgRNAs that may be devised by one of skill in the art, can be evaluated for their efficiency in directing the base editors above to the locus of interest.

Example 7. 3: Assay for activity in cells from Hurler disease patients

[0241] To verify the genotype strategy and evaluate the constructs described above, fibroblasts from Hurler disease patients are used. A vector is designed containing appropriate promoters upstream of the fusion protein coding sequence and the sgRNA encoding sequence for expression of these in human cells, similar to those vectors described in Example 4. It is recognized that promoters and other DNA elements (for example enhancers, or terminators) which either are known for high levels of expression in human cells or may specifically express well in fibroblast cells may also be used. The vector is transfected into the fibroblasts using standard techniques, for example transfection similar to what is described in Example 4. Alternatively, electroporation may be used. The cells are cultured for 1 - 3 days. Genomic DNA (gDNA) is isolated using standard techniques. The editing efficiency is determined by performing a qPCR genotyping assay and/or next generation sequencing on the purified gDNA, as described further below.

[0242] Taqman™ qPCR analysis utilizes probes specific for the wild-type and mutant allele. These probes bear fluorophores which are resolved by their spectral excitation and/or emission properties using a qPCR instrument. A genotyping kit containing PCR primers and probes can be obtained commercially (i.e. Thermo Fisher Taqman™ SNP genotyping assay ID C_27862753_10 for SNP ID rs121965019) or designed. An example of a designed primer and probe set is shown in Table 13.

Table 13: RT-PCR primers and probes

Description	Sequence	SEQ ID NO.
Forward Amplification Primer	5'-GACTCCTTCACCAAG-3'	219
Reverse Amplification Primer	5'-GTAGATCAGCACCG-3'	220
Wild Type Probe	5'-CTCTGGGCCGAAGT-3'	221
W402X Probe	5'-CTCTAGGCCGAAGT-3'	222

[0243] Following the editing experiment, the gDNA is subjected to qPCR analysis using standard methods and the primers and probes described above. Expected results are shown in Table 14. This *in vitro* system can be used to expediently evaluate constructs and choose one with high editing efficiency for further studies. The systems will be evaluated in comparison with cells with and without the W402X mutation, and preferably with some that are heterozygous for this mutation. The Ct values will be compared to either a reference gene or the total amplification of the locus using a dye such as Sybr green.

Table 14: Expected qPCR results

Genotype	Transfected with base editor	Expected PCR result
Idua ^{WT/WT}	No	Homozygous WT
Idua ^{WT/W402X}	No	Heterozygous: 50% WT, 50% W402X
Idua ^{W402X/W402X}	No	Homozygous W402X
Idua ^{W402X/W402X}	Yes	Variable

[0244] The tissues can also be analyzed by next generation sequencing. Primer binding sites such as the ones shown below (Table 15), or other suitable primer binding sites that can be identified by a person of skill in the art, can be used. Following PCR amplification, products containing Illumina Nextera XT overhang sequences undergo library preparation following the Illumina 16S Metagenomic Sequencing Library protocol. Deep sequencing is performed on an Illumina Mi-Seq platform. Typically, 200,000 of 250 bp paired-end reads (2 x 100,000 reads) are generated per amplicon. The reads are analyzed using CRISPResso (Pinello et al., 2016) to calculate the rates of editing. Output alignments are hand-curated to confirm insertion and deletion sites as well as identify microhomology sites at the recombination sites.

Table 15: NGS primer binding sites

Direction	Sequence	SEQ ID NO.
Forward	5' -ACTTCCTCCAGCC-3'	223
Reverse	5' -GAACCCCGGCTTA-3'	224

[0245] Western blotting of cell lysate of transfected cells and control cells using an anti-IDUA antibody is performed to verify expression of the full-length protein and an enzyme activity assay on the cell lysate using substrate 4-methylumbelliferyl α-L-iduronide verifies that the enzyme is catalytically active (Hopwood et al., Clin.Chim. Acta (1979), 92(2): 257-265, incorporated by reference herein). These experiments are performed in comparison with the original Idua^{W402X/W402X} cell line (without transfection), the Idua^{W402X/W402X} cell line transfected with the base editing construct and a random guide sequence, and a cell line expressing wild-type IDUA.

Example 7. 4: Disease treatment validation in a murine model

[0246] To verify the efficacy of this therapeutic approach, a mouse model with a nonsense mutation in the analogous amino acid is used. The mouse strain bears a W392X mutation in its Idua gene (Gene ID: 15932) which corresponds to the homologous mutation in Hurler

syndrome patients (Bunge et al., (1994), Hum. Mol. Genet. 3(6): 861-866, incorporated by reference herein). This locus comprises a distinct nucleotide sequence relative to that in humans, which lacks the PAM sequence necessary for correction with the base editors described in the previous examples, and thus necessitates design of a distinct fusion protein to perform the nucleotide correction. Amelioration of the disease in this animal can validate the therapeutic approach of correcting the mutation in tissues accessible by a gene delivery vector.

[0247] Mice homozygous for this mutation display a number of phenotypic characteristics similar to Hurler syndrome patients. A base editing-RGN fusion protein as described above (Table 12) along with an RNA guide sequence are incorporated into an expression vector that allows protein expression and RNA transcription in mice. A study design is shown below in Table 16. The study includes groups that are treated with a high dose of the expression vector comprising the base-editing fusion protein and RNA guide sequence, a low dose of same expression vector, control which is the model mouse treated with an expression vector that does not comprise the base editing fusion protein or the guide RNA, and a second control which is a wild type mouse treated with the same empty vector.

Table 16: Genome editing experiment in murine model

Group	Mouse strain	N	Treatment
1	Idua-W392X ¹	≥ 5	Low dose of vector
2	Idua-W392X	≥ 5	High dose of vector
3	Idua-W392X	≥ 5	Vehicle
4	129/Sv (WT)	5	Vehicle

[0248] Endpoints to evaluate include body weight, urine GAG excretion, serum IDUA enzymatic activity, IDUA activity in tissues of interest, tissue pathology, genotyping of tissues of interest to verify correction of the SNP, and behavioral and neurological evaluation. Since some endpoints are terminal, additional groups may be added for evaluation of, for example, tissue pathology and tissue IDUA activities before the end of the study. Additional examples of endpoints can be found in published papers establishing Hurler syndrome animal models (Shull et al. (1994), Proc. Natl. Acad. Sci. U.S.A., 91(26): 12937-12941; Wang et al. (2010), Mol. Genet. Metab., 99(1): 62-71; Hartung et al. (2004), Mol. Ther., 9(6): 866-875; Liu et al. (2005), Mol. Ther., 11(1): 35-47; Clarke et al. (1997), Hum. Mol. Genet. 6(4): 503-511; all herein incorporated by reference).

[0249] One possible delivery vector utilizes the adeno associated virus (AAV). A vector is produced to include a base editor-dRGN fusion protein coding sequence (for example, Nuc-ADAT-Linker-dAPG19748-Linker-SV40, as described above) preceded by a CMV enhancer (SEQ ID NO: 259) and promoter (SEQ ID NO: 258), or other suitable enhancer and promoter combination), optionally a Kozak sequence, and operably fused at the 3' end to a terminator sequence and a poly-adenylation sequence such as the minimal sequence described in Levitt, N.; Briggs, D.; Gil, A.; Proudfoot, N. J. Definition of an Efficient Synthetic Poly(A) Site. Genes Dev. 1989, 3 (7), 1019-1025. The vector may further comprise an expression cassette encoding for a single guide RNA operably linked at its 5' end to a human U6 promoter (SEQ ID NO: 260) or another promoter suitable for production of small non-coding RNAs, and further comprising inverted terminal repeat (ITR) sequences necessary and well-known in the art for packaging into the AAV capsid. Production and viral packaging is performed by standard methods, such as those described in U.S. Patent No. 9,587,250, herein incorporated by reference.

[0250] Other possible viral vectors include adenovirus and lentivirus vectors, which are commonly used and would contain similar elements, with different packaging capabilities and requirements. Non-viral delivery methods also be used, such as mRNA and sgRNA encapsulated by lipid nanoparticles (Cullis, P. R. and Allen, T. M. (2013), Adv. Drug Deliv. Rev. 65(1): 36-48; Finn et al. (2018), Cell Rep. 22(9): 2227-2235, both incorporated by reference) hydrodynamic injection of plasmid DNA (Suda T and Liu D,)2007 Mol. Ther. 15(12): 2063-2069, herein incorporated by reference), or ribonucleoprotein complexes of sgRNA and associated with gold nanoparticles (Lee, K.; Conboy, M.; Park, H. M.; Jiang, F.; Kim, H. J.; Dewitt, M. A.; Mackley, V. A.; Chang, K.; Rao, A.; Skinner, C.; et al. Nanoparticle Delivery of Cas9 Ribonucleoprotein and Donor DNA in Vivo Induces Homology-Directed DNA Repair. Nat. Biomed. Eng. 2017, 1 (11), 889-90).

Example 7.5: Disease correction in a murine model with a humanized locus

[0251] To evaluate the efficacy of an identical base editor construct as would be used for human therapy, a mouse model in which the nucleotides near W392 are altered to match the sequence in humans around W402 is needed. This can be accomplished by a variety of techniques, including use of an RGN and an HDR template to cut and replace the locus in mouse embryos.

[0252] Due to the high degree of amino acid conservation, most nucleotides in the mouse locus can be altered to those of the human sequence with silent mutations as shown in Table 17. The only base changes resulting in altered coding sequence in the resulting engineered mouse genome occur after the introduced stop codon.

Table 17: Nucleotide mutations to generate a humanized mouse locus

Feature	Human (W402X)		Mouse (W392X)		Humanized Mouse	
	Nucleotide (SEQ ID NO: 225)	Encoded AA	Nucleotide (SEQ ID NO: 226)	Encoded AA	Nucleotide (SEQ ID NO: 227)	Encoded AA
Protospacer	Human (W402X)		Mouse (W392X)		Humanized Mouse	
	G	E	A	G	G	G
	G	E	G	E	G	E
	A		A		A	
	G		A		G	
	C	Q	C	Q	C	Q
	A		A		A	
	G		A		G	
	C	L	C	L	C	L
	T		T		T	
	C		C		C	
	T	STOP	T	STOP	T	STOP
	A		A		A	
	G		G		G	
	G	A	G	A	G	A
	C		C		C	
	C		A		C	
	G	E	G	E	G	E
	A		A		A	
	A		G		A	
	G	V	G	V	G	V
	T		T		T	
	G		C		G	
	T	S	T	S	T	S
	C		C		C	
	G		A		G	
PAM, noncritical	C	Q	A	K	C	Q
	A		A		A	
	G		G		G	
	G	A	G	A	G	A
PAM, critical	C		C		C	
	C		T		C	

[0253] Upon engineering of this mouse strain, similar experiments will be performed as described in Example 7.4.

Example 8: Targeting mutations responsible for Friedrich Ataxia

[0254] The expansion of the trinucleotide repeat sequence causing Friedrich's Ataxia (FRDA) occurs in a defined genetic locus within the FXN gene, referred to as the FRDA instability region. RNA guided nucleases (RGNs) may be used for excising the instability region in FRDA patient cells. This approach requires 1) an RGN and guide RNA sequence that can be programmed to target the allele in the human genome; and 2) a delivery approach for the RGN and guide sequence. Many nucleases used for genome editing, such as the commonly used Cas9 nuclease from *S. pyogenes* (SpCas9), are too large to be packaged into adeno-associated viral (AAV) vectors, especially when considering the length of the SpCas9 gene and the guide RNA in addition to other genetic elements required for functional expression cassettes. This makes a viable approach using SpCas9 unlikely.

[0255] Compact RNA guided nucleases of the invention, for example APG03850, are uniquely well suited for the excision of the FRDA instability region. APG03850 has a PAM requirement that is in the vicinity of the FRDA instability region. Additionally, APG03850 can be packaged into an AAV vector along with a guide RNA. Packing two guide RNAs would likely require a second vector, but this approach still compares favorably to what would be required of a larger nuclease such as SpCas9, which would require splitting the protein sequence between two vectors.

[0256] Table 18 shows the location of genomic target sequences suitable for targeting APG03850 to the 5' and 3' flanks of the FRDA instability region, as well as the sequence of the sgRNAs for the genomic targets. Once at the locus, the RGN would excise the FA instability region. Excision of the region can be verified with Illumina sequencing of the locus.

Table 18: Genomic target sequences for RGN systems

Guide No.	Location relative to FRDA instability region	Genome target sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
1	5'	228	229
2	5'	230	231
3	3'	232	233
4	3'	234	235

Example 9: Targeting mutations responsible for Sickle Cell Diseases

[0257] Targeting sequences within the BCL11A enhancer region (SEQ ID NO: 236) may provide a mechanism for increasing fetal hemoglobin (HbF) to either cure or alleviate the symptoms of sickle cell diseases. For example, genome wide association studies have identified a set of genetic variations at BCL11A that are associated with increased HbF levels. These variations are a collection of SNPs found in non-coding regions of BCL11A that function as a stage-specific, lineage-restricted enhancer region. Further investigation revealed that this BCL11A enhancer is required in erythroid cells for BCL11A expression (Bauer et al, (2013) Science 343:253-257, incorporated by reference herein). The enhancer region was found within intron 2 of the BCL11A gene, and three areas of DNaseI hypersensitivity (often indicative of a chromatin state that is associated with regulatory potential) in intron 2 were identified. These three areas were identified as "+62", "+58" and "+55" in accordance with the distance in kilobases from the transcription start site of BCL11A. These enhancer regions are roughly 350 (+55); 550 (+58); and 350 (+62) nucleotides in length (Bauer et al., 2013).

Example 9.1: Identifying preferred RGN systems

[0258] Here we describe a potential treatment for beta-hemoglobinopathies using an RGN system that disrupts BCL11A binding to its binding site within the HBB locus, which is the gene responsible for making beta-globin in adult hemoglobin. This approach uses NHEJ which is more efficient in mammalian cells. In addition, this approach uses a nuclease of sufficiently small size that can be packaged into a single AAV vector for *in vivo* delivery.

[0259] The GATA1 enhancer motif in the human BCL11A enhancer region (SEQ ID NO: 236) is an ideal target for disruption using RNA guided nucleases (RGNs) to reduce BCL11A expression with concurrent re-expression of HbF in adult human erythrocytes (Wu et al. (2019) Nat Med 387:2554). Several PAM sequences compatible with APG03850 or APG09208 are readily apparent at the genetic locus surrounding this GATA1 site. These nucleases have a PAM sequence of 5'-nnnnG-3' (SEQ ID NO: 42) and 5'-nnnnC-3' (SEQ ID NO: 62), respectively, and are compact in size, potentially allowing their delivery along with an appropriate guide RNA in a single AAV or adenoviral vector. This delivery approach bestows multiple advantages relative to others, such as access to hematopoietic stem cells and a well-established safety profile and manufacturing techniques.

[0260] The commonly used Cas9 nuclease from *S. pyogenes* (SpyCas9) requires a PAM sequence of 5'-NGG-3', (SEQ ID NO: 256) several of which are present near the GATA1 motif. However, the size of SpyCas9 prevents packaging into a single AAV or adenoviral vector and thus forgoes the aforementioned advantages of this approach. While a dual delivery strategy may be employed, it would add significant manufacturing complexity and cost. Additionally, dual viral vector delivery significantly decreases the efficiency of gene correction, since a successful edit in a given cell requires infection with both vectors.

[0261] An expression cassette encoding a human codon optimized APG03850 or APG09208 is produced, similar to those described in Example 4. Expression cassettes which express guide RNAs for RGNs APG03850 or APG09208 are also produced. These guide RNAs comprise: 1) a protospacer sequence that is complementary to either the non-coding or coding DNA strand within the BCL11A enhancer locus (the target sequence) and 2) an RNA sequence required for association of the guide RNA with the RGN. Because several potential PAM sequences for targeting by APG03850 or APG09208 surround the BCL11A GATA1 enhancer motif, several potential guide RNA constructs are produced to determine the best protospacer sequence that produces robust cleavage and NHEJ mediated disruption of the BCL11A GATA1 enhancer sequence. The target genomic sequences in Table 19 are evaluated to direct the RGN to this locus using the sgRNA provided in Table 19.

Table 19: Target Sequences for BCL11A GATA1 enhancer locus using APG03850 or APG09208

Guide	RGN	Target genomic sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
1	APG03850	237	238
2	APG03850	239	240
3	APG03850	241	242

Guide	RGN	Target genomic sequence (SEQ ID NO.)	sgRNA (SEQ ID NO.)
4	APG09208	243	244
5	APG09208	245	246
6	APG09208	247	248

[0262] To evaluate the efficiency with which APG03850 or APG09208 generates insertions or deletions that disrupt the BCL11A enhancer region, human cell lines such as human embryonic kidney cells (HEK cells) are used. A DNA vector comprising an RGN expression cassette (for example, as described in Example 4) is produced. A separate vector comprising an expression cassette comprising a coding sequence for a guide RNA sequence of Table 16 is also produced. Such an expression cassette may further comprise a human RNA polymerase III U6 promoter (SEQ ID NO: 260), as described in Example 4. Alternatively, a single vector comprising expression cassettes of both the RGN and guide RNA may be used. The vector is introduced into HEK cells using standard techniques such as those described in Example 4, and the cells are cultured for 1-3 days. Following this culture period, genomic DNA is isolated and the frequency of insertions or deletions is determined by using T7 Endonuclease I digestion and/or direct DNA sequencing, as described in Example 4.

[0263] A region of DNA encompassing the target BCL11A region is amplified by PCR with primers containing Illumina Nextera XT overhang sequences. These PCR amplicons are either examined for NHEJ formation using T7 Endonuclease I digestion, or undergo library preparation following the Illumina 16S Metagenomic Sequencing Library protocol or a similar Next Generation Sequencing (NGS) library preparation. Following deep sequencing, the reads generated are analyzed by CRISPResso to calculate rates of editing. Output alignments are hand-curated to confirm insertion and deletion sites. This analysis identifies the preferred RGN and the corresponding preferred guide RNA (sgRNA). The analysis may result in both APG03850 and APG09208 being equally preferred. Additionally, the analysis may determine there is more than one preferred guide RNA, or that all target genomic sequences in Table 16 are equally preferred.

Example 9.2: Assay for expression of fetal hemoglobin

[0264] In this example, APG03850 or APG09208 generated insertions or deletions disrupting the BCL11A enhancer region are assayed for expression of fetal hemoglobin. Healthy human donor CD34⁺ hematopoietic stem cells (HSCs) are used. These HSCs are cultured and vector(s) comprising expression cassettes comprising the coding regions of the preferred RGN and the preferred sgRNA are introduced using methods similar to those described in Example 8.1. Following electroporation, these cells are differentiated *in vitro* into erythrocytes using established protocols (for example, Giarratana et al. (2004) Nat Biotechnology 23:69-74, herein incorporated by reference). The expression of HbF is then measured using western blotting with an anti-human HbF antibody, or quantified via High Performance Liquid Chromatography (HPLC). It is expected that successful disruption of the BCL11A enhancer locus will lead to an increase in HbF production when compared to HSCs electroporated with only the RGN but no guide.

Example 9.3: Assay for decreased sickle cell formation

[0265] In this example, APG03850- or APG09208-generated insertions or deletions disrupting the BCL11A enhancer region are assayed for decreased sickle-cell formation. Donor CD34⁺ hematopoietic stem cells (HSCs) from patients afflicted with sickle cell disease are used. These HSCs are cultured and vector(s) comprising expression cassettes comprising the coding regions of preferred RGN and the preferred sgRNA are introduced using methods similar to those described in Example 8.1. Following electroporation, these cells are differentiated *in vitro* into erythrocytes using established protocols (Giarratana et al. (2004) Nat Biotechnology 23:69-74). The expression of HbF is then measured using western blotting with an anti-human HbF antibody, or quantified via High Performance Liquid Chromatography (HPLC). It is expected that successful disruption of the BCL11A enhancer locus will lead to an increase in HbF production when compared to HSCs electroporated with only the RGN but no guide.

[0266] Sickle cell formation is induced in these differentiated erythrocytes by the addition of metabisulfite. The numbers of sickled vs normal erythrocytes are counted using a microscope. It is expected that the numbers of sickled cells are less in cells treated with APG03850 or APG09208 plus sgRNAs than with cells untreated, or treated with RGNs alone.

Example 9.4: Disease treatment validation in a murine model

[0267] To evaluate the efficacy of using APG03850 or APG09208 for disruption of the BCL11A locus, suitable humanized mouse models of sickle cell anemia are used. Expression cassettes encoding for the preferred RGN and for the preferred sgRNA are packaged into AAV vectors or adenovirus vectors. In particular, adenovirus type Ad5/35 is effective at targeting HSCs. A suitable mouse model containing a humanized HBB locus with sickle cell alleles is chosen, such as B6;FVB-Tg(LCR-HBA2,LCR-HBB*E26K)53Hhb/J or B6.Cg-Hb^{atm1Paz}Hbb^{tm1Tow} Tg(HBA-HBBs)41Paz/HhbJ. These mice are treated with granulocyte colony-stimulating factor alone or in combination with

plerixafor to mobilize HSCs into circulation. AAVs or adenoviruses carrying the RGN and guide plasmid are then injected intravenously, and the mice are allowed to recover for a week. Blood obtained from these mice is tested in an *in vitro* sickling assay using metabisulfite, and the mice are followed longitudinally to monitor mortality rates and hematopoietic function. It is expected that treatment with AAVs or adenoviruses carrying an RGN and guide RNA will reduce sickling, mortality, and improve hematopoietic function when compared to mice treated with viruses lacking both expression cassettes, or with viruses carrying the RGN expression cassette alone.

Example 10: Testing different delivery formats

[0268] To determine if the RGNs are capable of delivery in different formats, mRNA and RNP nucleofection delivery was tested with primary T-cells. Purified CD3+ T-cells or peripheral blood mononuclear cells (PBMCs) were thawed, activated using CD3/CD28 beads (ThermoFisher) for 3 days, then nucleofected using the Lonza 4D-Nucleofector X unit and Nucleocuvette strips. The P3 Primary Cell kit was used for both mRNA and RNP delivery. Cells were transfected using the EO-115 and EH-115 programs for mRNA and RNP delivery respectively. Cells were cultured in CTS OpTimizer T cell expansion medium (ThermoFisher) containing IL-2, IL-7, and IL-15 (Miltenyi Biotec) for 4 days post nucleofection before being harvested using a Nucleospin Tissue genomic DNA isolation kit (Machery Nagel).

[0269] Amplicons surrounding the editing sites were generated by PCR using primers identified in Table 4 and subjected to NGS sequencing using the Illumina Nextera platform using 2x250bp paired end sequencing following the method in Example 4.

Table 20: mRNA and RNP delivery of RGNs in primary T-cells

RGN	Delivery Method	SGN	% Editing
APG01604	mRNA, Nucleofection	SGN001671	1.18
APG01604	mRNA, Nucleofection	SGN001673	22.7
APG01604	RNP, Nucleofection	SGN001673	0.56
APG01604	mRNA, Nucleofection	SGN001674	0.63
APG01604	RNP, Nucleofection	SGN001674	0.77
APG01868	mRNA, Nucleofection	SGN001684	77.85
APG01868	RNP, Nucleofection	SGN001684	83.73
APG01868	mRNA, Nucleofection	SGN001691	82.53
APG01868	RNP, Nucleofection	SGN001691	80.7
APG01868	mRNA, Nucleofection	SGN001692	76.84
APG01868	RNP, Nucleofection	SGN001692	86.06
APG01868	mRNA, Nucleofection	SGN001785	0.22
APG01868	RNP, Nucleofection	SGN001785	0.43

[0270] Both mRNA and RNP delivery showed successful editing with APG01868. APG01868 showed successful editing with RNPs at several genomic targets. RNP delivery was limited with APG01604, but showed equal editing rates with mRNA delivery.

Example 11: Base Editor Testing

[0271] To determine if APG09298 and APG01604 could perform cytosine base editing in mammalian cells, a cytosine deaminase was operably fused to the nickase version of each RGN to produce a fusion protein. Residues predicted to deactivate the RuvC domain of the RGNs APG09298 and APG01604 were identified and the RGNs were modified to nickase variants. A nickase variant of an RGN is referred to herein as "nRGN". It should be understood that any nickase variant of an RGN may be used to produce a fusion protein of the invention.

[0272] Deaminase and nRGN nucleotide sequences codon optimized for mammalian expression were synthesized as fusion proteins with an N-terminal nuclear localization tag and cloned into the pTwist CMV (Twist Biosciences) expression plasmid. Each fusion protein comprises, starting at the amino terminus, the SV40 NLS (SEQ ID NO: 251) operably linked at the C-terminal end to 3X FLAG Tag (SEQ ID NO: 252), operably linked at the C-terminal end to a deaminase (APG05840), operably linked at the C-terminal end to a peptide linker, operably linked at the C-terminal end to the nRGN (nAPG09298 or nAPG01604), operably linked at the C-terminal end to a peptide linker, operably linked at the C-terminal end to a uracil stabilizing protein (USP2 set forth as SEQ ID NO: 1089), finally operably linked at the C-terminal end to the nucleoplasmin NLS (SEQ ID NO: 253). The amino acid sequence of the APG05840-nAPG09298-USP2 and APG05840-nAPG01604-USP2 fusion proteins are set forth as SEQ ID NOs: 1090 and 1091, respectively.

[0273] Expression plasmids comprising an expression cassette encoding a sgRNA were also produced. Human genomic target sequences and the sgRNA sequences for guiding the fusion proteins to the genomic targets are indicated in Table 3 and the primers for amplification of the genomic region are listed in Table 4. The same methods in Example 4 for plasmid delivery to mammalian cells and amplicon sequencing were used to test the base editing capabilities of these RGNs when tethered to a cytosine deaminase.

Table 21: Estimated Base Editing Rates for each RGN tested

Construct	Target	% Mutated Reads
APG05840-nAPG09298-USP2	SGN001159	6.96
APG05840-nAPG09298-USP2	SGN001159	9.91
APG05840-nAPG09298-USP2	SGN001162	21.59
APG05840-nAPG09298-USP2	SGN001162	27.05
APG05840-nAPG09298-USP2	SGN001163	17.85
APG05840-nAPG09298-USP2	SGN001163	20.74
APG05840-nAPG09298-USP2	SGN001164	4.74
APG05840-nAPG09298-USP2	SGN001164	7.89
APG05840-nAPG09298-USP2	SGN001165	31.99
APG05840-nAPG09298-USP2	SGN001165	62.47
APG05840-nAPG09298-USP2	SGN001166	23.49
APG05840-nAPG09298-USP2	SGN001166	29.56
APG05840-nAPG01604-USP2	SGN001245	9.67
APG05840-nAPG01604-USP2	SGN001246	1.4
APG05840-nAPG01604-USP2	SGN001249	1.72
APG05840-nAPG01604-USP2	SGN001250	13.41
APG05840-nAPG01604-USP2	SGN001251	0.87
APG05840-nAPG01604-USP2	SGN001252	4.28

Example 12: Off Target Analysis

[0274] To assess the specificity of the nucleases, off target editing was determined at potential sites identified via bioinformatics. Potential off target sites for APG01604 were identified by targets with less than five mismatches in the target sequence and at least one residue match in the PAM sequence.

[0275] The same methods as those described in Example 4 for plasmid delivery to mammalian cells and amplicon sequencing were used to test the specificity and off target editing of APG01604. From the same experiment where the SGNs in Table 22 were tested for on target editing, the potential off target locations in Table 23 were assayed for potential editing. The primers in Table 24 were used to amplify potential off target sites with sequence similarity to the on target site to look for off target editing.

Table 22: SGNs used to look for off target editing

SGN	Gene	On Target Forward Primer (SEQ ID NO)	On Target Reverse Primer (SEQ ID NO)
SGN001675	TRA	CCCTTGTCATCACTGGCAT (1096)	ACCAAAGCTGCCCTTACCTG (1097)
SGN001594	B2M	CCTTAATGTGCCTCCAGCCT (1092)	AGGAGAGACTCACGCTGGAT (1093)
SGN001674	TRA	CCCTTGTCATCACTGGCAT (1094)	ACCAAAGCTGCCCTTACCTG (1095)

Table 23: Off target sequences assayed

SGN	Off Target Number	Off target locus sequence	SEQ ID NO
SGN001594	1594-2	AGCACAGCTAAGGCCTAAAGTTGAA	1098
SGN001594	1594-3	AGCACAGCTAAGGCACCGGATTGGA	1099
SGN001594	1594-4	AGCACAGCCAAGGCCAAGGGCTGAC	1100
SGN001594	1594-5	AGCAGAGCTAAGGCCAAGGCAGGTG	1101
SGN001594	1594-6	GGCACAGCTAAGGCCAGCAGTGGCC	1102
SGN001674	1674-2	GTCTCTGAGCTGGTACATGGCAGAG	1103
SGN001674	1674-3	GTCTTTTAGCTGGTACACGTGTGTC	1104
SGN001675	1675-2	AGAAGATTGTCACTGGATTCTGAG	1105
SGN001675	1675-3	AGGACACTTGTCAGTGGATTAGGA	1106
SGN001675	1675-4	AGGACACTTGTCAGTGGATTAGGA	1107
SGN001675	1675-5	TGAGGACTTGTCAGTGGATTAGGG	1108
SGN001675	1675-6	AGGAGACTTTTCACTGGATTAGGG	1109
SGN001675	1675-7	TGGACACTTGTCAGTGGATTAGGG	1110
SGN001675	1675-8	CACAGACTTGTCAGTGGATGTGGGG	1111

SGN	Off Target Number	Off target locus sequence	SEQ ID NO
SGN001675	1675-9	TACAGACATGTCACTGGATCTGGAA	1112
SGN001675	1675-10	AACACACTTGTCATTGGATTAGGG	1113
SGN001675	1675-11	TACAGACTGGTCACTGGATGCTGGT	1114
SGN001675	1675-12	AGGACACTTGTCCTGGATTAGGA	1115
SGN001675	1675-13	CTAAGACTTGTTACTGGATTGTGTG	1116
SGN001675	1675-14	CTCAGACTGGTCACTGGATAATGTA	1117

Table 24: Primers used to amplify off target regions

Description	Primer sequence	SEQ ID NO
1594-2 FWD	CCAGAAGCCAGCAGATGACA	1118
1594-2 REV	GAGTGGTGGGCTCTCAATCC	1119
1594-3 FWD	AGCAACACCATCCAAAGGTT	1120
1594-3 REV	GGGAGTGATGATAATGCGGG	1121
1594-4 FWD	TGGACTAGAGAGGGTTGGGG	1122
1594-4 REV	TCTCTTTCCACGAGCAGCAG	1123
1594-5 FWD	GCCTTTGACCTTCCCAGATT	1124
1594-5 REV	ACCATTGGAAAGGTGGATGC	1125
1594-6 FWD	GGCTTCAGGCTTTCTCTGT	1126
1594-6 REV	AGCATGCTGGCCTAAAGTGA	1127
1674-2 FWD	ACCATTGGTCTGCTCAGGTG	1128
1674-2 REV	CCAAAACCTGCAGTGGCTTC	1129
1674-3 FWD	GGAGAGGAACTGGGCATGAG	1130
1674-3 REV	TCCGTCTCTCCTAGGTCTGC	1131
1675-2 FWD	CCATGACTGGCCCTTCTGTT	1132
1675-2 REV	GGGTAGAGTACATGGCGACG	1133
1675-3 FWD	CCCTCCCACCAGAAGCTCTA	1134
1675-3 REV	GATAAGAGGCCCAAGGACCG	1135
1675-4 FWD	CACTTGACACGTGAGCCTCT	1136
1675-4 REV	CCTCTTTCAGCCTCTGGTGG	1137
1675-5 FWD	GACAGACTTGTTCTGCCCT	1138
1675-5 REV	CCTCCCCTCCTTCTAGCTT	1139
1675-6 FWD	TGCTGTAGTGGGTGGAACAG	1140
1675-6 REV	TTTCACCATGCTGGCTAGGC	1141
1675-7 FWD	CCCAGCCACATGGAACAAAG	1142
1675-7 REV	GGACCCTAGGAGTTCCTTGT	1143
1675-8 FWD	GCAGGTTGATAGGGAAGAGC	1144
1675-8 REV	TCATCTCCCAGCTGATGACA	1145
1675-9 FWD	CCACCTGTTGCACAAATCCG	1146
1675-9 REV	TCCTCCCCTGGGAACATGAT	1147
1675-10 FWD	GAGGTACTGGGAGTGGGGAT	1148
1675-10 REV	CTTCCTGCCTCTTCCAGCTC	1149
1675-11 FWD	GCACAGCTTTTGTCATGGGG	1150
1675-11 REV	GGGGATGAGAAAACAGAGCCA	1151
1675-12 FWD	CCATGCCCCATTCTGAAGGT	1152
1675-12 REV	TTCCCCTCCTCTAGACTGCC	1153
1675-13 FWD	CTTGAGCCCAGGAGTTTGAG	1154
1675-13 REV	TGCATTCTGGGATGACCTC	1155
1675-14 FWD	ACTGCTTTTCCCTGGACACA	1156
1675-14 REV	GGTCACAAGTCCCACTGGTC	1157

[0276] Using plasmid delivery, there was no detectable off target editing at two of the three guides tested. One off target site for

SGN001675, 1675-8, showed 2% editing at the off target locus. There was duplication of 132bp of the genomic region at the cut site in the NGS reads. Two off target sites, 1675-7 and 1675-13, were unable to be sequenced due to poor primer amplification.

Table 25: Off Target Editing for SGN001594 and APG08167

Off target Number	Total Mismatches in Target	Total Mismatches in Seed	Total Matches in PAM	% Editing
SGN001594	0	0	3	42.79
1594-2	2	2	3	0
1594-3	2	2	3	0.01
1594-4	2	1	2	0
1594-5	3	2	2	0
1594-6	2	1	1	0

Table 26: Off Target Editing for SGN001675 and APG08167

Offtarget Number	Total Mismatches in Target	Total Mismatches in Seed	Total Matches in PAM	% Editing
SGN001675	0	0	3	33.115
1675-8	2	1	3	2.02
1675-5	4	0	3	0.06
1675-10	3	1	3	0.03
1675-12	4	0	2	0.02
1675-6	4	0	3	0
1675-2	4	0	3	0
1675-3	4	0	3	0
1675-4	4	0	3	0
1675-9	3	1	3	0
1675-11	2	0	2	0
1675-14	4	1	2	0
1675-13	4	0	2	Issue sequencing
1675-7	4	0	3	Issue sequencing

Table 27: Off Target Editing for SGN001674 and APG08167

Offtarget Number	Total Mismatches in Target	Total Mismatches in Seed	Total Matches in PAM	% Editing
SGN001674	0	0	3	52.17
1674-2	2	1	3	0
1674-3	2	0	1	0.03

Example 13: Guide RNA backbone variant testing

[0277] APG08167 and APG01604 are approximately 62.72% identical, but recognize the same PAM, share the same crRNA, and have a closely related tracrRNA sequence. Because of the similarity of the guide RNA sequences, all data previously generated for APG01604 used the APG08167 tracrRNA backbone. These studies were performed to confirm that the APG01604 protein is more active with a tracrRNA encoded in the APG08167 genome (the native APG08167 tracrRNA). Different spacer lengths in the crRNA were also tested to determine if the APG01604 protein prefers a 20 or 25 base pair spacer sequence.

[0278] To do this, synthetic crRNAs with six different target sequences that contained a 20 or 25 base pair target were generated. The different crRNAs were combinatorially combined with a synthetic tracrRNA from the APG08167 or APG01604 genome. RNPs were formed and the RNP complexes were nucleofected into HEK293T cells. The standard methods in Example 4 were used for determining the editing rate in cells.

Table 28: crRNA Sequences

Gene	Spacer	Spacer Length	SEQ ID NO
B2M	A	20	1158
	B	20	1159
	C	20	1160
	D	20	1161
	A	25	1162
	B	25	1163

Gene	Spacer	Spacer Length	SEQ ID NO
TRA	C	25	1164
	D	25	1165
	E	20	1166
	F	20	1167
	E	25	1168
	F	25	1169

Table 29: tracrRNA Sequences

tracrRNA	SEQ ID NO
APG08167 tracrRNA	1170
APG01604 tracrRNA	1171

Table 30: Sequencing Primer Sequences

Primer	SEQ ID NO
TRAC Left Primer	1170
TRAC Right Primer	1171
B2M Left Primer	1172
B2M Right Primer	1173

Table 31: Editing results for APG01604 backbone and target length testing

Gene	Spacer	Spacer Length	Backbone	Editing efficiency (%)
B2M	A	20	APG01604 tr	0.21
	B	20	APG01604 tr	0.08
	C	20	APG01604 tr	0.27
	D	20	APG01604 tr	0.17
	A	25	APG01604 tr	0.15
	B	25	APG01604 tr	0
	C	25	APG01604 tr	1.33
	D	25	APG01604 tr	0.31
	A	20	APG08167 tr	6.58
	B	20	APG08167 tr	1.75
	C	20	APG08167 tr	6.99
	D	20	APG08167 tr	64.6
	A	25	APG08167 tr	22.7
	B	25	APG08167 tr	2.36
	C	25	APG08167 tr	52.51
	D	25	APG08167 tr	82.58
TRA	E	20	APG01604 tr	0.05
	F	20	APG01604 tr	0.01
	E	25	APG01604 tr	0.02
	F	25	APG01604 tr	0.01
	E	20	APG08167 tr	0
	F	20	APG08167 tr	0.29
	E	25	APG08167 tr	2.64
	F	25	APG08167 tr	1.13

[0279] The editing rates in mammalian cells demonstrated that there was no robust editing when the native APG01604 tracrRNA sequence was used. The APG01604 RNP showed editing at much higher rates when using the APG08167 tracrRNA sequence. Additionally, when comparing the same target, the 25 base pair spacer length showed higher editing at targets A, C, D, E and F than the crRNAs that had the 20 bp spacer length. These results combined demonstrate that the APG08167 tracrRNA exhibits higher editing than the APG01604 tracrRNA. Additionally, the APG01604 RNP functions better with a 25bp spacer sequence than a 20bp spacer sequence.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US2019264232A1 \[0004\]](#)
- [CN110551762A \[0004\]](#)
- [US20140068797A \[0027\]](#)
- [US9790490B \[0027\]](#)
- [US20170121693A \[0030\] \[0038\]](#)
- [US20180073012A \[0030\] \[0038\]](#)
- [WO2018027078A \[0030\] \[0038\]](#)
- [WO2020139873A \[0030\]](#)
- [US63052175A \[0030\]](#)
- [US9840689B \[0038\] \[0160\]](#)
- [US20170275648A \[0052\]](#)
- [US5380831A \[0072\]](#)
- [US5436391A \[0072\]](#)
- [US5039523A \[0076\]](#)
- [US4853331A \[0076\]](#)
- [EP0480762A2 \[0076\]](#)
- [WO9943836A \[0078\]](#)
- [US8575425B \[0078\] \[0092\]](#)
- [US7790846B \[0078\]](#)
- [US8147856B \[0078\]](#)
- [US8586832B \[0078\]](#)
- [US7772369B \[0078\]](#)
- [US7534939B \[0078\]](#)
- [US6072050A \[0078\]](#)
- [US5859026A \[0078\]](#)
- [US5508149A \[0078\]](#)
- [US5808144A \[0078\]](#)
- [US5804121A \[0078\]](#)
- [US5569597A \[0078\]](#)
- [US5466785A \[0078\]](#)
- [US5399600A \[0078\]](#)
- [US5258463A \[0078\]](#)
- [US5808142A \[0078\]](#)
- [US6177611B \[0078\]](#)
- [US5364760A \[0080\]](#)
- [US0122169A \[0080\]](#)
- [US5814618A \[0080\]](#)
- [US5789156A \[0080\]](#)
- [US7692068B \[0092\]](#)
- [US8802924B \[0092\]](#)
- [US7541517B \[0092\]](#)
- [US5049386A \[0103\]](#)
- [US4946787A \[0103\] \[0103\]](#)
- [US4897355A \[0103\]](#)
- [WO9117424A \[0103\]](#)
- [WO9116024A \[0103\]](#)
- [US4186163A \[0103\]](#)
- [US4217344A \[0103\]](#)
- [US4235871A \[0103\]](#)
- [US4261975A \[0103\]](#)
- [US4485054A \[0103\]](#)

- [US4501728A \[0103\]](#)
- [US4774085A \[0103\]](#)
- [US4837028A \[0103\]](#)
- [US9405700W \[0105\]](#)
- [US4797366A \[0106\]](#)
- [WO9324641A \[0106\]](#)
- [US5173414A \[0106\]](#)
- [US20030087817A \[0108\]](#)
- [US5605783A \[0128\]](#)
- [US5837458A \[0128\]](#)
- [US4196265A \[0132\]](#)
- [US62966202A \[0138\]](#)
- [US9856247B \[0185\]](#)
- [US20110182867A \[0194\]](#)
- [US2020045759W \[0229\] \[0229\]](#)
- [US2019088079W \[0239\]](#)
- [US10167457B \[0239\]](#)
- [US9587250B \[0249\]](#)

Non-patent literature cited in the description

- GAUDELLI et al. Nature, 2017, vol. 551, 464-471 [0030] [0030]
- LANGE et al. J. Biol. Chem., 2007, vol. 282, 5101-5105 [0032]
- RAY et al. Bioconj Chem, 2015, vol. 26, 61004-7 [0032]
- NASSOURYMORSE Biochim Biophys Acta, 2005, vol. 1743, 5-19 [0033]
- KUNZEBERGER Front Physiol, 2015, [0033]
- HERRMANNNEUPERTIUBMB Life, 2003, vol. 55, 219-225 [0033]
- SOLL Curr Opin Plant Biol, 2002, vol. 5, 529-535 [0033]
- CARRIESMALL Biochim Biophys Acta, 2013, vol. 1833, 253-259 [0033]
- CARRIE et al. FEBS J, 2009, vol. 276, 1187-1195 [0033]
- SILVA-FILHO Curr Opin Plant Biol, 2003, vol. 6, 589-595 [0033]
- PEETERSMALL Biochim Biophys Acta, 2001, vol. 1541, 54-63 [0033]
- MURCHA et al. J Exp Bot, 2014, vol. 65, 6301-6335 [0033]
- MACKENZIE Trends Cell Biol, 2005, vol. 15, 548-554 [0033]
- GLASER et al. Plant Mol Biol, 1998, vol. 38, 311-338 [0033]
- MILLETTI F. Drug Discov Today, 2012, vol. 17, 850-860 [0034]
- BELFORT et al. Nucleic Acids Res., 1997, vol. 25, 3379-3388 [0037]
- LINN et al. Nucleases Cold Spring Harbor Laboratory Press 19930000 [0037]
- ZUKERSTIEGLER Nucleic Acids Res., 1981, vol. 9, 133-148 [0040]
- GRUBER et al. Cell, 2008, vol. 106, 123-24 [0048]
- BRINER et al. Molecular Cell, 2014, vol. 56, 333-339 [0052]
- BRINERBARRANGOU Cold Spring Harb Protoc 20160000 [0052]
- MEINKOTHWAHL Anal. Biochem., 1984, vol. 138, 267-284 [0057]
- TIJSSEN Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes Elsevier 19930000 [0057]
- Current Protocols in Molecular Biology Greene Publishing and Wiley-Interscience 19950000 [0057]
- SAMBROOK et al. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press 19890000 [0057]
- CAMPBELL GOWRI Plant Physiol., 1990, vol. 92, 1-11 [0072]
- MURRAY et al. Nucleic Acids Res., 1989, vol. 17, 477-498 [0072]
- GUERINEAU et al. Mol. Gen. Genet., 1991, vol. 262, 141-144 [0075]
- PROUDFOOT Cell, 1991, vol. 64, 671-674 [0075]
- SANFACON et al. Genes Dev., 1991, vol. 5, 141-149 [0075]
- MOGEN et al. Plant Cell, 1990, vol. 2, 1261-1272 [0075]
- MUNROE et al. Gene, 1990, vol. 91, 151-158 [0075]
- BALLAS et al. Nucleic Acids Res., 1989, vol. 17, 7891-7903 [0075]
- JOSHI et al. Nucleic Acids Res., 1987, vol. 15, 9627-9639 [0075]
- SAMBROOK et al. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press 19920000 [0076]
- Advanced Bacterial Genetics Cold Spring Harbor Laboratory Press 19800000 [0076]
- ODELL et al. Nature, 1985, vol. 313, 810-812 [0078]
- MCELROY et al. Plant Cell, 1990, vol. 2, 163-171 [0079]

- CHRISTENSEN et al.Plant Mol. Biol., 1989, vol. 12, 619-632 [0079]
- CHRISTENSEN et al.Plant Mol. Biol., 1992, vol. 18, 675-689 [0079]
- LAST et al.Theor. Appl. Genet., 1991, vol. 81, 581-588 [0079]
- VELTEN et al.EMBO J., 1984, vol. 3, 2723-2730 [0079]
- SCHENA et al.Proc. Natl. Acad. Sci. USA, 1991, vol. 88, 10421-10425 [0080]
- MCNELLIS et al.Plant J., 1998, vol. 14, 2247-257 [0080]
- GATZ et al.Mol. Gen. Genet., 1991, vol. 227, 229-237 [0080]
- AUSUBEL et al.Current Protocols in Molecular BiologyJohn Wiley & Sons20030000 [0085]
- SAMBROOKRUSSELLMolecular Cloning: A Laboratory ManualCold Spring Harbor Press20010000 [0085]
- RAKOCZY-TROJANOWSKA, MCell Mol Biol Lett., 2002, vol. 7, 849-858 [0092]
- JONES et al.Plant Methods, 2005, vol. 1, 5- [0092] [0092]
- RIVERA et al.Physics of Life Reviews, 2012, vol. 9, 308-345 [0092]
- BARTLETT et al.Plant Methods, 2008, vol. 4, 1-12 [0092]
- BATES, G.W.Methods in Molecular Biology, 1999, vol. 111, 359-366 [0092]
- BINNSTHOMASHOWAnnual Reviews in Microbiology, 1988, vol. 42, 575-606 [0092]
- CHRISTOU, P.The Plant Journal, 1992, vol. 2, 275-281 [0092]
- CHRISTOU, P.Euphytica, 1995, vol. 85, 13-27 [0092]
- TZFIRA et al.TRENDS in Genetics, 2004, vol. 20, 375-383 [0092]
- YAO et al.Journal of Experimental Botany, 2006, vol. 57, 3737-3746 [0092]
- ZUPANZAMBRYSKIPlant Physiology, 1995, vol. 107, 1041-1047 [0092]
- SVAB et al.Proc. Natl. Acad. Sci. USA, 1990, vol. 87, 8526-8530 [0094]
- SVABMALIGAProc. Natl. Acad. Sci. USA, 1993, vol. 90, 913-917 [0094]
- SVABMALIGAEMBO J., 1993, vol. 12, 601-606 [0094]
- MCBRIDE et al.Proc. Natl. Acad. Sci. USA, 1994, vol. 91, 7301-7305 [0094]
- MCCORMICK et al.Plant Cell Reports, 1986, vol. 5, 81-84 [0095] [0292]
- ANDERSONScience, 1992, vol. 256, 808-813 [0102]
- NABELFEIGNERTIBTECH, 1993, vol. 11, 211-217 [0102]
- MITANICASKEYTIBTECH, 1993, vol. 11, 162-166 [0102]
- DILLONTIBTECH, 1993, vol. 11, 167-175 [0102]
- MILLERNature, 1992, vol. 357, 455-460 [0102]
- VAN BRUNTBiotechnology, 1988, vol. 6, 101149-1154 [0102]
- VIGNERestorative Neurology and Neuroscience, 1995, vol. 8, 35-36 [0102]
- KREMERPERICAUDETBritish Medical Bulletin, 1995, vol. 51, 131-44 [0102]
- HADDADA et al.Current Topics in Microbiology and Immunology, 1995, [0102]
- YU et al.Gene Therapy, 1994, vol. 1, 13-26 [0102]
- CRYSTALScience, 1995, vol. 270, 404-410 [0103]
- BLAESE et al.Cancer Gene Ther., 1995, vol. 2, 291-297 [0103]
- BEHR et al.Bioconjugate Chem., 1994, vol. 5, 382-389 [0103]
- REMY et al.Bioconjugate Chem., 1994, vol. 5, 647-654 [0103]
- GAO et al.Gene Therapy, 1995, vol. 2, 710-722 [0103]
- AHMAD et al.Cancer Res., 1992, vol. 52, 4817-4820 [0103]
- BUCHSCHER et al.J. Viral., 1992, vol. 66, 2731-2739 [0105]
- JOHANN et al.J. Viral., 1992, vol. 66, 1635-1640 [0105]
- SOMMNERFELT et al.Viral., 1990, vol. 176, 58-59 [0105]
- WILSON et al.J. Viral., 1989, vol. 63, 2374-2378 [0105]
- MILLER et al.Viral., 1991, vol. 65, 2220-2224 [0105]
- WEST et al.Virology, 1987, vol. 160, 38-47 [0105]
- KATINHuman Gene Therapy, 1994, vol. 5, 793-801 [0106]
- MUZYCZKAClin. Invest., 1994, vol. 94, 1351- [0106]
- TRATSCHIN et al.Mol. Cell. Biol., 1985, vol. 5, 3251-3260 [0106]
- TRATSCHIN et al.Mol. Cell. Biol., 1984, vol. 4, 2072-2081 [0106]
- HERMONATMUZYCZKAPNAS, 1984, vol. 81, 6466-6470 [0106]
- SAMULSKI et al.Viral., 1989, vol. 63, 03822-3828 [0106]
- STEMMERProc. Natl. Acad. Sci. USA, 1994, vol. 91, 10747-10751 [0126]
- STEMMERNature, 1994, vol. 370, 389-391 [0126]
- CRAMERI et al.Nature Biotech., 1997, vol. 15, 436-438 [0126]
- MOORE et al.J. Mol. Biol., 1997, vol. 272, 336-347 [0126]
- ZHANG et al.Proc. Natl. Acad. Sci. USA, 1997, vol. 94, 4504-4509 [0126]
- CRAMERI et al.Nature, 1998, vol. 391, 288-291 [0126]
- A model of evolutionary change in proteinsDAYHOFF et al.Atlas of Protein Sequence and StructureNatl. Biomed. Res. Found.19780000vol. 5, 345-352 [0130]
- HENIKOFF et al.Proc. Natl. Acad. Sci. USA, 1992, vol. 89, 10915-10919 [0130]
- ALTSCHUL et al.Nucleic Acids Res., 1997, vol. 25, 3389-3402 [0130] [0130]
- HARLOWLANEAntibodies: A Laboratory ManualCold Spring Harbor Laboratory19880000 [0132]

- WEI et al.PNAS USA, 2015, vol. 112, 27E3495-504 [0138]
- TROELSTRA et al.Cell, 1992, vol. 71, 939-953 [0138]
- MARNEF et al.J Mol Biol, 2017, vol. 429, 91277-1288 [0138]
- VAN DEN BOOM et al.J Cell Biol, 2004, vol. 166, 127-36 [0138]
- VAN GOOL et al.EMBO J, 1997, vol. 16, 195955-65 [0138]
- TENG et al.Nat Commun, 2018, vol. 9, 14115- [0138]
- ZHANG et al.Chem. Sci., 2016, vol. 7, 4951-4957 [0143]
- GUSCHIN et al.Methods Mol Biol, 2010, vol. 649, 247-256 [0143]
- BUNGE et al.Hum. Mol. Genet., 1994, vol. 3, 6861-866 [0184] [0246]
- VELLODI et al.Arch. Dis. Child., 1997, vol. 76, 292-99 [0185]
- PETERS et al.Blood, 1998, vol. 91, 72601-2608 [0185]
- PANDOLFO et al.Handbook of Clinical Neurology, 2012, vol. 103, 275-294 [0186]
- CAMPUZANO et al.Science, 1996, vol. 271, 1423-1427 [0186]
- PANDOLFOAdv. Exp. Med. Biol., 2002, vol. 516, 99-118 [0186]
- DESIMONEProc Nat'l Acad Sci USA, 1982, vol. 79, 144428-31 [0194]
- LEY et al.N. Engl. J. Medicine, 1982, vol. 307, 1469-1475 [0194]
- LEY et al.Blood, 1983, vol. 62, 370-380 [0194]
- CONSTANTOULAKIS et al.Blood, 1988, vol. 72, 61961-1967 [0194]
- SANKARANScience, 2008, vol. 322, 1839- [0194]
- KLEINSTIVER et al.Nature, 2015, vol. 523, 481-485 [0215]
- ZETSCHE et al.Cell, 2015, vol. 163, 759-771 [0215]
- PINELLO et al.Nature Biotech, 2016, vol. 34, 695-697 [0226]
- BUNGE et al.Hum. Mol. Genet, 1994, vol. 3, 6861-866 [0234]
- RYU et al.Nat. Biotechnol., 2018, vol. 36, 6536-539 [0237]
- HOPWOOD et al.Clin.Chim. ACta, 1979, vol. 92, 2257-265 [0245]
- SHULL et al.Proc. Natl. Acad. Sci. U.S.A., 1994, vol. 91, 2612937-12941 [0248]
- WANG et al.Mol. Genet. Metab., 2010, vol. 99, 162-71 [0248]
- HARTUNG et al.Mol. Ther., 2004, vol. 9, 6866-875 [0248]
- LIU et al.Mol. Ther., 2005, vol. 11, 135-47 [0248]
- CLARKE et al.Hum. Mol. Genet., 1997, vol. 6, 4503-511 [0248]
- LEVITT, N.BRIGGS, D.GIL, A.PROUDFOOT, N. J.Definition of an Efficient Synthetic Poly(A) Site.Genes Dev., 1989, vol. 3, 71019-1025 [0249]
- CULLIS, P. R.ALLEN, T. M.Adv. Drug Deliv. Rev., 2013, vol. 65, 136-48 [0250]
- FINN et al.Cell Rep., 2018, vol. 22, 92227-2235 [0250]
- SUDA TLIU DMol. Ther., 2007, vol. 15, 122063-2069 [0250]
- LEE, K.CONBOY, MPARK, H. M.JIANG, F.KIM, H. J.DEWITT, M. AMACKLEY, V. A.CHANG, K.RAO, A.SKINNER, C. et al.Nanoparticle Delivery of Cas9 Ribonucleoprotein and Donor DNA in Vivo Induces Homology-Directed DNA Repair.Nat. Biomed. Eng., 2017, vol. 1, 11889-90 [0250]
- BAUER et al.Science, 2013, vol. 343, 253-257 [0257]
- GIARRATANA et al.Nat Biotechnology, 2004, vol. 23, 69-74 [0264] [0265]

PATENTKRAV

1. Nukleinsyremolekyle, der omfatter et polynukleotid, som koder for et RNA-guidet nuklease-(RGN)-polypeptid, hvor nævnte polynukleotid omfatter en nukleotidsekvens, der koder for et RGN-polypeptid, som omfatter en aminosyresekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 83;
hvor nævnte RGN-polypeptid er i stand til at binde en mål-DNA-sekvens på en RNA-guidet sekvensspecifik måde, når det er bundet til et guide-RNA (gRNA), der er i stand til at hybridisere til nævnte mål-DNA-sekvens, og
hvor nævnte RGN-polypeptid genkender en sekvens af et protospacer-tilstødende motiv (PAM), der omfatter konsensussekvensen af SEQ ID NO: 82.
2. Nukleinsyremolekyle ifølge krav 1, hvor nukleinsyremolekylet er kodonoptimeret til ekspression i en eukaryot celle.
3. Nukleinsyremolekyle ifølge krav 1 eller 2, hvor nævnte polynukleotid, der koder for et RGN-polypeptid, er operativt bundet til en promotor.
4. Nukleinsyremolekyle ifølge krav 3, hvor promotoren er heterolog til polynukleotidet.
5. Nukleinsyremolekyle ifølge et hvilket som helst af kravene 1-3, hvor RGN-polypeptidet er operativt fusioneret til et effektordomæne.
6. Nukleinsyremolekyle ifølge krav 5, hvor effektordomænet omfatter et spaltningsdomæne, et deaminasedomæne eller et ekspressionsmodulatoromæne.
7. Nukleinsyremolekyle ifølge krav 5 eller krav 6, hvor effektordomænet er operativt fusioneret ved N-terminalen, C-terminalen eller ved en intern placering af nævnte RGN-polypeptid.
8. Vektor, der omfatter nukleinsyremolekylet ifølge et hvilket som helst af kravene 1-7.
9. Vektor ifølge krav 8, som yderligere omfatter mindst en nukleotidsekvens, der koder for nævnte gRNA, der er i stand til at hybridisere til nævnte mål-DNA-sekvens.
10. Celle, der omfatter nukleinsyremolekylet ifølge et hvilket som helst af kravene 1-7.

11. Isoleret RNA-guidet nuklease-(RGN)-polypeptid, hvor nævnte RGN-polypeptid omfatter en aminosyresekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 83; og hvor nævnte RGN-polypeptid er i stand til at binde en mål-DNA-sekvens af et DNA-molekyle på en RNA-guidet sekvensspecifik måde, når det er bundet til et guide-RNA (gRNA), der er i stand til at hybridisere til nævnte mål-DNA-sekvens; og hvor nævnte RGN-polypeptid genkender en sekvens af et protospacer-tilstødende motiv (PAM), der omfatter konsensussekvensen af SEQ ID NO: 82.

12. RGN-polypeptid ifølge krav 11, hvor RGN-polypeptidet er operativt fusioneret til et effektordomæne.

13. RGN-polypeptid ifølge krav 12, hvor effektordomænet omfatter et spaltningsdomæne, et deaminasedomæne eller et ekspressionsmodulatoromæne.

14. RGN-polypeptid ifølge krav 12 eller krav 13, hvor effektordomænet er operativt fusioneret ved N-terminalen, C-terminalen eller ved en intern placering af nævnte RGN-polypeptid.

15. System til binding af en mål-DNA-sekvens af et DNA-molekyle, idet nævnte system omfatter:

a) et eller flere guide-RNA'er, der er i stand til at hybridisere til nævnte mål-DNA-sekvens, eller et eller flere polynukleotider, der omfatter en eller flere nukleotidsekvenser, som koder for det ene eller flere guide-RNA'er (gRNA'er); og

b) et RNA-guidet nuklease-(RGN)-polypeptid, der omfatter en aminosyresekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 83, eller et polynukleotid, der omfatter en nukleotidsekvens, som koder for RGN-polypeptidet;

hvor det ene eller flere guide-RNA'er er i stand til at hybridisere til mål-DNA-sekvensen;

hvor det ene eller flere guide-RNA'er er i stand til at danne et kompleks med RGN-polypeptidet for at dirigere nævnte RGN-polypeptid til at binde til nævnte mål-DNA-sekvens af DNA-molekylet; og

hvor nævnte RGN-polypeptid genkender en sekvens af et protospacer-tilstødende motiv (PAM), der omfatter konsensussekvensen af SEQ ID NO: 82.

16. System ifølge krav 15, hvor mindst en af nævnte nukleotidsekvenser, der koder for det ene eller flere guide-RNA'er, og nukleotidsekvensen, der koder for RGN-polypeptidet, er operativt bundet til en promotor, der er heterolog til nævnte nukleotidsekvens.

17. System ifølge krav 15 eller 16, hvor mål-DNA-sekvensen er en eukaryot mål-DNA-sekvens.

18. System ifølge et hvilket som helst af kravene 15-17, hvor nukleotidsekvenserne, der koder for det ene eller flere guide-RNA'er, og nukleotidsekvensen, der koder for et RGN-polypeptid, er placeret på én vektor.

19. System ifølge et hvilket som helst af kravene 15-18, hvor nævnte gRNA er valgt fra:

a) et gRNA, der omfatter en CRISPR-gentagelsessekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 84 og et tracrRNA med mindst 90 % sekvensidentitet med SEQ ID NO: 85; og

b) et gRNA, der omfatter en CRISPR-gentagelsessekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 84 og et tracrRNA med mindst 90 % sekvensidentitet med SEQ ID NO: 78.

20. Nukleinsyremolekyle ifølge et hvilket som helst af kravene 1-4, isoleret RGN-polypeptid ifølge krav 11 eller system ifølge et hvilket som helst af kravene 15-19, hvor RGN-polypeptidet er nukleaseinaktivt eller er en nickase.

21. Nukleinsyremolekyle ifølge et hvilket som helst af kravene 1-4 og 20, isoleret RGN-polypeptid ifølge krav 11 eller 20 eller system ifølge et hvilket som helst af kravene 15-20, hvor RGN-polypeptidet er operativt fusioneret til et baseredigerende polypeptid.

22. Nukleinsyremolekyle, isoleret RGN-polypeptid eller system ifølge krav 21, hvor det baseredigerende polypeptid er en deaminase.

23. Nukleinsyremolekyle ifølge et hvilket som helst af kravene 1-4 og 20-22, isoleret RGN-polypeptid ifølge et hvilket som helst af kravene 11 og 20-22, eller system ifølge et hvilket som helst af kravene 15-22, hvor RGN-polypeptidet omfatter et eller flere nukleare lokaliseringssignaler.

24. *In vitro*- eller *ex vivo*-fremgangsmåde til binding af en mål-DNA-sekvens af et DNA-molekyle omfattende levering af et system ifølge et hvilket som helst af kravene 15-19 til nævnte mål-DNA-sekvens eller en celle, der omfatter mål-DNA-sekvensen, hvor fremgangsmåden ikke er en fremgangsmåde til modificering af et menneskes genetiske kimlinjeidentitet.

25. *In vitro*- eller *ex vivo*-fremgangsmåde til spaltning og/eller modificering af en mål-DNA-sekvens af et DNA-molekyle, der omfatter at bringe DNA-molekylet i kontakt med:

- a) et RNA-guidet nuklease-(RGN)-polypeptid, hvor nævnte RGN omfatter en aminosyresekvens med mindst 90 % sekvensidentitet med SEQ ID NO: 83; og
- b) et eller flere guide-RNA'er, der er i stand til at målrette nævnte RGN fra (a) til mål-DNA-sekvensen;

hvor nævnte RGN-polypeptid genkender en sekvens af et protospacer-tilstødende motiv (PAM), der omfatter konsensussekvensen af SEQ ID NO: 82;

hvor det ene eller flere guide-RNA'er hybridiserer til mål-DNA-sekvensen og derved dirigerer nævnte RGN-polypeptid til at binde til nævnte mål-DNA-sekvens, og spaltning og/eller modificering af nævnte mål-DNA-sekvens finder sted, og

hvor fremgangsmåden ikke er en fremgangsmåde til modificering af et menneskes genetiske kimlinjeidentitet.

26. Fremgangsmåde ifølge krav 25, hvor spaltning med nævnte RGN-polypeptid genererer et dobbeltstrenget brud eller et enkeltstrenget brud.

27. Fremgangsmåde ifølge krav 25 eller 26, hvor den modificerede mål-DNA-sekvens omfatter:

- a) deletion af mindst ét nukleotid fra mål-DNA-sekvensen; eller
- b) mutation af mindst ét nukleotid i mål-DNA-sekvensen.

28. Nukleinsyremolekyle ifølge et hvilket som helst af kravene 1-7, vektor ifølge krav 8 eller 9, celle ifølge krav 10, isoleret RGN-polypeptid ifølge et hvilket som helst af kravene 11-14, system ifølge et hvilket som helst af kravene 15-19 eller fremgangsmåde ifølge et hvilket som helst af kravene 24-27, hvor nævnte RGN-polypeptid omfatter aminosyresekvensen angivet som SEQ ID NO: 83.

SEKVENSLISTE

Sekvenslisten er udeladt af skriftet og kan hentes fra det Europæiske Patent Register.

The Sequence Listing was omitted from the document and can be downloaded from the European Patent Register.

